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s t e l l i n g e n  b e h o r e n d e  b i j  h e t  p r o e f s c h r i f t :
THE POWER OF HOMOZYGOSiTY MAPPiNG: 
DiSCOVERY OF NEW GENETiC DEFECTS iN PATiENTS 
WiTH RETiNAL DYSTROPHY
1 Uit het feit dat homozygotie mapping ook leidt tot het vinden van het genetisch 
defect in niet-consanguine patienten uit Nederland -  dit proefschrift -  zou men 
kunnen concluderen dat sommige Nederlanders minder reislustig zijn ingesteld 
dan onze VOC geschiedenis doet vermoeden.
2 Fenotypische variatie is waarschijnli jk  vaker dan we weten het resultaat van 
een modifier allel. -  dit proefschrift -  De huidige opvatting dat retina dystrofie 
een monogenetische aandoening is, word t daarmee discutabel.
3 De bevinding dat next generation sequencing ~80 pathogene mutaties in één 
humaan genoom detecteert, leidt tot de vraag of monogenetische ziektebeelden 
überhaupt bestaan.
4 Hoewel interculturele relaties de effectiviteit van homozygotie mapping niet 
bevorderen, zijn ze vanuit persoonlijk oogpunt toch een aanrader.
5 Als " ik  heb het gen voor ...(aandoening)..." een correcte uitspraak zou zijn, 
dan zou ieder mens een zeer groot aantal erfelijke aandoeningen hebben.
6 Zonder artsen geen patiënten, zonder lab geen mutaties.
7 Iedere onderzoeker lijdt een beetje aan tunnelvisie.
8 Het schrijven van een proefschrif t is als een trekking in de bergen; de eerste dag 
is vreselijk, maar als je eenmaal het ritme te pakken hebt wil je niet meer stoppen. 
Dit in tegenstell ing tot de 4daagse, waarbij  de finish meer dan welkom is.
9 You can reach anything if the desire to reach the goal is bigger than the fear to fail. 
(M edical genetics course, Bertinoro, may 2008)
10 Logic will get you from A to B. Imagination will take you everywhere. (AlbertEinstein)
11 Geluk is niet afhankelijk van dingen buiten ons, maar van de manier waarop wij  
die zien. (Lev Tolstoj)
12 Too much thinking -  bad for health (Health museum, Hyderabad, India)
Karin Littink, 03-11-2010
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CHAPTER 1
Vision is a fascinating phenomenon, and over the last millennia scientists have 
reflected on a large number of theories to explain the actual mechanism of sight. 
Although the earl iest scientists probably understood that the eye was the organ that 
mediated vision, the actual formation of an image remained a mystery.
One of the first reports about the eye go back to Hippocrates (~460-377 B.C.), who  
described several components of the eye and distinguished the retina as a separate 
membrane. About one century later Greek anatomists were able to describe a more 
detailed anatomy by dissecting animal eyes. During dissections, the retina easily 
detached from the eyeball and appeared as a collapsed membrane in the shape 
of a fishing net, and was therefore called 'ret ina', meaning 'netlike-membrane' in 
Latin. The next characterization that improved the knowledge about the dif ferent eye 
components was made by the Roman physician and philosopher Galen of Pergamum 
(129-199 A.D.), who described the retina as a displaced part of the brain, based on its 
similari ty in color and consis tency w ith the brain.1
In contrast to the relatively correc t ideas about anatomy, the speculations about the 
function of the dif ferent components of the eye were far from our current knowledge.  
Several theories were posed to explain how the eye was able to perceive an image: 
'the wa te r inside the eyeball is the photosensitive organ' (Hippocrates), 'objects  
continuously send images of themselves' (Democritos, 460-370 B.C.), 'rays of light 
emanated from an object meet w ith the rays of light sent from the pupil' (Plato, 427­
347 B.C.), 'objects discharge countless shell-like moulds that leave a print in the visual 
organ' (Epicuros, 341-270 B.C.). Eventually, two main thoughts continued to exist.
First, the eye was  thought to send light -  like a sun -  in a cone shaped projection,  
with  the tip of the cone in the pupil and the base of the cone projected on the subject  
of interest ('the emanation theory', by Pythagoras in 532 B.C). Second, the lens was  
thought to be the photosensitive organ in the eye. The retina appeared to contain 
many blood vessels, and was thought to be the provider of nutrition as well as the 
conveyor of the 'visual spiri t' -  a mysterious force by wh ich vision was effectuated.
After the decline of the Classical Civilization due to invasion of the barbarians, the 
ophthalmic knowledge passed on to the Arab Civilization. It was at the end of the 
fi rst millennium that the Arab optics student Ibn al-Haitham (965-1039) criticized the 
emanation theory and proposed that 'vision is accomplished by rays coming from 
external objects and entering into the visual organ'. Around the 12th century, the Greek 
and Arab knowledge slowly reached Western Europe when Arab manuscripts were  
translated into Latin, and it was only in the 16th century that the anatomist Platter (1536-
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1614) overthrew the long-lasting idea of a photosensitive role of the lens. In his opinion, 
the lens was 'the spectacle of the optic nerve', and the true photoreceptor was the 
retina. The model of vision was finalized by Kepler (1571-1630), who explained that an 
image is projected to the retina inverted and diminished in size based on refraction.
The knowledge of retinal anatomy accelerated after the invention of the microscope  
by Anthonie van Leeuwenhoek (1632-1723), wh ich made it possible to visualize 
the photoreceptor cells and the retinal layers. The fi rst observations were  
confusing, because the order of the retinal layers seemed to be inside-out, w ith  the 
photoreceptor layer in the posterior position. Nevertheless, it was in the 19th century  
that Helmholtz (who also developed the fi rst ophthalmoscope), Corti and Koelliker 
(~1850) laid the foundation for the present understanding of the three-layered retina 
and its connection to the optic nerve. The distr ibution of photoreceptors and the 
dif ference in diurnal and nocturnal function between cone and rod photoreceptors  
was clarif ied by Schultz in 1872. In 1877 Boll discovered the visual pigment 
'rhodopsin'. The bipolar, horizontal and amacrine cells were elucidated by Cajal 
around 1900.1
From then on there was an expansion of understanding the visual processes due to 
the elucidation of the phototransduction cascade, wh ich gave the first insights into 
the inner part of the retinal cells. Since two decades this knowledge is expanded to 
the genetic level, due to the identif ication of genes involved in retinal dystrophies. In 
1990, only 113 years after the discovery of the visual pigment, the gene encoding this 
rhodopsin molecule, termed rhodopsin (RHO), was identified as the fi rst genetic cause 
of retinal dystrophy.2 In the same year, Cremers et al. published the identi fication of 
the choro ideremia -  an X-linked chorioretinal dystrophy -  gene.3 These two studies 
marked the beginning of an era of positional candidate gene cloning. Since then, 
the number of genes associated w ith retinal dystrophies has grown tremendously,  
which has led to a detailed knowledge about the visual processes, insight into 
disease mechanisms that cause the dif ferent types of retinal dystrophies, and -  most 
importantly -  to the development of possible interventions of degeneration of retinal 
cells in humans. This all has led to the first clin ical tr ials of gene-specif ic therapy in 
patients w ith retinal dystrophy,4-7 wh ich emphasizes the need to continue exploration 
of the unknown.
The next paragraphs w il l focus on the present knowledge about the retina, visual 
processes and the molecular genetics of mainly three retinal dystrophies; cone-rod  
dystrophy (CRD), Leber congenital amaurosis (LCA) and retinit is pigmentosa (RP).
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THE RETINA
R e t in a l  a n a to m y
The retina consists of two layers: the neural retina and the retinal pigment epithelium 
(RPE). The RPE is a single layer of cells that separates the photoreceptors from the 
choroid (Figure 1), and exchanges nutr ients and waste products between the retina 
and the choro idal blood vessels. The neural retina is a sect ion of the central nervous 
system that covers the inner back side of the eye, and consists of three layers 
(Figure 1).8 and refs therein The first layer -  which is the posterior layer from the perspective 
of the incoming light -  consists of photoreceptor cells (cones and rods), which convert 
the energy of an absorbed photon into an electrical signal that is then transferred via 
their synaptic terminal to the second layer of bipolar, horizontal and amacrine cells 
(the second order neurons). These cells are responsible for interconnecting the input 
from single photoreceptors, wh ich is the first stage of image processing. The signals 
are then communicated to the third layer of cells; the ganglion cells, which transport  
the neuronal signal via the optic nerve to the visual cortex of the brain.
The blood supply to the retina is provided by the retinal artery (15-35%) and the 
choroidal vessels (65-85%).9 The blood supply of the choro idal vessels is vital for 
the maintenance of the photoreceptors in the outer retina, wh ich makes the 'inside­
out design' of the retina -  w ith  the photoreceptors (the cells that absorb the light) 
separated from the light w ith  two layers of cells -  more logical.9- 10
F IG U R E  1 . Schematic 
overview  o f the various cells 
w ith in  the three retinal layers
(Figure derivedfrom  
http://webvision. med. utah. edu).
amacrine cells 
ganglion cells
nerve fiber
inner limiting 
membrane
There are two types of photoreceptors, both w ith a special ized function. Only 5% 
of the photoreceptors (~3 million) are cones, wh ich are concentrated in the central 
retina (the fovea), and are responsible for the visual acuity, bright light (photopic)
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vision and for color vision. The other 95% (~60 million) are rods, wh ich mediate dim 
l ight (scotopic) vision. Rods are absent in the inner part of the fovea, but are highly 
concentrated in a rim surrounding the fovea and they are the major photoreceptor 
cells in the mid-peripheral and peripheral retina (Figure 2A). Rods are able to detect 
even a single photon, wh ich explains why stars can be seen when focusing slightly 
beside a star, so that the photons project to the rods, and may not be visible when  
focusing straight at a star w ith the cones, that are not sensitive enough to process  
this low-in tensity light.8
Photoreceptors have an inner segment in which proteins are synthesized, which  
are then transported towards the outer segment via the connecting cilium of the 
cell (Figure 2B). The outer segment contains membranous discs that carry the 
photopigment -  color opsins in case of cones and rhodopsin in case of rods -  and 
other proteins necessary for phototransduction. The anatomy of the outer segment 
differs among cone and rod photoreceptors; the rod outer segments are rod shaped 
and contain internalized discs, which do not attach to the cell membrane, the cone 
outer segments are cone shaped and the discs and surface membrane are continuous.
Every day, new discs are generated from the base of the outer segment, and -  at 
the apical end -  daily 10% of the discs are phagocytosed by the RPE cells. The high 
turnover of photoreceptor discs makes the RPE cells the most active phagocytic  
cells in the human body.8
F IG U R E  2 . D istribution of rod and cone photoreceptors 
over the retina, and anatomy o f the rod photoreceptor.
a . D is tribu tion  o f the cones and rods, showing a high 
concentration o f cones and absence o f rods in the fovea, 
and a high concentration o f rods in the peripheral retina 
(Figure derivedfrom  http://www.cogsci.bme.hu/).
B. Detailed anatomy o f the rod 
photoreceptor (Figure designed 
by an d  published with permission o f  
E.A. Pierce).
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r e t i n a l  p r o c e s s e s
Two major processes are important for the conversion of light into an electrical signal. 
First, the phototransduction cascade; the process by wh ich the photoreceptors  
convert the energy of an absorbed photon into a neuronal signal. Second, the visual 
cycle; a continuous recycling process in wh ich the chromophores (all-frans-retinal) 
used in the phototransduction cascade are recycled into newly usable chromophores  
(11-c/s-retinal).
Both processes are described in more detail below.
P hototransduction cascade
The phototransduction cascade (Figure 3) takes place in the photoreceptor outer 
segment. The membranous discs of the outer segment contain a photosensitive  
pigment; a membrane protein that consists of an opsin protein (rhodopsin in rods, 
green, red or blue opsin in cones) joined w ith  an 11-c/s-retinal chromophore. When  
a light photon reaches the retina, it activates rhodopsin by changing the 11-c/s- 
retinal into all -frans-retinal. The activated rhodopsin (metarhodopsin II) tr iggers the 
activation of transducin, wh ich -  when bound to GTP -  then activates cGMP specific 
phosphodiesterase (PDE). The activated PDE a  and p subunit hydrolyze cGMP to 
5-GMP. The subsequent decrease of cytoplasmic cGMP leads to the closure of 
cGMP channels in the plasma membrane and, as a result, sodium cannot freely enter 
the cell, wh ich leads to the hyperpolarization of the cell. Due to hyperpolarization 
of the plasma membrane voltage-gated calc ium channels (for example the Cav1.4 
channel) at the synaptic terminal wil l close. As a result, the intracellular calcium  
concentrat ion suddenly decreases, which leads to the inhibition of neurotransmitter 
(glutamate) release. Thus, counter-intuitively, in the dark state there is a constant 
neurotransmit ter release, while activation of the photoreceptor leads to a decrease 
of neurotransmitter release.11- 12 and refs therein
Following activation of the phototransduction cascade, used molecules are converted 
into the ir initial conformation during the recovery phase (Figure 3).13 Metarhodopsin  
II is inactivated via phosphorylation by rhodopsin kinase and by binding to arrestin 
which results in free opsin and all-frans-retinal. Subsequently, activated transducin  
and PDE are deactivated by a complex of GTPase accelerator protein (Regulators 
of G-protein Signaling; RGS9-1) and Gp5L, wh ich together stimulate GTP hydrolysis. 
From this GTP, cGMP is synthesized by guanylate cyclase enzymes (GC-1 and GC-2) 
as a result of which cGMP concentration are restored to 'dark levels'. The end 
result is an outer segment in dark state, in wh ich the cation channels are open, the 
photoreceptor is depolarized, neurotransmit ter is steadily released from the synaptic
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terminal, all proteins involved in the phototransduction cascade are ready for the next 
activation, and all-frans-retinal is ready to be recycled in the visual cycle.
f i g u r e  3 . schematic ove v iew  of the activation and recovery of the phototransduction cascade.
A  photoreceptor outer segment disk membrane and plasma membrane are shown w ith  the most 
im portan t molecules that participate in  the phototransduction cascade. A c tiva tion  o f rhodopsin 
by a photon induces a cascade o f chemical reactions, leading to closure o f the plasma membrane 
cGMP-gated channel, leading in  tu rn  to hyperpolarization o f the photoreceptor cell.
(Figure designed by a n d  published with permission o f  B.P. Leroy.)
Visual cycle
The rod visual cycle is a recycle machinery that takes place in the RPE and 
photoreceptor outer segment, where it recycles 'used' all-f rans-retinal into 11-c/s- 
retinal that can be re-utilized in the phototransduction cascade (Figure 4A).14 and refs therein 
Following inactivation of the phototransduction cascade, all-frans-retinal dissociates  
from the opsin into the disc membranes of the photoreceptor outer segment, is then 
transferred to the cytoplasmic space facili tated by the ABCR protein in the disc 
membrane, and converted into all-f rans-retinol by retinol dehydrogenase (RDH12).
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All-trans-retinol (vitamin A) is then released into the interphotoreceptor matrix, 
which is accelerated by interphotoreceptor retinoid-binding protein (IRBP); a protein 
localized in the interphotoreceptor matr ix that strongly binds all-frans-ret inol. All- 
frans-ret inol is then taken up by the RPE cells, facili ta ted by cellu lar retinol-binding  
protein-1 (CRBP1). RPE cells also take up vitamin A from blood in the choroidal  
circulation. In the RPE cell, all- frans-retinol is esterified by lecithin retinol acyl 
transferase (LRAT) into al l- trans-retinyl ester, wh ich is the stable and non-cytotoxic  
storage form of vitamin A. Subsequently, RPE-specific 65-kDa protein (RPE65) 
isomerizes all- frans-retinyl ester into 11-c/s-retinol, and -  since free 11-c/s-retinol 
inhibits the isomerization of more all- frans-retinyl ester -  it then binds to cellular  
retinal-binding protein (CRALBP), and may be temporarily removed from the chemical  
equilibr ium by conversion into 11-c/s-retinyl by LRAT. 11-c/s-retinol is subsequently 
oxidized into 11-c/s-retinal, catalyzed by 11-c/s-retinol dehydrogenase (RDH5), and 
then released from the RPE cell into the interphotoreceptor matrix, again facili tated 
by IRBP. Finally, 11-c/s-retinal is taken up by the photoreceptor, where it binds to 
rhodopsin to be part of the phototransduction cascade again.
The rod photoreceptors are fully dependent on the visual cycle in the RPE for the 
regeneration of 11-c/s-retinal. Remarkable, the visual pigment regeneration in cones 
is 2000-fold higher than in rods, and the maximum throughput of the visual cycle is too 
slow to explain the sustained photosensitiv ity of cones in bright light. Based on these  
observations, a new pathway for regeneration of visual pigment was discovered that 
revealed that part of the visual cycle in cones takes place in the Muller cells, instead 
of the RPE cells (Figure 4B).15 Analysis of cone-dominated retinas (from chickens and 
ground squirrels) revealed that all-frans-retinol was directly isomerized to 11-c/s- 
retinol w ithou t the formation of al l- frans-retinyl ester as intermediate. Subsequently, 
11-c/s-retinol is removed from the equilibrium react ion by binding to CRALBP and 
by a palmitoyl-coenzyme A (palm-CoA)-dependent esterif ication of 11-c/s-retinol, 
to stimulate 11-c/s-retinol synthesis. The existence of this alternative visual cycle 
may function in conjunction w ith the visual cycle in the RPE-cells, to provide visual 
chromophores to the cone in the high rate that is required for daylight-vision.
ON and OFF pathw ays
The conversion of a neuronal signal from a photon is step one in vision. Step two  
comprises the processing of the neuronal signals into signals that eventually can 
build an image. This is conducted by two separate pathways: one that is activated 
by light input and by images that are lighter than their  background, and one that is 
activated by a dark input, or when a stimulus is darker than its background. These 
pathways are called the ON and OFF pathway, respectively, and were discovered
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F IG U R E  4 . schem atic presentation of the rod and cone v isual cycles. A ll-trans-re tina l is 
recycled via several steps in to  11-c/s-retinal that can be reused in  the phototransduction cascade. 
a . The rod visual cycle takes place in  the rod outer segment and the retinal p igment epithelium. 
B. The cone visual cycle takes place in  the cone outer segment and the M ü lle r cells. • , photon; 
M II, metarhodopsin II; R A L, retinal; RD H , re tino l dehydrogenase; RE, retinyl ester; REH, retinyl 
ester hydrolase; ROL, retinol; palm CoA, palm itoyl coenzyme A . Proteins are presented in  grey, 
and are encoded by the fo llow ing genes (in italic): 11-cis-RDH, RDH5; A BC R, A B C A 4;  
A ll-trans-R D H , RD H 12; CRALP, RLBP1, CRBP1, CRBP1, IRBP, IRBP; LRAT, LRAT; RGR,
RGR; RPE65 isomerase; RPE65.
when measurement of the optic nerve revealed that some nerve fibers fire when  
the light is switched on, while other nerve fibers fire when light is turned off. These 
separate pathways implicate that sensing black and white is not a continuum of grey 
intensity, but two separate pathways, one from gray to black, and one from gray to 
white .16
The separation into the ON and OFF pathways starts at the synapse between the 
photoreceptor and the bipolar cells. As mentioned before, neurotransmit ter release 
is favored in a dark state, and drops during light input. There are no separate ON and 
OFF photoreceptors, the bid irectional signaling appears at the stage of the bipolar
15
cells. There are mainly two types of bipolar cells; the ON (rod and cone) and OFF 
(cone) bipolar cells. These cells differ in the type of receptor molecules expressed 
at the synapse. ON bipolar cells have a metabotropic mGLuR6 receptor and OFF 
bipolar cells have an ionotropic glutamate receptor. Due to dif ferent properties of the 
receptors, OFF bipolar cells are excited when glutamate levels are high, i.e. a dark 
stimulus, and ON cone bipolar cells are excited when glutamate levels drop, i.e. a 
l ight stimulus (Figure 5). The cone ON or OFF signal is passed on to the ON and OFF 
ganglion cells, respectively, and subsequently passed on via the optic nerve towards  
the visual cortex. The rod ON bipolar cells cannot transfer their signal direct ly to the 
ganglion cells. Instead, there are three possible routes. First, the classical pathway  
(ON1/OFF1, Figure 5), in wh ich a signal from a rod bipolar cell is transferred to the 
amacrine cells in the inner plexiform layer. The amacrine cells then sum the input 
from several rod bipolar cells and transfer the signal to the axon terminal of the 
ON cone bipolar cell. These cone bipolar cells, in turn, synapse onto the ganglion 
cells. This rod bipolar pathway is the most sensit ive pathway, and is able to detect  
one single photon. The alternative pathways transfer the signal via a gap junct ion  
between the rod synaptic terminal and the cone synaptic terminal, and on to the cone 
bipolar cells (ON2/OFF2, Figure 5), and some rods have a direct synaptic connection 
to the OFF cone bipolar cells (OFF3, Figure 5).
ONI ON2 OFF1 OFF2 OFF3
F IG U R E  5. The various ON and OFF signal transm ission paths from rod and cone 
photoreceptors to bipolar cells.
OS, outer segment; IS, inner segment; O N L, outer nuclear layer; OPL, outer p lexiform  layer; IN L , 
inner nuclear layer; IPL, inner p lexiform  layer; G CL, ganglion cell layer. A II, amacrine cell; RB, 
rod bipolar cell. D ark arrows depict “OFF-signaling” v ia  glutamate receptors, whereas light grey 
arrows depict “ON-signaling” through m GLuR6 receptors. (Figure derivedfrom  Wässle, 2004,16 
a n d  published with permission.)
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RETINAL DYSTROPHIES; THE CLINICAL FEATURES
Monogenic retinal dystrophies affect approximately 1/2000 people, which  
corresponds to more than 2 million people wor ldw ide .17 There are several types 
of retinal dystrophies, representing a spectrum of cone-dominated (achromatopsia, 
cone dystrophy, cone-rod dystrophy) to rod-dominated (retinitis pigmentosa [i.e. 
rod-cone dystrophy]) diseases, or diseases that can present as either cone- or rod­
dominated (Leber congenital amaurosis). Beside the type of photoreceptor that is 
primarily involved, the sub-classif ication is based on the age of onset, the clinical 
features, and the course of the disease. However, clinical features can be very 
heterogeneous. Retinal dystrophies account for ~5% of blindness worldwide, in which  
bl indness is defined by the World Health Organization as a visual acuity lower than 
20/400 in the best eye and/or a visual field smaller than 10 degrees.
The three types of retinal dystrophy included in th is thesis w il l be discussed in more 
detail below.
C o n e - r o d  d y s t r o p h y
Cone-rod dystrophy (CRD) is character ized by the primary loss of cone photoreceptors 
fo llowed by or simultaneous w ith  the loss of rod photoreceptors.18- 19 The disease 
commonly becomes apparent during primary school years. The symptoms include photo­
aversion, a decrease in visual acuity w ith or w ithou t nystagmus, color vision defects, 
and decreased sensitivi ty of the central visual field. Rod photoreceptors can become 
affected as well, leading to night blindness and loss of peripheral vision. In comparison to 
the rod-cone type of disease, CRD patients have fewer difficulties to move independently 
in the initial stage, due to the remaining peripheral visual field, but are practically blind 
at a relatively young age, due to early and more rapid loss of macular function. The 
fundus of CRD patients is characterized by maculopathy and, in later stages, attenuated 
vasculature, pallor of the optic disc and pigmentary changes in the periphery can be seen.
The diagnosis of CRD is mainly based on electroretinogram (ERG) recordings, 
in wh ich cone (photopic) responses are more severely reduced than or equally 
reduced as rod (scotopic) responses.20 Goldmann kinetic perimetry can reveal a relative 
or absolute central scotoma. Fundus autofluorescence shows a predominant  
involvement of the macular region, and to a lesser extend, the peripheral region.
The prevalence of CRD is ~1:40,000 and it can be inherited in an autosomal recessive, 
autosomal dominant and X-linked manner.18 Usually CRD is a non-syndromic disease,
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but it can also appear as part of a syndrome, like in Bardet-Biedl syndrome (BBS) 
and spinocerebellar ataxia type 2 (Jalili syndrome), or in combination w ith  ectodermal 
diseases like amelogenesis imperfecta.
L e b e r  c o n g e n i t a l  a m a u r o s is
Leber congenital amaurosis (LCA), sometimes referred to as congenital blindness, 
is the earliest and most severe form of all retinal dystrophies. The diagnosis is 
established on the following clin ical features: severe and early visual loss, wandering  
nystagmus, amaurotic pupils (i.e. no pupillary reflex on light sensation), and absent 
or severely reduced signals on ERG testing before the age of one year.21-23 In the 
initial stage, LCA can be diff icult to dist inguish from other severe congenital retinal 
dystrophies like (complete or incomplete) achromatopsia, congenital stationary 
night blindness (CSNB; type 1 or 2), and albinism. However, early ERG responses are 
usually low or non-detectable for both cones and rods in LCA, whereas rod signals 
remain detectable in achromatopsia, ERG responses are electro-negative in CNSB, 
and supernormal in albinism. Hanein et al.22 divided the LCA phenotype in two groups; 
LCA type I is the cone-rod type of LCA, in wh ich photophobia is most remarkable.
In this group, patients often have a hypermetropic refractory error, macular as well  
as peripheral abnormalit ies on ophthalmoscopy, and the course of disease is usually 
stationary. In LCA type II, night blindness is more prominent, wh ich suggests a rod- 
cone type of disease, and it has a more progressive nature.
The prevalence of LCA is ~1:30,000-81,000,21- 23 and in most cases LCA is inherited 
in an autosomal recessive mode, but cases of autosomal dominant inheritance have 
also been described. Like many other retinal dystrophies, LCA can be a symptom  
of a syndrome as well , for examples in Joubert syndrome, Senior-L0ken syndrome 
and Alstrom syndrome.
R e t in i t i s  p ig m e n to s a
Retin itis pigmentosa (RP) is a retinal dystrophy in wh ich  the rods are primarily  
affected. The age of onset of symptoms is highly variab le in RP, ranging from early  
chi ldhood to later than 50 years of age. The initial symptoms are night blindness 
and loss of peripheral vis ion.24- 25 Both symptoms may be d if f icu lt to notice by a 
patient, because the curren t e lectr ica l n ight-t ime i l lumination is su ff ic ien t for  
cone-dependent vision, and loss of the periphera l field can be unnoticed until 
~50 degrees of remain ing visual f ie ld .26 Eventually, the cone photoreceptors  
become affected as well ,  often leading to blindness due to a combination of 
restr ic ted visual fields and maculopathy. A lthough there is no established
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t rea tment for RP yet, trea tment of common complicat ions, like posterior  
subcapsu lar ca ta rac t or cysto id maculopathy, can be of help for preserving  
a visual function.
The fundus of RP patients in the initial stage shows minimal changes, but in advanced  
stages pathognomic bone-spicule shaped pigmentation usually appear in the mid­
peripheral retina. These pigmentations are the result of RPE cells that migrate into 
the neural retina in response to photoreceptor cell death. Furthermore, the fundus  
shows a waxy pale optic disc and a narrow retinal vasculature. Chorioretinal atrophy 
can appear, wh ich makes the choro idal vessels more abundantly visible due to 
pronounced atrophy of the RPE.
The diagnosis is based on the ERG responses, in wh ich rods are more severely  
affected than cones. Goldmann perimetry can document the loss of peripheral visual 
field, and usually shows a ring scotoma, or loss of the peripheral visual field.
The prevalence of non-syndromic RP is ~1:4,000.24- 25 RP can appear as a symptom 
of a syndrome as well, for example in Usher syndrome, Jeune syndrome, metabolic 
syndromes like Refsum disease and Zellweger syndrome, and neurological syndromes 
like neuronal ceroid lipofuscinosis (Batten disease). Non-syndromic RP can be inherited 
in an autosomal recessive (50-60%), autosomal dominant (30-40%), X-linked (5-15%) and 
digenic manner. RP is the leading cause of visual disability in adults below the age of 60.27
m o l e c u l a r  g e n e t ic s  of a u t o s o m a l  r e c e s s iv e  c r d , 
l c a  a n d  rp
In order to achieve a neuronal signal from an absorbed photon, a properly working  
visual cycle, phototransduction cascade, and a well-developed and well-main tained  
retinal architecture are essential. Consequently, many mutations leading to CRD, LCA 
and/or RP are detected in genes that play an important role in the visual processes 
or the development of photoreceptors. Table 1 shows an overv iew of genes 
associated w ith autosomal recessive (ar) CRD, LCA and RP, and their accompanying  
function.17- 21 28 Some genes are responsible for a substantial percentage of CRD, RP 
and LCA patients, whereas most genes are involved in only one or two percent of 
cases (percentages indicated in Table 1). Still, in ~55%, ~35% and ~50% of arCRD, arLCA 
and arRP patients, respectively,18- 21 25 the genetic defect remains unsolved, and the 
discovery of new mutat ions and new genes associated to these phenotypes is
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ongoing. New genes and gene mutations can be discovered trough several methods, 
of which three have led to the identification of most of the genetic causes. In candidate 
gene analysis genes that turned out to play an important role in one of the visual 
processes were screened in large cohorts of patients.2, 29'31 In positional gene cloning 
the disease locus in the DNA of a patient was first established, for example by linkage 
analysis, fol lowed by a screening of genes in that particular genomic region.3, 32'34 The 
third method includes screening of genes that are mutated in animal models that exhibit 
a phenotype comparable to the human disease.35'37 Recently, one gene was identified 
by using mRNA expression profiling.38
In this thesis, homozygosity mapping has been used in order to identify the genetic 
defect in patients affected by CRD or allied disorders.
T A B L E  1. Overview of genes involved in autosomal recessive cone-rod dystrophy, autosomal 
recessive Leber congenital amaurosis and autosomal recessive re tin it is  pigmentosa.
Gene arCRD* arLCA i arRP*
Other
associated
diseases
Function
ABCA4 40% 1-2% MD, STGD1 Visual cycle32, 39, 40
ADAM9 1-2% Involved in outer segment- RPE junction41
AIPL1 5,3% adCRD Involved in posttranslational modification42-44
CABP4 <1% CCSD Synaptic transmission45
CEP290 15% EOSRD, JBTS, SLSN, BBS
Transport across the photo­
receptor connecting cilium46
CERKL 1-2% 1-2% Cellular apoptosis and survival47
CNGA1 2% Phototransduction48
CNGB1 1-2% Phototransduction49
CRB1 9,9% 2% Photoreceptor development and structure50
CRX 1,0% adRP, adLCA, adCRD
Transcriptional regulation 
(photoreceptor development)51
EYS <1% 5-12% Photoreceptor morphogenesis52, 53
GUCY2D 11,7% adCRD Phototransduction54
IDH3B 1-2% Krebs cycle38
LCA5 1,8% Transport across the photo­receptor connecting cilium55
LRAT 0,5% 1-2% Visual cycle56
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MERTK 0,6% 1-2% Photoreceptor outer segment phagocytosis57
NR2E3 1-2% adRP, ESC Transcriptional regulation (photoreceptor development)58, 59
NRL 1-2% adRP Transcriptional regulation (photoreceptor development)60-62
PDE6A 4% Phototransduction30
PDE6B 4% Phototransduction36
PRCD <1% Present in photoreceptor cytoplasm63
PROM1 1-2% 1-2% Photoreceptor disk membrane morphogenesis64
RBP3
(IRBP) <1% Visual cycle65
RD3 0,1% Early postnatal retinal development66
RDH12 2,7% adRP Visual cycle67
RGR 1-2% Visual cycle68
RHO 1-2% adCSNB, adRP Phototransduction69
RLBP1 1-2% FA, RPA Visual cycle70
RP1 1-2% adRP Photoreceptor structure71, 72
RPE65 6,0% 2% Visual cycle56, 73
RPGRIP1 1-2% 4,2% Transport across the photo­receptor connecting cilium74
SAG 2% CSNB Phototransduction75
SPATA7 1-2% 1-2% Expressed in cytoplasm of photoreceptor inner segment76
TULP1 0,8% 1-2% Transport across the photo­receptor connecting cilium37
USH2A 5% Ushersyndrome
Signaling, photoreceptor development77, 78
Total % 
estimated ~45% ~65% ~50%
Grey boxes indicate involvement in the above-mentioned disease. In italic, brief description 
o f putative function or localization o f the gene; in bold, associations that were identified in this thesis. *, 
percentages o f genes involved in arCRD and arRP are a rough estimate. +, percentages o f genes involved 
in arLCA are calculated on the basis o f publications up to 2008, except for SPATA7.21 ad, autosomal 
dominant; ar, autosomal recessive; BBS, Bardet-Biedl syndrome; CCSD, congenital cone-rod synaptic 
disorder (this thesis); CRD, cone-rod dystrophy; CSNB, congenital stationary night blindness; ESC, 
enhanced S-cone syndrome; EOSRD, early onset severe retinal dystrophy; FA, fundus albipunctatus; JBTS, 
Joubert syndrome; LCA, Leber congenital amaurosis; M D , macular degeneration; RP, retinitis pigmentosa; 
RPA, retinitis punctata albescens; SLSN, Senior-Loken syndrome; STGD1, Stargardt disease.
(Information derivedfrom RetNet™ (Retinal Information Network; http://www.sph.uth.tmc.edu/Retnet), 
den Hollander et al. 2008,21 Berger et al. 2010,17and  den Hollander et al. 201079)
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HOMOZYGOSiTY MAPPING
The human genome consists of 23 chromosome pairs: one set from the mother  
and one set from the father. The total of 46 chromosomes consists of ~3.200.000.000 
basepairs, in wh ich ~25.000 genes are encoded. The human genome is 99.5% identical 
between people, and the 0.5% variat ion is created by numerous insert ions or deletions, 
by thousands of copy number variations, and by about 3 million single nucleotide  
polymorphisms (SNPs).80- 81 A  SNP is a nucleotide that can differ between people (for 
example, a guanine (G) in one person and an adenine (A) in another person) in most 
cases without causing an obvious defect. As SNPs can be found throughout the entire 
genome, they can be used for linkage analysis or for the detection of homozygous 
regions. In contrast, a change in nucleotide is called a mutation only when it has 
a deleterious effect on the protein function. Analysis of all coding regions ('the exome') 
of a human genome revealed that a person may carry ~1.500 possible pathogenic variants.81
In autosomal recessive diseases, a person needs to carry mutat ions in both copies  
of one gene in order to become affected. These can be either two identical mutations, 
called homozygous mutat ions, as well as two dif fe rent mutations, called compound  
heterozygous mutations. Compound heterozygous mutations are most frequently  
found in patients in so-called mixed populations; i.e. populations in wh ich people are 
moving easily, and in wh ich people can choose a partner w ithou t clear restrict ions 
(Figure 6A). In an isolated population, people tend to stay in the same place, and/or 
the choice for a partner is based for example on religious or cultural restrictions.
In such a socie ty people have a higher chance to marry someone that is (distantly) 
related, and therefore the ir children, when affected by an autosomal recessive  
disease, mostly carry a homozygous defect (Figure 6B).82-84 Examples of (relatively) 
isolated populations are island populations, places w ith  a low percentage of 
migration, or a secluded population due to religious, cultural or language reasons.
Approximate ly 35% of mostly Dutch and German patients affected by a retinal 
dystrophy carry a homozygous mutation (F.P.M. Cremers, personal communication  
2010), and a similar percentage was detected in several genetic studies on autosomal 
recessive diseases in western European populations.85-89 The relatively high 
percentage of homozygous mutations in these populations may implicate that several 
western European populations are a combination of mixed and isolated populations.
Homozygous mutations may be detected by a method, named homozygosity mapping, 
as follows. When a mutat ion is passed on to the next generation, only part of the
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F IG U R E  6 . Schematic overv iew  of mutation d istribution in tw o  types of populations 
over several generations.
A. M ixed  population: mutations enter the population by de novo occurrence or by the im m igration 
o f an individual from  another population. As there is complete m ixture  o f variants, they can 
appear identical (homozygous; tw o identical m uta tion  symbols), but w ill o ften appear non­
identical (compound heterozygous; tw o different m utation symbols) in an affected individual.
B. The chance for one ancestral m uta tion  to be present on b oth  alleles (homozygous) in 
one person is higher in  a relatively isolated population in w hich parents o f a patient are likely 
to be distantly related.
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surrounding chromosomal region w il l be passed on as well . A  combination of 
alleles that a person inherits is called the 'haplotype'. The length and position of the 
original parental haplotype that wil l be present in a child depends on the positions 
of recombination during meiosis. Recombination occurs in reproductive cells 
during meiosis and implies the physical exchange between the two homologous  
chromosomes at random positions. As a result a person's genome is a mosaic of 
the preceding ancestors. Figure 7A illustrates the transfer of a mutation through  
dif ferent generations in a first-cousin marriage. The mutation, present in the 
great-grandmother, was  passed on to the next generations, including part of the 
surrounding genomic region. When the ancestral mutat ion is passed on via father 
and mother to their child, part of the original haplotype is still present, and in the child 
wil l be present as an identical-by-descent (i.e. homozygous) region. In a first-cousin  
family the size of a homozygous segment that harbors the mutat ion is on average 
26 Mb.90 When an ancestor who carried the mutation lived several generations ago, 
more recombinations took place, and as a result the homozygous region containing 
the mutation in a patient w il l be smaller (Figure 7B).
A homozygous region can be detected by using genome-wide genotyping arrays on 
which thousands of SNPs in the DNA of a person can be determined. When a SNP 
on one allele is identical to the SNP at the other allele, the SNP is called homozygous. 
A stretch of homozygous SNPs can indicate that th is region may originate from 
a common ancestor. Stretches of DNA can be homozygous by chance as well , for 
example in genomic regions that have a limited haplotype diversity, in a centromeric  
region, or in regions w ith little historical recombination (i.e. haplotype blocks).91 
Nevertheless, homozygosity mapping has been proven to be an effective method to 
identify the disease locus and, subsequently, the genetic defect in patients affected 
by autosomal recessive retinal diseases.52- 55- 92-94
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A . homozygous region -25 Mb
F iG U R E  7. Schematic presentation 
of the inheritance of an ancestral 
chromosome that harbors a mutation.
Every generation the original ancestral 
chromosome becomes 'smaller’ due to 
recombination between homologous 
chromosomes.
A. In consanguineous families, the 
m utation is likely inherited from  a recent 
com m on ancestor. Because the lim ited 
number o f generations between the 
ancestor and the patient, a large fraction 
o f the ancestral haplotype is present in 
both  chromosome copies o f the patient, 
resulting in  a relatively large homozygous 
region.90
O - p B ..........
O t "Ö Öt O
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B. W hen  the ancestor w ho carried the m utation lived m any generations ago, only a small fraction 
o f the ancestral haplotype w ill be present on b oth  chromosome copies o f a patient, and therefore 
the homozygous region in  such a patient w ill be relatively small.
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A IM  OF THIS THESIS
The aim of this thesis was  to identify the genetic defect underlying retinal dystrophy 
in patients affected by retinal dystrophy; mainly by cone-rod dystrophy or retinitis 
pigmentosa. The localization of the genetic defect was  detected by using high density 
genome-wide SNP arrays, fo llowed by homozygosity mapping or linkage analysis.
Chapter 2 summarizes all mutations that were identified using high-throughput SNP 
array analysis fo llowed by homozygosity mapping in 108 CRD patients, and shows  
the detailed clin ical features of the CRD patients in whom a mutation was identified.
Chapters 3 presents a detailed description of the phenotype that results from 
a CABP4 p.Arg216X mutation, as the detailed clinical examinations, including 
15Hz electroretinogram measurements, in both siblings led to the character ization 
of a distinct ive phenotype that is associated w ith a defect in processes in the 
photoreceptor synapse. In chapter 4, a family is presented in wh ich we identified 
mutations in CEP290 and MERTK by linkage analysis. A  novel nonsense mutation 
in CEP290 appeared to have a hypomorphic character, and led to a relatively mild 
phenotype, coined early onset severe retinal dystrophy. A third patient from the same 
family, affected by Leber congenital amaurosis, carr ied the same CEP290 mutations, 
and a heterozygous mutation in MERTK, wh ich may act as modifier allele.
Chapter 5A present the discovery of a new gene involved in retinitis pigmentosa; 
the EYS gene. In chapters 5B and 5C the prevalence of EYS mutations is determined  
in a Dutch and Israelian/Palestinian cohort, respectively, and the characteris tics  
of the EYS-associated phenotype are described.
A general discussion on the genetics of retinal dystrophies is given in chapter 6.
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ABSTRACT
PURPOSE. To determine the genetic defect, and to describe the clinical 
characteris t ics in a cohort of mainly non-consanguineous cone-rod dystrophy (CRD) 
patients.
METHODS. We collected 139 patients diagnosed w ith CRD. Ninety patients were  
screened for known mutations in ABCA4, and those carrying one or two mutat ions 
were excluded from further research. Genome-wide homozygosity mapping was  
performed in the remaining 108 patients. Known genes associated w ith  autosomal 
recessive retinal dystrophies located with in a homozygous region were screened 
for mutations. Patients in whom a mutation was detected underwent further  
ophthalmological examinations.
R E S U L T S .  We identified homozygous sequence variants in eight CRD families, six 
of wh ich were non-consanguineous. The variants were detected in the following six 
genes: ABCA4, CABP4, CERKL, EYS, KCNV2, or PROMT. Patients carrying mutations  
in ABCA4, CERKL and PROM1 had typical CRD symptoms, but a variety of retinal 
appearances on fundoscopy, optical coherence tomography and autofluorescence  
imaging.
CONCLUSiONS. Homozygosity mapping led to the identif ication of new  
mutations in consanguineous as well as in non-consanguineous retinal dystrophy 
patients. Detailed clin ical characterization revealed a variety of retinal appearances, 
ranging from nearly normal to extensive retinal remodeling, retinal thinning and debris 
accumulation. Although all patients were initially clinically diagnosed as CRD, the 
molecular f indings led to a reappraisal of the clinical diagnosis in patients carrying 
mutations in EYS, CABP4and KCNV2.
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iNTRODUCTiON
Cone-rod dystrophies (CRDs) belong to a heterogeneous group of inherited retinal 
dystrophies, characterized by the pr imary dysfunction or loss of cone photoreceptors  
followed by the dysfunction or loss of rod photoreceptors. The diagnosis is established by 
documenting decreased visual acuity -  usually noticed during childhood -  dyschromatopsia, 
central scotomas on visual field testing and an electroretinogram (ERG) that shows more 
severely reduced cone- than rod responses.1 The clinical course involves progressive 
loss of central vision, followed by peripheral visual field loss and progressive nyctalopia 
as more rod photoreceptors become involved in the disease process, and eventually may 
lead to complete blindness. CRD often presents as an isolated disease, but can be part of a 
syndrome as well,  as in Bardet-Biedl syndrome or Jalili syndrome.2, 3 Isolated CRD can be 
inherited as an autosomal recessive, autosomal dominant or X-linked trait, and is genetically 
heterogeneous. Currently, autosomal recessive CRD (arCRD) is associated with mutations 
in five genes, of which ABCA4 is the major contributing gene (40%).4-7 The other four genes 
(ADAM9, CERKL, PROM1, and RPGRIP1) all account for only few cases (1-2% each).8-11
Autosomal recessive disorders such as CRD can be caused by homozygous or by 
compound heterozygous mutations. Homozygous mutations are most frequently detected 
in patients of consanguineous parents, or in patients from relatively isolated populations, 
where the chance for the parents to have a common ancestor is relatively high. However, 
homozygous mutations are also detected in patients of non-consanguineous unions, 
and based on several genetic studies in large cohorts of patients with autosomal 
recessive diseases from western European countries, it is estimated that ~35% of those 
patients carry their mutation homozygously.12-16 A homozygous mutation is likely to reside 
within a homozygous region that is detectable with a high resolution single nucleotide 
polymorphism (SNP) array.17, 18 Mapping of these homozygous regions (homozygosity 
mapping) may lead to the identification of the genetic defect both in consanguineous 
and in non-consanguineous patients, as shown as proof-of-principle in patients with  
autosomal recessive kidney diseases,19 and as a successful method for the detection 
of new disease genes,20-23 and new mutations in known genes implicated in retinal 
dystrophies.24
The goal of this study was to identify and map homozygous regions in a large cohort of 
CRD patients, mainly born of non-consanguineous marriages, and to subsequently identify 
the causal mutations. Using this approach, we identified eight genetic variants, of which  
seven were novel, in four families and four sporadic patients, respectively. All patients 
carrying disease-causing mutations were clinically re-evaluated.
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PATiENTS AND METHODS
P a t ie n t s
A total of 126 probands and 13 affected siblings diagnosed as or suspected to have 
autosomal recessive or isolated CRD were included in this study by ophthalmologists 
from the Netherlands (LIvdB, MMvG, CBH, MJvS), Germany (KR) and Canada (RKK).
The study was approved by the ethical review board of the participating centers, and all 
patients signed an informed consent adhering to the tenets of the Declaration of Helsinki. 
After discovering the genetic defect clinical data were retrospectively reviewed, and 
patients were invited for ophthalmological examination by their  own ophthalmologist. 
Clinical evaluation included best-corrected projected Snellen visual acuity, objective 
refractive error after cycloplegia, biomicroscopy, and fundoscopy. Visual f ields were  
assessed using Goldmann kinetic perimetry (targets V-4e and I-4e). Color vision was  
tested using the American Optical Hardy-Rand-Ritt ler Test (AO-HRR), the Farnsworth 
D-15 Panel (saturated and desaturated) or the Ishihara color plates. Spectral domain 
optical coherence tomography (OCT) and fundus autof luorescence (FAF) imaging 
(Spectralis, Heidelberg Engineering, Heidelberg, Germany) were performed in four 
patients. Fundus photographs were made in all patients.
H o m o z y g o s i t y  m a p p in g
Blood samples for molecular genetic testing were obtained from all probands and 
affected family members. Total genomic DNA was extracted from leukocytes by 
a standard salting out procedure.25 DNA samples of 90 probands, mainly from the 
Netherlands and Germany were screened for known mutations in ABCA4 by the 
ABCA4 arrayed-primer extension (APEX) microarray (Asper Ophthalmics, Tartu, 
Estonia).26 The 46 probands and 13 siblings who did not carry known mutat ions in 
ABCA4, were genotyped on the GeneChip Mapping 250K NspI array (Affymetrix,
Santa Clara, CA), containing 262,000 SNPs. Forty-nine probands, mainly from eastern 
Canada, were included in the study in a later stage, and were not prescreened  
for known mutat ions in ABCA4. These samples were genotyped on the GeneChip 
Genome-Wide Human SNP Array 6.0 (Affymetrix), containing 906,600 polymorphic  
SNPs. Array experiments were performed according to protocols provided by the 
manufacturer. For both array platforms, genotypes were called by Genotype Console 
software (Affymetrix). For 250K-analyzed samples, the default confidence threshold  
was adjusted to 0.3 for samples w ith a quality control value of <93%. All samples 
analyzed on the 6.0 array had a quality control value of >93%, and for those samples 
default settings were used. Regions of homozygosity were determined by PLINK 
software,27 using a sliding w indow  of 50 SNPs, and allowing 2 heterozygous SNPs
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(miscalls) and 10 missing SNPs (no-calls) per w indow. Because the 250K and 6.0 
arrays contain dif ferent SNP densities, we  defined regions to be homozygous when  
they contained 200 or more consecutive homozygous SNPs on the 250K array and 600 
or more consecutive homozygous SNPs on the 6.0 array. The minimal length of the 
regions appeared to be on average ~3 Mb.
A n a ly s is  o f  h o m o z y g o u s  r e g io n s
Homozygous regions were ranked based on the number of SNPs. SNP positions 
were derived from the UCSC human genome browser build hg18, March 2006 (http:// 
genome.ucsc.edu/). All arCRD and autosomal dominant CRD (adCRD) genes residing 
in a homozygous region were selected for mutat ion analysis. We also analyzed all 
autosomal recessive retinal dystrophy genes (derived from RetNet: www.sph.u th .tmc . 
edu/Retnet/) residing in the six largest homozygous regions of each patient or, 
in case of multiple affected siblings, in the six largest homozygous regions shared by 
the siblings. Finally, we  determined overlap of the detected homozygous regions with  
known, published retinal dystrophy loci (RetNet).
S e q u e n c e  a n a ly s is
We selected a total of 15 retinal dystrophy genes for mutation analysis. Six genes 
known to be associated with arCRD and adCRD were analyzed (arCRD genes: ABCA4,
2 patients; ADAM9, 3 patients; CERKL, 3 patients; PROM1, 3 patients. adCRD genes: 
SEMA4A, 2 patients; UNC119, 2 patients). In addition, 9 genes associated w ith other 
retinal dystrophies were screened (CABP4, KCNV2, and RLBP1 each in 2 patients; 
C2orf71, CNGA1, IDH3B, RDH5, RDS, and RP1 each in 1 patient). All coding exons of the 
selected genes were PCR amplified and analyzed in sense or anti-sense direction on 
an automated sequencer (BigDye Terminator, ver. 3 on a 3730 DNA analyzer; Applied 
Biosystems, Inc., Foster City, CA). Primers were designed using Primer3 software.28 
Ethnically matched control individuals were screened for newly identified mutations 
using the ampli f ication-refractory mutation system (ARMS), or restriction fragment 
length polymorphism.29 Primer sequences and PCR conditions are available on request.
RESULTS
P a t ie n t  c o h o r t  a n d  A B C A 4  p r e s c r e e n in g
A total of 126 probands and 13 affected siblings, who received a clin ical diagnosis of 
autosomal recessive or isolated CRD were included in th is study. This cohort included 
ten families w ith two or three affected siblings. Six sporadic CRD patients and one
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T A B L E  1. Overview o f the genes in w hich mutations w ere  detected, 
and the size ranking of the homozygous regions in w h ich  these genes resided.
Retinal
dystrophy gene
Patient or 
fam ily iD 
(# of siblings)
Consanguinity Country (origin)
Ranking of 
region (total # 
of regions)
ABCA4 W00-409 (3) Yes Germany (Iraq) 1st (1)
ABCA4 50417 No Canada (Pakistan) 5th (10)
CABP4 W03-008 (2) No Netherlands 1st (2)
CERKL 50397 No Canada 1st (4)
CERKL 51456 No Canada (French Canadian) 1st (2)
EYS W05-112 (2) No Netherlands 2nd (2)
KCNV2 50222 Yes Netherlands (Morocco) 3rd (16)
PROM1 W02-077 (2) No Netherlands (Greece) 2nd (6)
#, number; *, in case o f m ultip le affected siblings the mean percentage o f the genome that is 
homozygous was calculated.
CRD family were reported to be consanguineous; the remaining patients and families 
were reported to be non-consanguineous. Prescreening of 90 probands, using the 
ABCA4 APEX microarray (Asper Ophthalmics),26 revealed mutat ions in ABCA4 in 31 
patients (1 homozygous, 15 compound heterozygous, and 15 heterozygous), of which  
19 patients have been published previously.4, 7 All patients carrying one or two ABCA4 
mutations were excluded from further research.
H o m o z y g o s i t y  m a p p in g
A total of 59 CRD samples were analyzed for 262,000 SNPs (250K array) and 
49 samples were analyzed for 906,600 SNPs (6.0 array), and homozygous regions 
were determined. Supplemental Table 1 gives an overv iew of the number and sizes 
of the homozygous regions for each individual patient, and the percentage of the 
total genome that was  homozygous.
Significant homozygous regions were identified in 76 (77%) of the non-consanguineous 
CRD patients. The average number of homozygous regions in these patients was
3 (range: 1-10), and the average total length of homozygous regions was 17.5 Mb 
(range: 1.7-83.3 Mb), wh ich corresponds to 0.5% (range: 0.1-2.9%) of the genome. 
Twenty-three (23%) non-consanguineous patients carr ied no signif icant homozygous 
regions. All consanguineous patients carried multiple large homozygous regions;
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Size
(Mb)
% of genome that is 
homozygous (regions 
>~3 Mb)
Homozygous mutations Reference for mutation
27.8 5.7%* c.160T>G; p.C54G Ozgül et al.31
4.2 1.5% c.6729+5_19del15; splice defect This study
8.9 0.9%* c.646C>T; p.Arg216X Littink et al.36
28.4 1.6% c.375C>G; p.C125W This study
10.6 0.5% c.847C>T; p.R283X This study
5.0 0.9%* c.9468T>A; p.Y3156X Collin et al.22
10.9 7.0% c.162C>A; p.Y54X This study
10.4 1.2%* c.1142-1G>A; splice defect This study
on average each patient carried 18 (range: 8-27) homozygous regions, w ith a total 
length of 204.3 Mb (range: 107.3-332.9 Mb), wh ich corresponds to 7.2% of the genome 
(range: 3.8-11.7%).
In affected siblings, we  compared the individual homozygous regions and included  
only those regions that were shared between siblings and displayed the same 
haplotype. In two non-consanguineous families, no shared homozygous regions were  
present. Five families (of wh ich one consanguineous) had one shared homozygous 
region and three families had two shared homozygous regions.
Figure 1 presents an overv iew of all detected homozygous regions sorted by 
chromosome. In these plots, known retinal dystrophy loci, centromeric regions 
(which are less likely to recombine), and common homozygous regions are indicated. 
A common homozygous region was defined as a region of £100 homozygous SNPs 
present in £25% of individuals in a cohort of 144 healthy controls.30 A  small number 
of homozygous regions seem to be shared among four, five or six individuals.
However, when excluding patients who carry mutations in another homozygous 
region, common homozygous regions, and regions close to the centromere, only regions 
shared among a maximum of three patients remain. This indicates that no major novel 
locus for arCRD is detected in this cohort by our homozygosity mapping approach.
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F IG U R E  1 . Chromosom; plots showing homozygous regions identified in 108 patients 
w ith  cone-rod dystrophy.
The chromosomal positions are plotted on the x-axis, and the patientnumbers are displayed 
on the y-axis. Centrom eric positions and retinal dystrophy loci are indicated in  the lower part 
o f each plot, and the chromosomal position o f retinal dystrophy genes are indicated at the top 
o f each plot.
W xx -xxx  numbers in the y-axis designate homozygous regions that are shared by all affected 
siblings o f a family. Black lines indicate homozygous regions in non-consanguineous patients. 
D otted  lines display homozygous regions in consanguineous patients, and grey lines indicate 
that a m utation was identified in  another homozygous region o f that patient. Black star 
indicates the identification o f a m utation at that position.
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M u t a t io n  a n a ly s is
Mutation analysis of four arCRD genes (ABCA4, ADAM9, CERKL and PROM1) in 
a total of 11 probands (eight sporadic CRD patients and three families) revealed 
sequence variants in seven of them (five sporadic patients and two families; Table 1). 
Screening of 9 other retinal dystrophy genes in a total of 12 probands, led to the 
identif ication of novel homozygous mutat ions in one sporadic patient (KCNV2), 
and in one family (CABP4) (Table 1).
Homo sapiens 5 
Pan troglodytes 5 
Cams lupus fam iliaris 5
F iG U R E  2 . Evolutionary conservation of the three missense variants detected in ADAM9, 
CERKL and PROM1. The p.C125 residue in  C ERKL shows fu ll conservation up to Danio rerio 
(zebrafish). The p.Q800 in A D A M 9  is fu lly  conserved in at least five o u t o f six residues, and 
the p.S649 residue in  PRO M 1 shows a sim ilar am ino acid in  six out o f seven residues, but both 
appeared to be non-pathogenic.
W h ite  lettered residues on a black background are fu lly  conserved. W h ite  letters on a gray 
background are relatively well-conserved or fo rm  a block o f sim ilar am ino acids. The amino 
acid sequences are aligned using default settings in  Vector N T I  software (Invitrogen, Breda,
The Netherlands). Protein sequences o f CERKL, PRO M 1 and A D A M 9  orthologs were derived 
from  the N C B I database (http ://www.ncbi.nlm .nih.gov/hom ologene). Accession numbers 
o f the protein sequences used for sequence comparison are as follows.
A D A M 9 .
H om o sapiens, NP_003807.1;
Pan troglodytes, XP_519719;
Canis lupus familiaris, XP_532798.2; A D A M 9 p.Q800H
Mus musculus, NP_031430.1;
Rattus norvergicus, NP_001014772.1;
Gallus gallus, NP_001026567.1;
Danio rerio, NP_001107911.1.
CERKL :
H om o sapiens, NP_963842.1;
Pan troglodytes, XP_515955.2;
Canis lupus familiaris, XP_545552.2;
Mus musculus, NP_001041641.1;
Rattus norvergicus, XP_578135.2;
Gallus gallus, XP_421973.2;
Danio rerio, NP_001082943.1.
PROM1:
H om o sapiens, NP_006008.1;
Pan troglodytes, XP_517115.2;
Canis lupus familiaris, XP_545934.2;
Bos taurus, XP_875477.2;
Mus musculus, NP_032961.1;
Gallus gallus, XP_001232165.1;
Danio rerio, NP_001108615.1
FPSRPPPPQPKVSSQGNLIPARPAPAPE
FPSRPPPPQPKVSSQGNLIPARPAPAPE
FPSRPPPPQPKVSSQGNLIPARPAPAPE
YPSRPPPPQPK§S§QGNLVPARPAP§PE
FPSRPPPPQPKISSQGNLIPARPAPAPMus musculus
Danio rerio FFFHuaasaEnoo-PK
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The p.C54G change in ABCA4 (family W04-009) is a known mutation, wh ich was not 
present yet on the 2001 version of the ABCA4 APEX array at the time the patient's 
DNA was screened.31 The other mutation in ABCA4 (c.6729+5_19del15) is new, and 
was not detected in 180 control alleles. This mutation may result in defective splicing, 
since the splice site consensus score decreases from 81.8 to 61.7, as calculated by 
the method of Shapiro &  Senapathy.32
T A B L E  2 . Overview of characteristics o f the m issense variants detected in CRD patients.
Sequence
change
Blosum-
62
score*
Polyphen
SIFT pre­
diction 
(score)t
Grant­
ham 
score t
Segregation
analysis
presence 
in control 
individuals
Conclusion
ADAM9,
c.2400G>T,
p.Q800H
3 Possiblydamaging
Not
tolerated
(0.03)
24
Homozygously 
present in 
unaffected 
brother
Excluded in 
210 Dutch 
alleles§
Not
pathogenic
CERKL,
c.375C>G,
p.C125W
-2 Probablydamaging
Tolerated
(0.08) 215
Homozygously 
present in 
affected 
brother
Excluded in 
200 alleles Pathogenic
PROM1,
c.1946C>T,
p.S649L
-3 Possiblydamaging
Tolerated
(0.14) 145
Both parents 
heterozygous, 
wildtype in 
non-affected 
brother
Present 
homozy­
gously in 
1/90 control 
individuals
Not
pathogenic
*, the more negative the BLO SU M 62 score, the more likely that a variant is pathogenic; t, S IFT 
score o f <0.05 is predicted to be pathogenic; +, Grantham score: > 60 possibly damaging; §, no 
ethnically matched controls available.
A homozygous nonsense mutation (c.847C>T; p.R283X) and a homozygous missense 
mutat ion (c.375C>G; p.C125W) were identified in CERKL, wh ich are both novel.
The missense mutation replaces a cysteine by a tryptophan, wh ich does not occur  
commonly during evolution (BLOSUM62 score -2; Table 2).33 The mutation affects 
a ful ly conserved residue (Figure 2), was also identified homozygously in the patient's 
affected sibling (patient 54684), and was not present in 200 ethnically matched control 
alleles, and is therefore likely to be pathogenic. The novel spl ice site mutation in 
PROM1 (c.1142-1G>A) affects the invariable AG-dinucleotide of the splice acceptor 
site of intron 10, and is predicted to impair splicing. The missense changes in PROM1 
(c.1946C>T; p.S649L) and ADAM9 (c.2400G>T; p.Q800H) both affect highly conserved 
residues (Figure 2). However, the variant in PROM1 was identified homozygously
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in one out of 90 ethnically matched control individuals, and is therefore likely to be 
nonpathogenic. The ADAM9 variant was detected homozygously in an unaffected  
brother, and is therefore likely to be nonpathogenic as well (Table 2).
O v e r la p  w i t h  r e t in a l  d is e a s e  lo c i
One homozygous region in a non-consanguineous Dutch CRD family from this 
cohort overlapped w ith  the RP25 locus, wh ich led to the discovery of EYS and the 
identif ication of a p.Y3156X mutation in the affected siblings. We published this finding 
elsewhere.22 In addition, several other homozygous regions were detected which  
overlapped w ith  previously published retinal dystrophy loci: LCA9, RP22, RP28, RP29, 
RCD1, and most interestingly, the 5.8 Mb CORD8 locus.34- 35 Two CRD patients of this 
study show an overlap w ith  the entire CORD8 locus, a region that harbors more than 
100 genes, of wh ich SEMA4A was excluded as being causative. No other obvious 
candidate genes were identif ied it this region. Since most of the published retinal 
dystrophy loci are very large, overlap w ith one of our homozygous regions might 
be coincidental.
C l in ic a l  f e a t u r e s
All 13 patients from eight families, in whom mutations were identified, underwent 
detailed ophthalmologic examinations. An overv iew of the clinical data is presented 
in Table 3. Nine patients showed clear signs of CRD. Remarkably, four patients from 
three families (two patients w ith mutations in CABP4, one of the patients w ith  EYS 
mutations, and one patient w ith KCNV2 mutations) original ly diagnosed as cone-rod  
dysfunction and therefore entered into th is study, appeared not to be affected with  
CRD. We have described the phenotype of the patients carrying mutations in CABP4 
and in EYS e lsewhere.22- 36 The fourth patient, carrying a homozygous KCNV2 mutation, 
initially received the diagnosis CRD. However, addit ional ERG testing at the age of
11 showed supernormal and delayed rod responses and decreased cone responses, 
characteris t ic  for cone dystrophy w ith supernormal rod responses (RCD3; OMIM  
entry 610024). The detection of the novel p.Y54X mutat ion in KCNV2 confirmed the 
corrected diagnosis, since this phenotype is specif ically associated w ith mutations  
in KCNV2.37
The remaining patients showed the typical signs of CRD, w ith  a w ide range of 
phenotypic features and severity. Visual acuity ranged from 20/50 at age 48 in patient 
50397 (CERKL, p.C125W) to light perception (LP) at age 53 in patient 51456 (CERKL, 
p.R283X). All patients experienced color vision abnormalit ies, central defects of the 
visual field on Goldmann perimetry, and -  when measurable -  more decreased cone
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TABLE 3. C lin ica l features of patients in w hich  a genetic defect w as identified.
Patient iD
(family
number)
Gene defect
Age 
Age of 
(yrs) diag­
nosis
Visual
acuity
(best
eye)
Color
vision
Goldmann
perimetry ERG, rodt
ERG,
conet
CRD patients
16875
(W00-409) 17 15 20/200
Diffuse
errors
Small central 
scotoma Sub-normal NR
Diffuse
16876
(W00-409)
ABCA4,
p.C54G 15 14 20/400
errors,
mostly
protan
axis
Large central 
scotoma u
16877
(W00-409) 13 8 20/300
Diffuse
errors NP u NR
50417 ABCA4,
c.6729+5_19del15 48 30 20/400 Abnormal
Central 
scotoma and 
decreased 
sensitivity
NR NR
50397
(W09-0340)
CERKL,
48 30 20/50 Abnormal Centralscotoma u u
p.C125W
54684
(W09-0340) 51 28 3/400 Abnormal
Central
scotoma NR NR
51456 CERKL,
p.R283X 53 29 LP NP
Not
measurable NR NR
20695
(W02-077)
PROMT,
18 13 20/200 Severelydisturbed
Substantial
central
scotoma
u NR
20696
(W02-077)
c.1142-1 G>A
16 9 20/125 Severelydisturbed
Central 
scotoma with 
relative ring 
scotoma
NR NR
Patient affected by cone dystrophy w ith  supernormal rod ERG responses
50222 KCNV2, p.Y54X 11 10 20/32 Moderatelydisturbed Normal T, delayed 1
t, isolated rod response; +, single flash cone response; reduced; severely reduced; ? , supernormal; 
LP, light perception; NR, no responses; NP, not performed; RPE, retinal pigment epithelium.
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T A B L E  4 . Overview of fundoscopy, autofluorescence imaging and spectral domain OCT 
of CRD patients.
Patient iD
(family
number)
Gene defect Fundoscopy Autofluorescence Spectralis OCT
16875
(W00-409)
Central glittering 
maculopathy and 
some peripheral 
fishtail pigment 
clusters
NP NP
16876
(W00-409)
ABCA4,
c.160T>G,
p.C54G
Central glittering 
maculopathy and 
some peripheral 
fishtail pigment 
clusters
NP NP
16877
(W00-409)
Granular macular 
changes with 
irregular RPE
NP NP
50417
ABCA4, 
c.6729+5_ 
19del15, splice 
defect
Advanced
pigmentary
maculopathy
Striking macular 
absence of FAF
Loss of the IS-OS 
junction, massive debris 
accumulation between 
the retina and RPE, 
retinal thickening and 
foveal thinning
50397
(W09-0340)
CERKL,
Peri-foveal atrophy 
with a central RPE 
island
Striking macular 
absence of FAF with 
remaining central 
island
Single retinal single cyst 
formation
54684
(W09-0340)
c.375C>G,
p.C125W Advanced foveal and macular atrophy, 
choroidal show 
and sclerosis in the 
macula
Striking macular 
absence of FAF
Extensive retinal 
remodeling, severe 
diffuse retinal thinning 
to 1-2 layers
51456
CERKL,
c.874C>T,
p.R283X
Choroidal show 
and sclerosis in the 
macula
Striking macular 
absence of FAF RPE thinning
20695
(W02-007)
PROMT, 
c.1142-1 G>A, 
splice defect
Central atrophic 
lesions in the macula, 
severely attenuated 
retinal vessels
NP NP
20696
(W02-007)
Discrete central 
atrophy in the 
macula, severely 
attenuated retinal 
vessels, granular 
pigmentation in 
periphery
NP NP
FAF, fundus autofluorescence; IS-OS, inner segment-outer segment; NP, no t performed; RPE, retinal 
pigment epithelium.
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Patient 50417 Patient 50397 Patient 54684 Patient 51456 Patient 20695
ABCA4, c.6729+5_19del 15 CERKL, c.375C>G; p.C125W CERKL, c.375C>G; p.C125W CERKL, c.847C>T; p.R283X PROM1. c.1142-1G>A
F IG U R E  3 . fundus photographs, autofluorescence and spectral domain (spectra lis) ocT 
images o f cRD patients w ith  conclusive genetic defects. (See appendix for color figure)
The retina o f patient 50417 (ABCA4, c.6729+5_19del15; age 44) shows (A) extensive retinal pigment 
epithelium (RPE) cell loss, choroidal sclerosis and pigmentary macular changes on fundoscopy 
(B) marked loss o f central lipofuscin accumulation on fundus autofluoresence (FAF), and (c) a 
disorganized retina in which the six layers are not detectable, the fovea is extremely thin, w ith  loss o f 
the inner/outer segment junction. Extensive debris accumulation is noted. Patient 50397 (CERKL, 
p.C125W; age 48) has (D) a pigmentary maculopathy w ith  choroidal sclerosis, (E) absence o f central 
FAF, except in a tiny island, indicating nearly complete loss o f lipofuscin deposition, and (F) very 
extensive retinal remodeling and an unusual subretinal cystic structure in the fovea. His older brother 
(54684, age 51), although carrying the same mutation in CERKL, has (G) extensive retinal, RPE and optic 
disc atrophy and sclerosis, (H) loss o f central FAF, w ith  a peculiar salt and pepper pattern o f FAF outside 
the central retina, and (i) thinning and disorganization o f the retina. A  CERKL nonsense mutation 
(p.R238X) in patient 51456 (age 53) resulted in (J) extensive choroidal sclerosis, (K) loss o f FAF, and 
(L) retinal remodeling w ith  loss o f inner/outer segment junction. The retina o f patient 20695 (PROM1, 
c.1142-1G>A; age 18) showed (M) central atrophic lesions in the fovea and severely attenuated retinal 
vessels. N o  autofluorescence and spectral domain O C T  images were available for this patient.
than rod responses. Fundus photographs, spectral domain OCT and FAF images 
of selected patients are presented in Figure 3, and described in Table 4.
In summary, macular appearances ranged from subtle RPE changes (PROM1) to 
pronounced atrophy of the RPE and choriocapil laris (CERKL). FAF showed an absence 
of auto fluorescence in the macula in most of the patients. In vivo retinal architecture  
performed by spectral domain OCT, showed a variety of patterns, ranging from severe 
retinal thinning (CERKL) to th ickening (CERKL), loss of architecture (ABCA4), cysts 
(CERKL) and accumulation of subfoveal hyper-reflective debris (ABCA4).
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DiSCUSSiON
Homozygosity mapping in 95 probands and 13 affected siblings revealed significant 
homozygous regions in 77% of non-consanguineous patients and in all consanguineous 
patients, and led to the identification of the causative genetic defect in six non- 
consanguineous probands, and in two consanguineous probands. The percentage 
of homozygous regions in non-consanguineous patients seems to be high compared 
to other studies, in which homozygous regions were detected in 5-52% of patients from 
outbred populations.24- 38- 39 This could be explained by the less stringent software settings 
were used to avoid false-negative regions. In addition, the cutoff for minimum length of 
homozygous regions varies among different studies. Genotyping studies in large cohorts 
show that individuals from outbred populations commonly carry homozygous regions, 
although they are usually shorter than those in individuals from isolated populations.17, 40
In all patients in whom a mutation was detected, the retinal phenotypes were  
reassessed. The mutations residing in ABCA4, PROM/, and CERKL, all previously 
associated w ith CRD,4, 9 10 indeed caused a CRD phenotype, although w ith  variable 
characteris tics. Three siblings carrying mutations in ABCA4 and two siblings with  
PROM1 mutations showed a decrease in visual acuity during childhood (8-15 years  
of age), wh ich is consistent w ith  the previously described ABCA4 and PROM/-related  
phenotypes.9, 41 One patient (50417) carrying a defective splice site in ABCA4 had 
a later age of onset at 30 years of age, wh ich suggests that this mutat ion could have 
a moderately damaging effect on the protein. The three patients carrying mutations 
in CERKL had an age of onset around the age of 30 as well , but their  visual acuity 
around the age of 50 differed considerable, even in the two brothers carrying the 
same mutation (20/50 at age 48, and 3/400 at the age of 51, respectively, and light 
perception at age 53 in the third patient). A  w ide variety of visual acuit ies in CRD 
patients w ith CERKL mutations, were described by Aleman et al. as we l l .10
A variabil ity in retinal and macular appearances, retinal OCT findings and FAF 
patterns was noted, even for the same gene in different families (Figures 3D-3I versus  
3J-3L) and the same mutation in the same family (Figure 3D-3F versus 3G-3I). A  variety  
of maculopathies were documented, w ith  geographic atrophy, choroidal show and 
sclerosis, and hyperpigmentations. Detailed OCT studies revealed retinal remodeling, 
loss of retinal layers, debris accumulation between the retina and RPE, single cysts, 
a subretinal cystic structure, and foveal thinning. Finally, FAF showed a complete  
absence of auto fluorescence in the macular region in most patients, suggesting 
integral RPE- and photoreceptor loss. Documenting structural (OCT) and functional 
(FAF) disease patterns in genotyped patients are crucial for future therapeutic trials
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and deciding the appropriate therapeutic  modalit ies for the genotyped patients 
(gene replacement and drug trials in relatively intact retinas versus cell replacements  
in relatively destroyed maculas) but also for refining the clin ical diagnosis and the 
visual prognosis.
Interestingly, one patient w ith  EYS mutations was  diagnosed as CRD, but her brother 
received the diagnosis RP. Mutat ions in EYS have been shown to be causative for 
~5-12% of arRP cases, while no mutations were found in additional CRD patients.42'45 
EYS is therefore not a frequent cause of CRD. The clinical diagnoses of the patients 
carrying mutations in CABP4 and KCNV2 were revised to congenital cone-rod  
synaptic disorder and cone dystrophy w ith supernormal rod responses, 
respectively.36, 37, 46 These revisions illustrate the complexity of diagnosing retinal 
dystrophies, the signif icant clinical overlap of genetically dis tinct disorders and 
the power and utility of molecular genetic testing.
Overall, the percentage of CRD cases that can be attributed to each gene in this 
cohort is ~1 % for PROM1 (1/123), ~2 % for CERKL (2/123), and ~27 % for ABCA4 
(33/123), wh ich is consistent w ith previous publications.4-7- 9 10 We identif ied EYS 
mutations in 1% (1/123) of the CRD patients, but no other mutations in CRD patients 
were identified in other studies.42- 43 The percentages include patients in which  
homozygous and heterozygous ABCA4 mutations were detected by APEX screening. 
For these calculations, we excluded the four patients in wh ich other clinical 
diagnoses were established.
Which patients are most suitable for mutat ion detection by homozygosity mapping? 
Gibson et al. showed that long homozygous segments are common in unrelated 
individuals from the HapMap database.40 However, long and numerous homozygous 
segments usually indicate parental rela tedness.17- 18 Also, the average genome-wide  
homozygosity in non-consanguineous patients of the entire cohort was  0.5% (0-2.9%), 
while the average was 1.06% (0.5-1.6%) in patients in whom homozygous mutations 
were identified. Although Carothers et al.47 showed that the percentage of 
homozygosity is unreliable in predicting the relatedness, our data suggest that the 
chance to find a homozygous mutation is higher in patients w ith a high percentage  
of homozygosity. A  better estimate to determine the chance to find a homozygous 
defect is to know the family origin. In at least four of our patients, the paternal and 
maternal grandparents originated from the same geographical region; one family from 
a province in Greece, one from the south-west of the Netherlands, one from the east 
of the Netherlands, and one family originated from the French-Canadian founder 
population. Therefore, detailed information about the origin of grandparents of
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a patient is desired when considering whether homozygosity mapping w il l be effic ient  
in identifying a genetic defect in a particular patient. Furthermore, for four out of eight 
probands in wh ich the genetic defect was  identified one or more affected siblings 
were available for homozygosity mapping.
In agreement w ith  a previous study by Woods et al.,48 families w ith  two or more 
affected siblings are the most powerfu l to pinpoint the homozygous region containing  
the mutation.
The homozygosity data generated in this study are likely to be a valuable resource for 
the detection of novel disease genes. The discovery of the EYS gene in a family of this 
cohort, for example, shows how relatively small homozygous regions in non- 
consanguineous families can fine map the causative locus and thereby facil itate the 
identif ication of a new causative gene. Moreover, th is type of data may be valuable 
now that "next generation sequencing" is emerging, wh ich enables the screening  
of all genes with in a homozygous region in one experiment.49
In conclusion, th is study shows that homozygosity mapping can lead to the 
identif ication of novel genetic defects in consanguineous as well as non- 
consanguineous families. Our results show that many more CRD genes may exist. 
Finding them and identifying the associated detailed phenotypes wil l provide more 
insight into patients suitable for gene-specif ic therapies.
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SUPPLEMENTAL DATA
S U P P L E M E N T A L  T A B L E  1 . Overview of genomic homozygosity information for each patient.
N Q N - C O N S A N G U iN E Q U S  P A T I E N T S
Patient iD Country
(origin)
Maximum 
number of 
consecutive 
homozygous 
SNPs
Size of 
region 
w ith 
largest 
amount of 
SNPs (Mb)
Number
of
regions
Total
homo­
zygous
tract
length
(Mb)
% of 
genome 
(>~3 Mb) 
covered by 
homozygous 
segments
Genetic
defect
250K SNP array
8577 Netherlands 210 2,9 1 2,9 0,1
9052 Netherlands 247 3,3 2 5,5 0,2
9554 Germany 376 3,0 1 3,0 0,1
9661 Germany 0 0 0 0 0
9979 Germany 230 3,1 5 11,6 0,4
12734 Germany 264 2,2 2 4,2 0,1
13165 Germany 0 0 0 0 0
13166 Germany 254 2,4 4 8,2 0,3
13340 Germany 205 2,1 2 4,4 0,2
13421 Germany 987 9,9 6 29,3 1,0
14751 Germany 271 1,7 1 1,7 0,1
14963 Germany 337 2,5 4 9,2 0,3
14967 Germany 295 3,0 2 5,0 0,2
15102 Germany 360 4,5 1 4,5 0,2
15930 Germany 242 2,5 6 12,7 0,4
16599 Germany 263 5,1 4 11,3 0,4
16754 Germany 249 2,1 1 2,1 0,1
16755 Germany 228 2,2 3 7,6 0,3
16896 Germany 472 7,4 2 7,4 0,3
16897 Germany 207 2,5 2 4,5 0,2
17579 Germany 328 3,9 1 3,9 0,1
17580 Germany 542 6,6 2 9,4 0,3
18429 USA 292 4,7 8 25,3 0,9
20760 Germany 0 0 0 0 0
20761 Germany 0 0 0 0 0
20885 Netherlands 259 2,8 4 9,9 0,3
20888 Germany 0 0 0 0 0
20945 Netherlands 239 2,8 1 2,8 0,1
21480 Netherlands 1781 17,7 3 32,8 1,2
21511 Netherlands 554 5,9 2 7,9 0,3
21761 Netherlands 249 3,7 1 3,7 0,1
21814 Germany 850 16,4 5 26,4 0,9
23347 Netherlands 320 3,0 3 6,8 0,2
28837
35029
Netherlands
Netherlands
(Suriname)
1192
258
9,0
1,6
4
2
19,4
4,1
0,7
0,1
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Patient iD Country Maximum Size of Number Total % of
(origin) number of region of homo- genome
consecutive w ith regions zygous (>~3 Mb)
homozygous largest tract covered by
SNPs amount of length homozygous
sNps (Mb) (Mb) segments
Genetic
defect
6.0 SNP array
40964 Netherlands 1098 4,9 1 4,9 0,2
42024 Netherlands 1744 6,2 1 6,2 0,2
42297 Canada 0 0 0 0 0
43442 Netherlands 1066 5,0 1 5,0 0,2
50387 Canada 0 0 0 0 0
50388 Canada 0 0 0 0
50389 Canada 3132 11,2 3 19,9 0,7
50390 Canada 972 3,4 3 7,7 0,3
50391 Canada 5675 22,2 5 55,2 1,9
50392 Canada 0 0 0 0 0
50393 Canada 4210 12,5 7 43,6 1,5
50394 Canada 0 0 0 0 0
50396 Canada 888 3,1 2 6,5 0,2
50397 Canada 7745 28,4 4 44,7 1,6
50398 Canada 4746 14,8 9 59,8 2,1
50399 Canada 0 0 0 0 0
50400 Canada 0 0 0 0 0
50401 Canada 2673 10,6 1 10,6 0,4
50402 Canada 0 0 0 0 0
50403 Canada 0 0 0 0 0
50404 Canada 0 0 0 0 0
50405 Canada 0 0 0 0 0
50406 Canada 0 0 0 0 0
50407 Canada 9002 19,9 6 65,2 2,3
50408 Canada 5941 20,2 5 55,4 1,9
50409 Canada 0 0 0 0 0
50410 Canada 744 2,8 1 2,8 0,1
50411 Canada 2088 4,3 1 4,3 0,2
50412 Canada 4734 16,3 2 25,2 0,9
50413 Canada 0 0 0 0 0
50414 Canada 684 2,0 1 2,0 0,1
50416 Canada 1936 8,4 7 28,3 1,0
50417 Canada 2810 9,5 10 43,9 1,5
50424 Canada 4084 13,8 5 26,3 0,9
50425 Canada 0 0 0 0 0
50427 Canada 0 0 0 0 0
50429 Canada 3028 6,7 1 6,7 0,2
50430 Canada 3881 10,4 7 28,9 1,0
50431 Canada 860 1,8 1 1,8 0,1
50503 Netherlands 906 2,7 1 2,7 0,1
CERKL; c.375C>G; 
p.C125W
ABCA4, c.6729+5_ 
19del15; splice defect
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Patient ID Country
(origin)
Maximum 
number of 
consecutive 
homozygous 
SNPs
Size of 
region 
w ith 
largest 
amount of 
SNPs (Mb)
Number
of
regions
Total
homo­
zygous
tract
length
(Mb)
% of 
genome 
(>~3 Mb) 
covered by 
homozygous 
segments
Genetic
defect
51453
Canada
(Middle
East)
0 0 0 0 0
51454
Canada
(French
Canadian)
1564 5,0 2 9,6 0,3
51455
Canada
(French
Canadian)
0 0 0 0 0
51456
Canada
(French
Canadian)
3097 10,6 2 14,3 0,5
CERKL;
c.847C>T;
p.R283X
C O N S A N G U IN E O U S  P A T IE N T S
Patient iD Country
(origin)
Maximum 
number of 
consecutive 
homozygous 
SNPs
Size of 
region 
w ith 
largest 
amount of 
SNPs (Mb)
Number
of
regions
Total
homo­
zygous
tract
length
(Mb)
% of 
genome 
(>~3 Mb) 
covered by 
homozygous 
segments
Genetic
defect
250K SNP array
20780 Germany 2068 16,5 19 158,0 5,5
6.0 SNP array
50222 Netherlands 11970 32,1 16 198,7 7,0
KCNV2,
c.162C>A;
p.Y54X
50415 Canada 8438 29,6 27 332,9 11,7
50434 Canada 7209 19,3 20 164,5 5,8
51452 Canada(Italy) 10373 30,8 21 247,8 8,7
51457
Canada
(Middle
East)
9178 33,7 21 246,8 8,7
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N O N - C O N S A N G U IN E O U S  F A M iL I E S
Patient ID Country Maximum Size of Number Total % of Genetic
(origin) number of region of homo- genome defect
consecutive w ith regions zygous (>~3 Mb)
homozygous largest tract covered by
SNps amount length homozygous
of SNPs (Mb) segments 
(Mb)
250K SNP array
W97-037,
overlap Netherlands 0 0 0 0 0,0
9007 223 2,5 1 2,5 0,1
9033 252 3,9 2 6,3 0,2
11253 218 2 1 2 0,1
W98-057,
overlap Netherlands 0 0 0 0 0,0
9519 1374 13,4 3 25,2 0,9
13753 560 6 6 21,4 0,8
W00-107,
overlap Germany 236 5,3 1 5,3 0,2
14746 241 3,3 2 8,6 0,3
14747 238 5,3 1 5,3 0,2
W00-237,
overlap Germany 209 3,0 1 3,0 0,1
15732 274 3,6 6 15,2 0,5
15733 246 2,1 3 9,1 0,3
W00-391,
overlap Germany 592 4,7 1 4,7 0,2
21096 592 4,7 2 6,7 0,2
21097 1767 15,2 6 36,6 1,3
21098 1566 13,7 3 20,6 0,7
W00-426,
overlap Germany 2156 20,8 1 20,8 0,7
15104 3574 24,0 7 83,3 2,9
20963 3280 31,4 6 50,0 1,8
W02-077,
overlap Greece 2037 16,1 2 26,5 0,9
20965 2646 20,7 3 34,4 1,2 PROMT,
20966 2037 16,0 2 32,0 1,1 c.1142-1G>A; splice defect
W03-008,
overlap Netherlands 538 11,3 2 15,7 0,5
20867 790 5,6 8 33,0 1,2 CABP4,
20868 539 11,3 3 17,3 0,6 c.646C>T;p.Arg216X
W05-112,
overlap Netherlands 689 6,6 2 16,8 0,6
26323 695 10,3 4 25,7 0,9 EYS;
26836 694 6,7 4 26,0 0,9 c.9468T>A;p.Y3156X
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C O N S A N G U IN E O U S  F A M I L Y
Patient iD Country 
(origin)
Maximum 
number of 
consecutive 
homozygous 
SNPs
Size of 
region 
w ith 
largest 
amount of 
SNPs (Mb)
Number
of
regions
Total
homo­
zygous
tract
length
(Mb)
% of 
genome 
(>~3 Mb) 
covered by 
homozygous 
segments
Genetic
defect
250K SNP array
W00-409 Iraq 2850 28,3 1 28,3 1,0
16875 4003 38,1 12 166,5 5,8 ABCA4,
16876 3573 35,9 17 216,0 7,6 c.160T>G;
16877 3278 32,9 8 107,3 3,8 p.C54G
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I l l

a b s t r a c t
p u r p o s e . The purpose of th is study was to identify the causative gene defect  
in two siblings w ith  an uncharacterized cone-rod dysfunction and to describe the 
clin ical characteristics.
m e t h o d s  . Genome-wide homozygosity mapping, w ith a 250K SNP-array fo llowed  
by a search for candidate genes, was performed. The patients underwent ophthalmic  
examination, including elaborate electroretinography.
RESULTS. In a Dutch sib pair, a shared 9-Mb homozygous region was found on 
11q13.1-q13.5 that encompasses the CABP4 gene, previously implicated in autosomal 
recessive incomplete congenital stationary night blindness (CSNB2) in two small 
families. A  novel homozygous p.Arg216X mutation in CABP4 was detected in 
the sib pair. Quantitative RT-PCR on RNA isolated from patient lymphoblast cells 
showed no nonsense mediated degradation of mutant CABP4 mRNA. Clinically, 
patients presented w ith reduced visual acuity, photophobia, and abnormal color 
vision, but they did not experience night blindness. Electroretinograms showed 
electronegative mixed rod-cone responses and severely reduced cone responses, 
as in CSNB2. Isolated rod responses, however, were (sub)normal.
CoNCLUSioNS. A novel homozygous nonsense mutat ion in CABP4 in two  
siblings resulted in a phenotype w ith  severely reduced cone function and only 
negligibly reduced rod function on electroretinography and psychophysical 
testing. Since these patients and two of three previously described patients 
do not experience night blindness, the name CSNB2 is confusing for patients 
as wel l as clinic ians. Therefore, the authors propose to name the phenotype 
congenital cone-rod synaptic disorder.
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ín t r o d u c t ío n
CABP4(C a lc ium -B ind ing  p ro te in  4) has re ce n tly  been d e sc rib ed  in assoc ia tion  
w ith  au tosom a l re cess ive  in com p le te  congen ita l s ta tio n a ry  n ig h t b lindness  (CSNB2).1 
CSNB is a nonp rog re ss ive  re tina l d is o rd e r cha ra c te riz e d  by im pa ired  n ig h t vis ion , 
m yopia o r hype rop ia , nys tagm us, and reduced  v isua l acu ity , w ith  a w id e  in tra - and 
in te r fam ilia l va ria b ility . A ll m odes o f M ende lia n  in h e rita n ce  have been d esc rib ed  fo r  
th is  d isorde r. The genes a ssoc ia ted  w ith  CSNB encode  d iffe re n t com ponen ts  o f the  
pho to tra n sdu c tio n  cascade  o r p ro te in s  invo lved in s igna ling  from  ph o to re ce p to r to  the  
a d ja cen t b ipo la r ce lls .1-11 M o s t pa tien ts  w ith  CSNB (X -linked  and au tosom a l recess ive )  
have a c h a ra c te r is tic  e le c tro n ega tive  e le c tro re tin o g ram  (ERG) (S chube rt-B o rn sche in  
type ) -  th a t is, a nea r-no rm a l a -w ave  and a sub s ta n tia lly  reduced  b -w ave  -  on te s tin g  
unde r s co to p ic  con d it io n s .12 The X -lin ked  type  o f CSNB w a s  fu r th e r subd iv ided  by 
M iyake  et a l.12 in to com p le te  CSNB (CSNB1) and in com p le te  CSNB (CSNB2), based  
on d iffe re n ce s  in e le c trophys io lo g y . In CSNB1 (O M IM  310500), no res idua l rod fu n c tio n  
is de te c ted . In CSNB2 (O M IM  300071) the  rod con trib u tio n  to  the  s co to p ic  b -w ave  
is reduced  bu t re co rdab le . A t a 30-Hz f l ic k e r  s tim u la tio n , am p litudes  are ove ra ll 
dec reased , bu t th e y  in c rease  in tim e  w ith  a c h a ra c te r is tic  doub le -p ea k  appea rance  
(w ave  sepa ra tio n  phenom enon ).13 M iya ke  et a l.12 sugges ted  d is tin c t pa thogen ic  
m echan ism s fo r the  d iffe re n t fo rm s  o f CSNB, w h ic h  w a s  con firm ed  by th e  id e n tif ica tio n  
o f th e  m o le cu la r causes o f CSNB. For CSNB1 m u ta tions  in NYX (M IM  300278)7 w e re  
id e n tif ie d  in pa tien ts  w ith  the  X -lin ked  fo rm  and m u ta tions  in GRM6 (M IM  604096)9 14 in 
pa tie n ts  w ith  the  au tosom a l re cess ive  fo rm . Pa tien ts  w ith  m u ta tions  in GRM6 and NYX 
can be d is tin gu ished  c lin ic a lly  by a c h a ra c te r is tic  pa tte rn  a t a 15-Hz f l ic k e r s tim u la tio n .14 
X -lin ked  CSNB2 is caused  by m u ta tions  in CACNA1F (M IM  3001 10),6 w h ic h  encodes  
th e  L-type v o lta g e -d ependen t ca lc ium  channe l 1.4 (Cav1.4).15 In tw o  sm all fam ilie s  w ith  
a CSNB2-like pheno type  and an au tosom a l re cess ive  mode o f in h e rita n ce , Ze itz et a l.1 
re ce n tly  id e n tif ie d  m u ta tions  in th e  CABP4 gene (M IM  608965), w h ic h  encodes  the  
ca lc ium  b ind ing  p ro te in  CaBP4. CaBP4 co lo ca lizes  and in te ra c ts  w ith  Cav1.4 in both  
cone  and rod p h o to re cep to r synap tic  te rm in a ls , th e re b y  regu la ting  th e  ca lc ium  in flux  
in the  pho to recep to r. Pa tien ts  ca rry in g  m u ta tions  in CACNA1F and CABP4 show  
a com pa rab le  pheno type . A  tru e  geno type -pheno type  c o rre la tio n  fo r CABP4 has 
no t been es tab lished  ye t, s in ce  on ly  th re e  pa tie n ts  have been d e sc r ib e d .1 
In th is  a r tic le , w e  p resen t tw o  s ib lings , ca rry in g  a nove l hom ozygous nonsense  
m uta tion  in CABP4, w ith  an ERG sugges tive  o f CSNB2 bu t w ith  nea rly  no rm al rod 
fu n c tio n  and no n ig h t b lindness . W e show  s im ila r it ie s  be tw een  th is  pheno type  and 
o th e r d is o rde rs  in fluenc ing  p h o to re ce p to r synap tic  ca lc ium  channe ls  and propose  
to  add th is  d is o rd e r to  a nove l spec trum  o f ca lc ium  channe lopa th ie s .
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SUBJECTS A n d  METHoDS
P a t ie n t s
Two a ffe c te d  s ib lin g s  w e re  c lin ic a lly  and g e n e tic a lly  exam ined . B lood  sam p les  w e re  
o b ta in e d  from  p a tie n ts  and th e ir  pa ren ts . In fo rm ed  con se n ts  s igned  by th e  pa ren ts  
w e re  o b ta in e d  a cco rd in g  to  the  te n e ts  o f th e  D e c la ra tio n  o f H e ls ink i and th e  p ro to co l 
w a s  app ro ved  by th e  e th ic s  com m itte e s  o f The R o tte rdam  Eye H osp ita l and the  
Radboud U n ive rs ity  N ijm egen  M e d ic a l Centre . C lin ica l a ssessm en t in c lu d e d  best 
c o r re c te d  v isu a l a cu ity , re fra c tiv e  e rro r, s lit lam p e xam ina tio n , fu n d u s co p y , k in e tic  
G o ldm ann p e rim e try  ( ta rg e ts  V -4e and I-4e), c o lo r v is io n  te s ts  ( Is h ih a ra  Test fo r  
C o lo r B lin dness , A m e r ic a n  O p tica l H a rd y -R and -R itt le r Test (AO-HRR), F a rnsw o rth  
Pane l D15 Test) and d a rk  a d a p tom e try  (G o ldm ann -W eeke rs  d a rk  adap tom e te r). 
E le c tro re tin o g ram s  (ERGs) w e re  re co rd ed  a c c o rd in g  to  a p re v io u s ly  d e sc rib ed  
p ro to c o l.12 For the  s ta n da rd  ISCEV ERG m ea su rem en ts ,16 X enon  tu b e  fla shes  
(du ra tion  <10 ps) w e re  de live red  in a Ganzfe ld (Color Dome; D iagnosys, L ittle ton , MA). 
The 15-Hz p ro to co l w a s  re co rd ed  in te rm ixe d  w ith  th e  s ta n da rd  ISCEV ERG 
a t th e  a p p ro p r ia te  in te n s itie s , us ing  LED fla s h e s  o f 4 ms du ra tio n .
H o m o z y g o s i t y  m a p p in g
Tota l genom ic  D NA w a s  e x tra c te d  from  EDTA -trea ted  b lood  sam p les  by using  
s ta nda rd  p ro c e d u re s .17 D N A  sam p les  fo r SNP ana lys is  w e re  geno typed  fo r  262,000 
SNPs (GeneChip M app in g  250K NspI a rra y ; A ffym e tr ix , Santa C lara , CA). A rra y  
e xpe r im en ts  w e re  pe rfo rm ed  a cco rd in g  to  p ro to co ls  p rov id ed  by th e  m anu fa c tu re r. 
The 250K SNP geno types  w e re  ana lyzed  w ith  th e  s o ftw a re  p a ckage  CNAG ,18 and  
ch rom osom a l segm en ts  w e re  a cce p te d  as hom ozygous  if th e  lo s s -o f-h e te ro z yg o s ity  
(LOH) sco re  w a s  >15, w h ic h  c o rre sp o n d s  w ith  an a rea  o f >200 SNPs.
S e q u e n c e  a n a ly s is
A ll six cod ing  exons, a noncod ing  exon and the  in tron /exon boundaries  o f the  CABP4 
gene (NM_145200), w e re  am p lified  by po lym erase cha in  reac tion  (PCR). Genom ic PCR 
w a s  pe rfo rm ed in 50 pL vo lum es con ta in ing  100 ng genom ic DNA, 0.2 mM o f each p rim er 
(Table 1), 2 m M  M gC l2, 1 m M  dNTPs, PCR bu ffe r p rov ided by the  m anu fac tu re r, and 5 U 
Taq po lym erase (Inv itrogen , Breda, The Nethe rlands). PCR reac tions  w e re  pe rfo rm ed as 
fo llow s : 92°C (3 m inutes); cyc le s  w ith  a dena tu ra tion  at 95°C (30 seconds), an annealing  
tem pe ra tu re  o f 68°C (3 cyc les), 66°C (3 cyc les), 64°C (3 cyc les), 62°C (31 cyc les; 30 
seconds) and an e longa tion  at 72°C (45 seconds); and a fina l extension at 72°C (5 m inutes). 
PCR p roduc ts  w e re  pu rified  (Qia Q u ick Gel Extraction Kit; Q iagen, Venlo, The Netherlands) 
acco rd ing  to  the  m anu fac tu re r's  p ro toco l and analyzed in sense and an ti-sense d irec tions
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with dye termination chemistry (BigDye Terminator, version 3 on a 3730 DNA analyzer; 
Applied Biosystems, Inc., Foster City, CA). The control panel included 300 alleles from 
ethnically matched unrelated unaffected individuals and were screened for the c.646C>T 
mutation, detected in this study, using the Amplification-Refractory Mutation System 
(ARMS)19 (Table 1). Furthermore, 71 patients with cone-rod dystrophy and 14 with cone 
dystrophy were screened for mutations in CABP4. DNA of 79 of these patients had been 
screened before for known ABCA4 mutations with the ABCA4 arrayed-primer extension 
microarray (Asper Ophthalmics, Tartu, Estonia).20 In 62 patients, known ABCA4 mutations 
were excluded, whereas in 17 patients, one mutation in ABCA4 was detected.
C e ll c u l t u r e
Human B-lymphocytes were immortalized by transformation w ith the Epstein- 
Barr virus according to established procedures.22 Epstein-Barr virus transformed  
lymphoblastoid cell lines (EBV-LCLs) of the patients and controls were grown to 
a density of 0.7 million cells per mil lil iter RPMI 1640 medium (Invitrogen-Gibco,
Breda, The Netherlands) containing 10% (vol/vol) fetal calf  serum (Sigma-Aldrich,  
Zwijndrecht, The Netherlands), 1% penic il lin-streptomycin (Invitrogen-Gibco), and 
1% cell culturing medium (GlutaMAX; Invitrogen-Gibco). Thirty-f ive million cells
T A B L E  1. Primers used fo r molecular studies of CABP4
Procedure Sequence ( 5 '^  3') Product size
Gene and exon Forward Reverse (base pair)
Direct DNA sequencing
CABP4 promotor GGCCAGCAGGAAGAGGC GACCCCAAATGGACACTACC 377
CABP4 exon 1 GGGTCCTGAAAGCCAAGG GGTGAGCTGAGCCCAAGG 502
CABP4 exon 2-3 AGGGGATGAAGGAGGAAGG CCACTAGCACCCCGATGG 426
CABP4 exon 4 TTT CTT CCTAGGTGCAGAGC GCTGAGACCTGAGTGAGAGG 299
CABP4 exon 5-6 AGCTGGCTGAGGCTGAGG CTGCTGGGTCTCCATCTCC 554
QPCR
CABP4 exon 3-4 AGGTCTCGCAGCACATCAAG CTCAG CTTTGG GCCTATCAG 81
GUSB AGAGTGGTGCTGAGGATTGG CCCTCATG CTCTAG CGTGTC 80
FTSJ1 CAACTCTTCCAAGGCGTGAC ATCTTCTGGCTCAGCACCTG 80
Sequence ( 5 '^  3')
ARMS primers
Wildtype forward 5'-TGGGGGTGCGAGAGCTGCGCATCGCCTTAC-3'
Mutant forward 5'-TGGGGGTGCGAGAGCTGCGCATCGCCTTAT-3'
Reverse__________________5'-TAGCTGGTAGTGATCTGAACCATCTCTGA-3'________________
Primers were designed using Primer3 software (h ttp ://frodo .w i.m it.edu /cg i-b in /p rim e r3 / 
primer3_www.cgi, provided in  the public domain by the Whitehead Institute, Massachusetts 
Institu te o f Technology, Cambridge, M A ).21
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w e re  ha rve s te d  by c e n tr ifu g a tio n  at 200 g fo r  5 m inu te s  a t room  te m p e ra tu re  and 
re su spended  in 500 ^L 8 m M  N a2HPO4, 2 m M  KH2PO4, 137 m M  NaC l, and 2.7 m M  KCl 
(pH 7.2; PBS). Cell p e lle ts  w e re  sub se q u en tly  s to red  a t -80°C u n til R NA  iso la tion .
Q u a n t i t a t iv e  P C R  a n a ly s is
Tota l RNA w a s  iso la ted  from  EBV-LCLs a cco rd ing  to  the  m anu fa c tu re r's  p ro toco l 
(RNeasy m in ik it; Q iagen). cD N A  w a s  syn thes ized  from  2.0 ^g  o f to ta l RNA using  
random  prim ed hexam ers  (GE H ea lth ca re , H oeve laken , The N e the rlands ) and M ­
M LV  reve rse  tra n sc r ip ta se  (In v itrogen ) in a to ta l vo lum e o f 85 ^L, a cco rd in g  to  the  
m anu fa c tu re r s p ro to co l. P rim er pa irs  (Table 1) w e re  va lid a ted  by se ria l cD N A  d ilu tions , 
syn thes ized  from  Un ive rsa l Human Re fe rence  RNA (S tra tagene , La Jo lla , CA) in 5x 
to  80x d ilu tions , in tr ip lic a te . The p rim e r pa irs  w e re  100% e ff ic ie n t, in th a t th e  am oun t 
o f DNA w a s  doub led  in each cyc le . The PCR cond itio n s  w e re  95°C (3 m inu tes) and  
c yc le s  o f 95°C (15 seconds) and 60°C (30 seconds) in a 25-^L reac tion  m ix con ta in ing  
5 ^L o f cDN A , supe rm ix  (IQ SYBR G reen; B io-Rad, H ercu les , CA), and 0.3 ^M  o f each  
primer. For th e  ac tua l qPCR expe rim en t, cD N A  w a s  d ilu ted  tw ic e  to  make su re  th a t the  
th re sho ld  c yc le s  (Ct) w e re  w ith in  the  range o f the  d ilu tion  curve . qPCR re ac tio n s  w e re  
pe rfo rm ed  on a th e rm o cy c le r (7500 fa s t re a l-t im e  PCR sys tem ; A pp lie d  B iosys tem s) and 
quan tif ica tio n  w a s  pe rfo rm ed  using the  AACt m e thod .23- 24 GUSB w a s  used as a re fe rence  
gene to  no rm alize  exp ress ion  leve ls  o f CABP4, as th is  gene is s ta b ly  exp ressed  
in EBV-LCLs.25 RNA o f a pa tie n t w ith  a p.Q66X m u ta tion  in FTSJ1, know n  to  re su lt in 
nonsense -m ed ia ted  d e ca y  (NM D ), w a s  used as a pos itive  con tro l fo r  the  o ccu rre n ce  
o f N M D .26 The qPCR expe rim en t w a s  repea ted  fo r both pa tien ts  on RNA iso la ted  from  
tw o  in dependen tly  g row n  EBV-LCLs to  con firm  the  resu lts  o f the  f irs t qPCR experim en t.
M o le c u l a r  m o d e l in g
S ince  no c ry s ta l s tru c tu re  fo r  CaBP4 w a s  know n , w e  pe rfo rm ed  hom o logy  m ode ling  
to  p re d ic t th e  e ffe c t o f th e  g enom ic  m u ta tio n . The C -te rm ina l re s id u e s  o f CaBP4 w e re  
m ode led  on a s tru c tu re  o f c a lm odu lin  (PDB id e n tif ie r  1a29, 44% id e n tity ) .27 M ode lin g  
o f th e  N -te rm in a l re s id u e s  o f CaBP4 w a s  no t p o ss ib le  as th e  c a lm odu lin  tem p la te  
c o n ta in s  no s tru c tu ra l in fo rm a tio n  fo r th e se  res idues . H om o logy  m ode ling  w a s  
pe rfo rm ed  w ith  th e  W HAT IF W eb  In te r fa c e .28 The e ffe c t o f th e  genom ic  m u ta tion  
on th e  th re e -d im en s io n a l s tru c tu re  o f th e  p ro te in  w a s  ana lyzed  w ith  YASARA NOVA.29
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TABLE 2. Characteristics of two patients w ith p.Arg216X mutations in the CABP4 gene
Patient Sex Age
(y)
Visual acuity n * Refractive
errort
Color
v is ion !
Goldmann
perimetry
(V4e)
DA (log 
units) §
OD OS OD OS
II-1 M 12 20/200 20/200 pos +5.0 +5.5 severely
abnormal
(deutan)
normal 0.5
II-2 F 10 20/200 20/400 pos +4.5 +4.5 severely
abnormal
(deutan)
normal 0.75
*N, nystagmus (pos, positive); t, spherical equivalent in diopters; +, Ishihara, AO -HRR , D-15 Test; 
§DA, dark adapted final threshold elevation; OD, righ t eye; OS, le ft eye.
RESULTS
C l in i c a l  f e a t u r e s
A brother and sister, 12 (patient ii-1) and 10 (patient II-2) years of age, respectively, 
presented w ith a history of decreased visual acuity and nystagmus since early 
childhood. The clin ical characteris t ics of the patients are shown in Table 2. Both 
reported photophobia, but did not experience night blindness. Visual acuities had 
not changed over the past 6 years. Slit lamp examinations were unremarkable  
and funduscopy showed no abnormalities, except for a mild granular aspect of 
the peripheral retinal pigment epithelium in patient ii-1. Dark-adaptation curves 
were biphasic w ith  a slightly elevated final threshold. The standard ISCEV ERG 
measurements16 of both patients are shown in Figure 1. The amplitude of the rod 
isolated (scotopic) responses were normal in patient ii-1 (124 ^V) and were 2 SD 
below the mean in patient ii-2 (46 ^V; normal >45 ^V).30 in both children, the mixed rod- 
cone responses had absent cone a-waves, and an electronegative configuration with  
absent b-waves. Cone responses were severely reduced and 30-Hz photopic fl icker 
responses showed the double-peak waveform characteris t ic of CSNB2. Rod ERG 
responses to a 15-Hz f licker st imulation are shown in Figure 2. The measurements  
showed intact, slow, sensitive rod pathway responses, but no minimum ERG response 
or 180° phase shift, indicating absent or severely abnormal fast insensitive rod 
pathway responses.
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Normal subject Patient 11-1 Patient II-2
200 nV
200 2 00 |iV
200
200 nV 40 |j.V
100
+w w 20
20,iV 20 nV
100 ms
F iG U R E  1. ISCEV standard ERG of a normal sub ject and patients 11-1 and 11-2. The amplitude  
o f the rod response o f patient I I - 1 was 124 |iV  and o f patient II-2, 46 |iV; norm al is >45 |iV.30 In  
the m ixed rod -cone  responses, the a-wave in the norm al subject contains two dis tinct peaks, one 
at 19 ms, supposedly the cone peak, and a later one at 24 ms, supposedly the rod peak. In  both  
patients only one peak at 24 ms was distinguished. Therefore these m ixed responses featured an 
absent cone a-wave, w ith  a normal rod a-wave. The b-wave remained too small, resulting in a 
negative wave shape. Under photopic conditions, the b-wave amplitude was severely reduced but 
w ith  normal im p lic it tim e in bo th patients. Photopic 30-Hz flicker stimulus revealed decreased 
amplitude w ith  double peak waveform and norm al im p lic it time. There were no recordable 
oscilla tory potentials under scotopic conditions.
G e n e t ic  a n a ly s is
Genome-wide homozygosity mapping revealed two homozygous regions; a 9-Mb  
area on 11q13.1-q13.5 and a 4-Mb area on 6p22.1. The largest area comprised CABP4, 
a gene previously associated w ith CSNB.1- 15 Sequence analysis of CABP4 revealed 
a homozygous c.646C>T substitut ion in exon 4 in both patients, replacing an arginine 
residue at posit ion 216 by a stop codon (p.Arg216X). In both parents this change 
was identified heterozygously (Figure 3). The mutation was not found in 300 alleles 
of ethnically matched control individuals. Jalkanen et al.32 showed that a splice-site  
mutat ion in the CACNA1F gene, the causative gene for X-linked CSNB2, resulted in 
cone-rod dystrophy. Cabp41- mice show a progressive retinal phenotype. Therefore, 
Zeitz et al.1 hypothesized that mutat ions in CABP4 could also lead to cone-rod  
dystrophy. Sequence analysis of all coding exons of CABP4 was  performed on 
85 patients affected w ith  cone or cone-rod dystrophy. No mutations were found 
in these patients, indicating that mutations in CABP4 are not a frequent cause 
of cone or cone-rod dystrophy.
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Normal subject
Jog scot-td-s
Patient II-
10 nv 10 nv 7 nv
F IG U R E  2 . Rod ERG responses to 15-Hz flicke r s timula tion obtained from a normal subject 
and patients II-1 and II-2. Stimulus in tens ity  was -2 .3  log scot-td-s, increasing in  steps o f 
approximately 0.25 log scot-td-s up to 0.4 log scot-td-s. In  the norm al subject, the 15-Hz 
scotopic flicke r ERG showed a m in im um  response at approximately -1 .0  log scot-td-s, caused 
by destructive interference o f the slow, sensitive (between -2 .3  and -1 .3  log scot-td-s) and fast, 
insensitive (above -0 .9  log scot-td-s) rod  pathway signals.31 In  bo th  patients, the amplitudes  
o f the slow, sensitive rod  pathway signals were w ith in  norm al lim its . The fast, insensitive rod  
pathway signals appeared absent or severely subnormal, because no m in im um  response and 
phase sh ift was recorded. Furthermore, from  -0 .5  log scot-td-s up the amplitudes o f the signals 
were subnormal.
^ ^ 5
I-1 I -2 
p.Arg216X / + p.Arg216X/ +
II-1 II-2
p.Arg216X / p.Arg216X p.Arg216X / p.Arg216X
F IG U R E  3 . Pedigree of a Dutch fam ily w ith  tw o  sib lings affected w ith  congenital 
synaptic cone-rod  disorder, caused by a homozygous p.Arg216X mutation.
Black symbols: affected individuals
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E x p r e s s io n  a n a ly s is
Since the premature termination codon is localized more than 55 nucleotides upstream 
of the last exon-exon boundary (Figure 4), in theory the c.646C>T mutation should result 
in NMD.33-35 Considering the absence of NMD as the null hypothesis, comparison of 
normalized expression levels of CABP4 of the two patients w ith four control samples 
showed a nonsignificant 1.58-fold increase (P = 0.58, Student's f-test; unequal sample 
size, equal variance). Repetition of the experiment w ith RNA from independently grown 
lymphoblast cell lines confirmed these results and showed that NMD of CABP4 mRNA 
of patients carrying a homozygous p.Arg216X mutation does not occur. Comparison 
of normalized levels of FTSJ1 in the cDNA of a patient with a p.Q66X mutation in FTJS1 
to four control samples showed a 5.7-fold decrease in FTSJ1 transcrip t in the patient 
(P = 0.021), showing that this experiment eff iciently demonstrated NMD.
1 EF-hand l| EF-hand 2*| EF-hand 3 EF-hand 4)
x -  / \ / \ / /
\  /
§ o > -------- 3 --------- i§  :u1 t  t 
c.370C>T c.646C>T c.800_801delAG
p.Arg124Cys p.Arg216X p.Glu267fsX91
F IG U R E  4 . The CABP4 gene. Boxes: exons; lines: introns; gray boxes: parts o f the gene that 
encode the EF hands, the calcium -binding elements in CaBP4; arrows: the location o f primers  
used for quantitative PCR analysis. In  bo ld  is the m utation described in this article and in italic are 
the previously identified mutations in  CABP4.1 *EF hand 2 is no t functional.
M o le c u l a r  m o d e l in g  a n d  s t r u c t u r a l  a n a ly s is
Since the premature stop codon does not seem to result in nonsense-mediated  
degradation of the mutant CABP4 mRNA, it is likely that a truncated CaBP4 protein of 
216 amino acids is present. We predicted the characteris t ics of this truncated protein 
by constituting a molecular model, using the crystal structure of calmodulin (Figure 5). 
The modeled domain of CaBP4 contains important negatively charged residues that  
can bind Ca2+. The locat ion of these residues results in a typical helix- loop-helix 
structure, also known as an EF hand. The calmodulin template contains four of such 
EF hands, but because of the absence of an important negatively charged residue 
in the second EF hand the wild-type CaBP4 has only three functional calc ium-binding  
EF hands.15 The nonsense mutation described in this study deletes the functional 
EF hands 3 and 4 (Figure 5B). For calmodulin, it is known that all four EF hands must 
be present to fulfill its function.36 Because of the functional and structural overlap 
between calmodulin and CaBP4,15 we conclude that the mutant CaBP4, lacking 
two functional EF hands, is not able to fulfill its physiological function.
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F IG U R E  5. CaBP4 protein model. (See appendix for color figure)
A. R ibbon model o f the calcium b inding domains in  norm al CaBP4.
B. M ode l showing the deleted calcium b ind ing domains (gray). Yellow balls: calcium atoms.
DiSCUSSiON
Using a genome-wide homozygosity mapping approach, we detected a novel 
homozygous nonsense mutation (p.Arg216X) in CABP4 in two  siblings with  
a remarkable cone-dominated dysfunction. Patients presented w ith  considerably  
reduced visual acuity at a young age, nystagmus, photophobia, and severely  
abnormal color vision. Mutat ions in CABP4 have been associated w ith  autosomal  
recessive incomplete congenital stationary night blindness (CSNB2). In two siblings 
diagnosed CSNB2, but w ithou t night bl indness, Zeitz et al.1 discovered  
a homozygous C-terminal frameshif t mutation (p.Glu267fsX91) in the last protein- 
coding exon, e ffective ly replacing the last 9 amino acids w ith  91 aberrant 
amino acids. In a th ird isolated patients w ith  CSNB2 compound heterozygous  
(p.Glu267fsX91/p.Arg124Cys) mutat ions were  found. Cabp41- mice carry ing  
a homozygous null allele show  a CSNB2-like phenotype. These mice showed  
a disturbed transmission of signals from rods and cones to bipolar cells with  
a more severely disturbed rod than cone func t ion .15 In contrast to findings in the 
Cabp4+ mice, our patients w ith  p.Arg216X mutat ions displayed a prominent cone  
dysfunction. The presence of th is e ffect w as  deduced from clinical presentations  
as we l l as from ERG responses, wh ich  showed an absent cone a-wave in the mixed 
response and severely reduced ampli tude in cone and 30-Hz f l icker responses.
The rods seemed to function nearly normal: scotopic  ERG responses were  normal 
to subnormal, dark-adapted thresholds were  only min imally elevated, and patients 
did not experience night blindness. Another indication that cones were  more 
affected than rods was  seen in the 15-Hz f l icker stimulation. The fast insensitive 
rod pathway uses the rod-cone gap junct ions and the cone terminal synapse to 
t ransmit its signal to the bipolar cells, whereas the s low  sensit ive rod pathway  
t ransmits its signal d irect ly to the rod bipolar cells.37 Therefore, the combination
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of a normal, slow, sensit ive rod pathway response to 15-Hz fl icker stimula tion w ith  
an abnormal, fast, insensit ive rod pathway response suggests an abnormal function  
of the cones and/or cone terminal synapses. While Morgans et al.38 suggest that  
residual rod function in patients carrying mutations in CACNA1F is maintained  
because rods signal through the rod-cone gap junct ion, our e lectrophysio logical  
data suggest that rod function in patients carrying CABP4 gene mutations is 
to some extent reduced because of th is pathway. In the two patients w ith  the 
frameshift mutation described by Zeitz et al.,1 no 15-Hz scotopic measurements,  
dark adaptometry, and color vision tests were  performed, and no differentiation  
was made between the cone and rod a-wave at the mixed rod-cone ERG response. 
Therefore, we  do not know to wha t  extent the phenotypes of these patients are 
comparable to ours. The th ird patient in Zeitz et al.1 did compla in of night blindness  
and had a mild ly elevated threshold on dark adaptometry (1 log unit). Comparison 
of all five patients descr ibed so far suggests that homozygous prote in -truncating  
mutations (nonsense or frameshif t)  leads to a more severe phenotype, w ith  
a reduced visual acuity at a young age (20/100 around the age of 10 years), 
whereas the patient w ith  a compound heterozygous frameshift /m issense mutat ion  
showed a relatively preserved visual acuity (20/30 at age 15).1 The phenotypical 
sim ilarit ies in patients carrying pro te in-truncating mutations do not correspond  
w ith  the dif fe rent f indings in mRNA expression levels found in Zeitz et al.1 and in 
our study. Quantitative PCR analysis of the previously described mutations revealed 
a 30% to 40% residual amount of CABP4 t ranscr ip t in both a homozygous and 
a compound heterozygous patient,1 despite the fac t that the prote in -truncating  
mutation resides in the last exon and there fore is theore t ica l ly  not susceptib le to 
nonsense mediated mRNA decay.33-35 In v iew  of the sign if icant amounts of CABP4 
mRNA in both patients, these mutations could not be conclusive ly classif ied as null 
mutations. The mutation described in our study results in the truncat ion of the 59 
(22%) most C-terminal amino acids. Based on the location of the p.Arg216X mutation  
in exon 4, the transcr ibed mRNA should theo re t ica l ly  be degraded through NMD.33-35 
Surprisingly, no dif fe rence in expression levels of CABP4 was  found in cDNA of our 
patients compared w ith  cDNA of control individuals, indicating that NMD does not 
occu r and suggesting the presence of CABP4 transcr ip ts. To explain why  dif ferent 
amounts of CABP4 mRNA can result in comparable retinal phenotypes, 
we hypothesize that the dif fe rentia l ly truncated CaBP4 prote ins both are degraded, 
or present in a nonfunctional form. Genotype-phenotype corre lat ions based on EBV- 
LCL mRNA quantif ication, however, should be interpreted w ith  caution, because  
CABP4 mRNA stabil ity may be dif fe rent in peripheral blood cells versus retinal cells, 
and because CABP4 mRNA levels in EBV-LCLs are quite low.
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CaBP4 is expressed in the photoreceptor synaptic terminals, both in rods and 
cones, where it colocalizes and interacts w ith the a1-subunit  of the L-type voltage-  
dependent calc ium channels Ca 1.339-41 and Ca 1.4.15 Although Ca 1.4 channelsr V V 3 V
are localized in the synaptic terminal of both cone and rod photoreceptors, Cav1.3 
channels are only localized in the synaptic terminal of the cones.38 On binding with  
these L-type voltage-dependent calcium channels, CaBP4 increases Ca2+ influx into 
the synapse, wh ich increases the amount of neurotransmit ter release.15 The effect 
of CaBP4 on Ca 1.3 and Ca 1.4 channels, result ing in the maintenance of calciumV V ' 3
influx through the channel, is achieVed in dif ferent ways. In CaV1.3 channels CaBP4 
inhibits a mechanism called calc ium-dependent inactiVation, a negatiVe feedback  
mechanism actiVated by calmodulin that rapidly inactiVates calcium channels when  
intracellular calc ium concentrat ions are eleVated.40- 42 CaV1.4 channels are not subject 
to this mechanism, but it has been suggested that CaBP4 increases calc ium influx 
through CaV1.4 channels by shifting the channels to a hyperpolarized Voltage.15 
Although CaBP4 interacts dif ferently w ith  the CaV1.3 and CaV1.4 channels and 
distr ibution of CaV1.3 and CaV1.4 channels differs among the synaptic terminals  
of rods and cones, it remains speculatiVe why dysfunctional human CaBP4 has 
a stronger effect on cone function than on rod function.
In our young patients w ith  short fo l low -up no defin ite conc lus ions about  
progression can be drawn. HoweVer, a progressiVe course of the disease was  
suggested by the fac t that all three patients descr ibed by Zeitz et al.1 had slowly  
progressiVe Visual loss. Furthermore, more pronounced changes in the outer 
plexiform layer were seen in 6- to 8-months-old Cabp4-/-mice than in 2-month-old 
mice. The presence of both stat ionary and progressive phenotypes caused by 
mutations in one gene has been described fo r mutations in CACNA1F, causing 
both X-linked CSNB2 and progressiVe cone-rod dystrophy.32 The absence of 
CABP4 mutations in 85 patients from the Netherlands affected w ith  cone or cone- 
rod dystrophy suggests that CABP4 mutations are not a major cause for these 
progressiVe retinal dystrophies. Of interest, a slowly progressiVe form of autosomal 
recessiVe cone dystrophy has been described, w ith  a rather similar, but milder 
phenotype than patients carrying mutations in CABP4. This disorder is caused  
by nonsense mutations in the CACNA2D4 gene, wh ich  encodes the a 28-subunit  
of L-type Voltage-dependent calc ium channels. These patients presented with  
increasing photophobia and mildly decreasing Visual acuity starting around age 30, 
and no night blindness. Their ERG showed mild ly reduced isolated rod responses, 
electronegatiVe mixed rod-cone responses, markedly dim in ished cone responses 
and the waVe separation phenomenon at 30-Hz fl icker st imula t ion.43 Thus, genes
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involved in the process of calc ium influx in the synaptic terminal seem to lead to 
a spectrum of phenotypes affecting predominantly cones (CACNA2D4 and CABP4)1-43 
or both rods and cones (CACNA1F)6- 11 in either a s tat ionary or s low ly progressive  
course.
In summary, we describe a novel homozygous nonsense mutation in CABP4 in 
two siblings w ith a phenotype in wh ich cones are predominantly affected. Based 
on the electronegative mixed rod-cone responses on ERG, the disorder has previously 
been classified as a form of CSNB2. However, four of five patients described with  
mutations in CABP4 do not experience night blindness, and a stationary course 
of the disease is not complete ly evident. Furthermore, the clinical characteris tics  
are more in agreement w ith a form of cone dystrophy, like the phenotype associated  
with  mutations in CACNA2D4.43 Moreover, the dysfunctional protein is localized within  
the photoreceptor synaptic terminal. Therefore, we propose to rename this phenotype 
congenital cone-rod synaptic disorder.
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I l l

a b s t r a c t
p U R p o s E. To identify the genetic defect in a family w ith variable retinal 
phenotypes. The proband had a diagnosis of Leber congenital amaurosis (LCA), 
whereas her two cousins had an early-onset severe retinal dystrophy (EOSRD) with  
useful vision. A distant family member was affected by retinitis pigmentosa (RP).
M E T H o D S .  DNA samples of the affected family members were genotyped 
with  250K genome-wide SNP microarrays. Genetic defects were localized by 
l inkage analysis and homozygosity mapping, and candidate genes were analyzed 
by sequencing. Patients underwent a full ophthalmic examination.
R E S U L T S .  Compound heterozygous mutations in CEP290 were identified in 
the proband and her two cousins: the frequent c.2991+1655A>G founder mutation 
and a novel nonsense mutation in exon 7 (c.451C>T, p.Arg151X). The proband had 
nystagmus, hyperopia, a flat electroretinogram (ERG), and decreased visual acuity 
(20/250) from birth. The two cousins had minimal scotopic ERG responses at the 
age of 2. In one of these patients, visual acuity had reached a level of 20/32 at age 
5, wh ich is high for patients w ith  CEP290 mutations. Analysis of the CEP290 mRNA 
in affected individuals revealed altered splice forms in wh ich either exon 7 or exons 
7 and 8 were skipped. In both mutant cDNA products, the open reading frame was  
not disrupted. Furthermore, homozygosity mapping and mutation analysis in the 
distant family member affected by RP revealed a homozygous mutation in MERTK, 
but no CEP290 mutations. This MERTK mutation was heterozygously present in the 
most severely affected (LCA) patient, but was absent in the two more mildly affected 
cousins.
C o n C L U S i o n S .  A novel nonsense mutation in CEP290results in nonsense- 
associated altered splicing. That the remaining open reading frame is intact may 
explain the less severe phenotype observed in the two affected cousins. The 
additional heterozygous mutation in MERTK may clari fy the more severe phenotype  
in the proband. This study extends the phenotypic spectrum of CEP290-associated 
diseases at the mild end.
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INTRODUCTION
Mutations in CEP290 cause a broad spectrum of diseases, ranging from Meckel-Gruber 
syndrome (MKS), a lethal multisystemic disorder, and Joubert syndrome (JBTS) at the 
more severe end, to Leber congenital amaurosis (LCA), at the milder end of the clinical 
spectrum.1-5 In addition, several families with Senior L0ken syndrome (SLSN) and one 
case of Bardet-Biedl syndrome (BBS) have been associated with mutations in CEP2906 7 
The CEP290 gene encodes a ciliary and centrosomal protein that is present in cells of 
different tissues, explaining the variable set of symptoms, including renal abnormalities 
(MKS, JBTS, SLSN, and BBS), neurologic abnormalities (MKS, JBTS, and BBS), retinal 
degeneration (JBTS, SLSN, BBS, and LCA), and polydactyly (MKS and BBS).
CEP290-associated LCA is a single-organ disease affecting the retina.4, 5 Mutations 
in CEP290 are the most common cause of LCA, responsible for up to 6% to 22% of 
cases.4, 5 8 9 A founder mutation in intron 26 (c.2991 + 1655A>G), leading to the insertion 
of a cryptic exon with a premature stop codon, is the most prevalent CEP290 mutation 
in LCA patients.4, 10 Since a fraction of wild-type CEP290 mRNA remains in patients 
carrying the intronic mutation, it is hypothesized that this hypomorphic character of 
the mutation explains why the mutation leads to LCA, instead of a multiorgan disease.4 
The CEP290-associated retinal phenotype is classified by Perrault et al.5 as a cone-rod  
type of LCA (type I as classified by Hanein et al.11), with a visual acuity of 20/400 or lower, 
high hyperopia (+6 or more), slight photo-aversion, and a salt-and-pepper appearance  
of the retina, with macular degeneration in the first decade, changing to the typical 
appearance of retinitis pigmentosa (RP) at later stages.5 In this study, we examined 
three patients with a LCA-like phenotype. However, two of them retained useful vision, 
and we therefore classified their disease as early-onset severe retinal dystrophy 
(EOSRD), which is considered to be milder than LCA. The less severe phenotype is 
caused by a novel nonsense mutation that induces exon skipping without disrupting 
the open reading frame. In addition, we report on the finding that one individual with  
the same set of CEP290 variants showed an LCA phenotype, which may be caused 
by the cumulative effect of a heterozygous MERTK frameshift mutation.
METHODS
This study was approved by the ethics review board of The Rotterdam Eye Hospital 
and adhered to the tenets of the Declaration of Helsinki. Informed consents were  
signed by all partic ipants and, in the case of minors, by the ir parents.
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C l in i c a l  e v a lu a t io n
The affected individuals (VI-3, VI-4, and VI-6; Figure 1) visited the University Medical 
Centre Groningen for the fi rst time at the age of 6 months and were seen for fo llow-  
up examinations regularly thereafter for up to 11 years. The examinations included  
electroretinograms (ERGs), recorded accord ing to the protocol of the International 
Society for Clinical Electrophysiology of Vision (ISCEV).12 The three patients were  
cl in ically re-evaluated at The Rotterdam Eye Hospital recently. Parents were  
extensively interviewed about the medical history of their children. Clinical evaluation 
included best corrected visual acuity using ETDRS charts and was expressed as 
Snellen equivalents, objective refractive error after cycloplegia, biomicroscopy,  
and fundoscopy. Visual fields were assessed w ith Goldmann kinetic perimetry  
(targets V-4e to I-4e for patients VI-3 and VI-4, and V-4e to II-4e for patient VI-6).
Color vision was tested w ith  the American Optical Hardy-Rand-Ritt ler Test (AO-HRR) 
and the Farnsworth Panel D-15 Test (saturated and desaturated) in all patients and by 
the Ishihara Test for Color Blindness in patient VI-4. Addit ional tests included fundus 
photography and spectral domain optical coherence tomography (OCT; Spectralis; 
Heidelberg Engineering, Heidelberg, Germany) for evaluating the in vivo retinal 
structure. Autofluorescence images (30°) were obtained w ith a confocal scanning  
laser ophthalmoscope w ith 488-nm excitation (Retinogram Angiograph 2; Heidelberg 
Engineering, Heidelberg, Germany) to detect alterations of the retinal pigment 
epithelium and lipofuscin accumulation. Kidney function was assessed by serum 
analyses of sodium, potassium, and creatinine levels. A  magnetic resonance imaging 
(MRI) scan of the brain was performed in patient VI-3 to exclude brain abnormalities, 
including the molar tooth sign typical of JBTS. Electroretinography was repeated in 
patient VI-3. Ophthalmic examination and ERG were also performed in the parents to 
search for clinical abnormalit ies in mutation carriers.
M o le c u l a r  g e n e t ic  a n a ly s is
Blood samples for molecular genetic analysis were obtained from all family members 
(Figure 1). Total genomic DNA was extracted from leukocytes by a standard salting- 
out procedure.13 DNA samples of the affected subjects, including a distant family  
member affected by RP (VI-3, VI-4, VI-6, and V-1; Figure 1), were genotyped for 
262,000 single nucleotide polymorphisms (SNPs; GeneChip Mapping 250K Nsp\ 
array; Affymetr ix, Santa Clara, CA). Array experiments were performed according  
to protocols provided by the manufacturer. Mult ipoin t linkage analysis was performed 
with  GeneHunter ver. 2.1r514 in the easyLINKAGE-Plus software package,15 w ith  use 
of the Caucasian allele frequencies. Homozygosity mapping was performed with  
the software package CNAG.16 Mutation analysis of the CEP290 gene was performed
CHARTER 4 A NOVEL NONSENSE MUTATION IN CEP290 INDUCES EXON SKIPPING AND LEADS TO A RELATIVELY MILD RETINAL PHENOTYPE
using previously described PCR primers and condit ions.1 Primers for the MERTK gene 
were designed by primer3 so ftware17 and are listed together w ith  the PCR conditions 
in Supplementary Table S1. Direct sequencing was performed in sense and antisense 
direction on an automated sequencer (BigDye Terminator, ver. 3, model 3730 DNA 
analyzer; Applied Biosystems, Inc. [ABI], Foster City, CA). Segregation analysis of the 
CEP290 and MERTK mutat ions in all family members was performed by sequencing.  
Eighty-five LCA patients and 123 patients affected by cone-rod dystrophy (CRD) were  
screened for the CEP290 c.2991+1655A>G mutation by allele-specif ic PCR18 and for the 
p.Arg151X mutation by restr ict ion fragment length polymorphism analysis using TaqI 
(ABI; Supplementary Table S1). To determine the effect of p.Arg151X on the CEP290 
mRNA level, we collected blood samples (PAX vials; Qiagen, Venlo, The Netherlands) 
of the three affected children (VI-3, VI-4, and VI-6, Figure 1) and six control individuals 
and isolated the RNA (PAXgene Blood RNA kit 50 ver. 2; Qiagen) accord ing to the 
protocol provided by the manufacturer. Total RNA (1.5 ^g) was reverse transcribed
F IG U R E  1. Pedigree w ith  inherited retinal diseases and pathologic CEP290and MERTK variants.
The proband (VI-6; arrow) is affected by LCA, two cousins (VI-3 and V I-4) are affected by EOSRD, 
and one distant fam ily member (V-1) is affected by RP. Mutations in CEP290 and MERTK  are 
indicated. For reasons o f privacy, mutations in the unaffected siblings are not presented. M1, CEP290 
c.451C>T, (p.Arg151X; Aexon7; Aexons7-8); M2, CEP290 c.2991+1655A>G (p.Cys998X;wildtype); 
and M3, MERTK  c.1179dup, p.Leu394SerfsX3; +, wild-type.
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to cDNA w ith  M-MLV reverse transcrip tase (Invitrogen, Breda, The Netherlands). 
RT-PCR experiments were performed on 2.5 ^L of synthesized cDNA or human retina 
Marathon-Ready cDNA (Clontech, Temecula, CA), w ith  pr imers in exon 5 and 10 
(35 cycles), fo llowed by nested PCR on 0.5 ^L, w ith the same forward primer in 
exon 5 and a reverse primer in exon 9 (15 cycles; Supplementary Table S1).
RESULTS 
c l i n i c a l  f e a t u r e s
Individuals VI-3, VI-4, and VI-6 visited the ophthalmologist within 6 months after birth 
because of nystagmus and lack of fixation. Ophthalmic assessment revealed a vertical 
nystagmus, normal pupil responses, a high hyperopia, and essentially normal-appearing 
fundi. In all three individuals, ERG was performed at the age of 2 years. In patient 
VI-6, both scotopic and photopic responses were nonrecordable. In patients VI-3 
and VI-4, photopic responses were nonrecordable, whereas the scotopic responses 
were severely reduced, but measurable (15% of normal values). Patient VI-3 was  
evaluated by a pediatric neurologist because of the vertical nystagmus, but intracranial 
abnormalities were excluded by neurologic assessment and by an MRI scan of the 
brain. The patients' histories did not reveal any abnormalities about pregnancy and 
delivery. Beside the ophthalmic symptoms, no other abnormalities in motor or cognitive 
development were reported, and their intelligence was normal. An overv iew of the most 
recent clinical data is presented in Table 1. In summary, all three patients experienced 
night blindness and no photophobia. Patients VI-4 and VI-6 displayed mild exotropia. 
Visual acuity varied from 20/40 in the best eye of patient VI-3 to 20/125 in patient VI-4 
and 20/250 in patient VI-6 at ages 11, 8, and 9, respectively (Figure 2).
F iG U R E  2 . v isua l acu ity of 
patients w ith  Eo sRD and LOA. The
course o f visual acuity is shown in 
decimals (y-axis) w ith  age (x-axis) 
in  patients V I-3  and V I-4  (EOSRD) 
and patient V I-6  (LCA). The 
improvement in  visual acuity at age 
5 in  patient V I-3  is most likely the 
effect o f better performance at visual 
acuity assessment.
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TABLE 1. Clinical characteristics of three patients w ith mutations in the CEP290gene
Refractive eRG
Age Nystag- Visual acuity error*  Color Goldmann tR "
Patient (yrs) mus RE LE RE LE visiont Ophthalmoscopy perimetry Rodt Cone§
IV-3
Mild 
horizontal 
w ith  slightly 
rotating 
component
20/80 20/40 +8.75 +8.75
Sat.:
normal
Desat:
mild
aspecific
errors
Pink optic disc 
w ith  sc lera l rim, 
mild attenuation 
of vessels, absent 
macula and 
fovea w ith  subtle 
RPE changes.
Faint w h ite  
patchy re flex in 
m idperiphery, dot­
like RPE atrophy 
in fa r  periphery, 
no in traretina l 
pigment
Horizontally 
constricted 
fie ld  up 
to 50-60 
degrees 
(15 degrees 
nasally,
50 degrees 
temporally]
NR NR
IV-4
Horizontal
w ith
rotating
component
20/100 20/100 +7.75 +7.75 Normal
Pink optic discs
w ith  sc lera l rim,
mild attenuation
of the vessels,
present foveal
reflex, mild Constriction
w rink-ling  ILM. up to 80
In m idperiphery degrees
normal aspect of (10 degrees
RPE, fa r  periphery nasally,
dot-like RPE 70 degrees
atrophy w ith tem porally
small num m ular
subretinal
pigmentations,
no in traretina l
pigment
NP1 NP18
High
frequency
IV-6 9 horizontally 20/320 20/250 
and 
ve rtica lly
+4.5 +4.5 NP2
Pink optic discs
w ith  sc lera l rim,
mild/moderate
attenuation of
the vessels,
absent foveal and Severely
m acular reflexes, constricted
RPE changes visua l field
in macula, up to 10
hypopigmented degrees
periphery w ith
dot-like RPE
atrophy and
in traretinal
pigmentations
NP1 NP1
*, spherical equivalent in  diopters; t ,  saturated (sat.) and desaturated (desat.) AO-HRR, Panel D-15 
Test; ERG, electroretinogram; t ,  isolated rod response; §, single flash cone response; ILM , inner 
lim iting  membrane; LE, left eye; NP1, no t performed at this age, because non-responsive at earlier age; 
NP2, not able to perform  due to low  visual acuity; RE, right eye; RPE, retinal pigment epithelium.
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On fundoscopy the posterior retina was relatively well preserved in all three patients, 
with  pink optic discs w ith  a scleral rim, attenuated retinal vasculature, and subtle 
retinal pigment epithelium (RPE) changes in the macular region. In patient VI-3, we  
found the remnants of a tapetal reflex that had a marbled appearance. This ref lex was  
more pronounced at the age of 5 years and was documented on fundus photographs 
(Figures 3A, 3B). In the far periphery, subretinal pigmentations were noted in patients 
VI-3 and VI-4. The periphery in patient VI-6 had a very hypopigmented appearance  
with  intraretinal bone spicule pigmentations (Figure 3E). Visual fields were constr icted  
in all patients, but most severely in VI-6, who was also not able to perform a color 
vision test. On OCT a preserved photoreceptor layer was noted in the posterior pole 
in the two patients tested (VI-3 and VI-4; Figure 3D).
Autof luorescence images, wh ich were diff icult to obtain because of the nystagmus, 
showed a mildly reduced intensity of the signal in the posterior pole and midperiphery, 
with  a normal decrease of intensity at the macular region in all three individuals 
(Figure 3C). Altogether, the phenotype of the proband (VI-6) was most similar to LCA. 
The phenotype of the two more mildly affected cousins (VI-3 and VI-4) was classified 
as EOSRD, to emphasize the fact that they were less severely affected.
Ophthalmic examination did not reveal abnormalit ies in three of four heterozygous  
carrie r parents. In one parent, we  detected a choroidal melanoma (V-2; Figure 1).
The ERG responses were in the high range of normal in three of the parents 
(V-3, V-4, and V-5) and complete ly normal in parent V-2.
M o le c u l a r  g e n e t ic s
Genome-wide linkage analysis was performed on DNA of the proband (VI-6) and 
her two cousins (VI-3 and VI-4). The family, originating from a northern province in 
The Netherlands, was reported to be non-consanguineous. However, the patients 
were related through both parental lineages: they were first cousins through one 
parent and fourth cousins through the other (Figure 1). Linkage analysis revealed 
only one signif icant chromosomal region, wh ich localized between SNPs rs10879550 
and rs1579244 on 12q21.1-q23.1, w ith a LOD score of 2.4. The region harbored 68 
genes, among wh ich we found CEP290, making this the most obvious candidate 
gene in this family. Mutation analysis of the CEP290 gene revealed a compound  
heterozygous combination of the most common CEP290 founder mutation in intron 26 
(c.2991+1655A>G)4 and a novel nonsense mutation in exon 7 (c.451C>T; p.Arg151X).
The mutations segregated w ith  the disease in the family (Figure 1). The deep intronic 
c.2991+1655A>G variant creates a functional 5' splice site and the insert ion of
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a cryptic exon into approximately 50% of the CEP290 mRNA.4 The cryptic exon 
contains a nonsense codon (p.Cys998X), resulting in a predicted truncation of the 
CEP290 protein. As ~50% of the CEP290 mRNA remains wild-type, the c.2991+1655A>G 
variant can be considered a hypomorphic change.4 Because patients VI-3 and VI-4 
had residual rod function and non-detectable cone ERGs at the age of 2 years, we 
screened 123 patients affected by CRD for both these CEP290 mutations.
F IG U R E  3 . Retinal imaging of patients VI-3 and VI-6. (See appendix for color figure)
A. Photograph o f the m idperipheral fundus o f patient V I-3  at the age o f 5, showing a marbled  
appearance. B. Fundus photograph o f the same patient V I-3  at the age o f 11, w h ich  shows that 
the marbled appearance had disappeared, and m ild  atrophy o f the RPE was noted. O. Mean  
autofluorescence image (30°) o f the le ft eye o f patient V I-3 , calculated from  12 single images 
(488 nm), showing a well preserved signal in  the posterior pole w ith  decreased intensity in  the 
macular region. D. Spectral domain O C T  o f the le ft eye o f patient V I-3  at the age o f 11 shows 
a recognizable photoreceptor layer, in tact retinal layers, and disappearance o f the foveal dimple.
E. Fundus photograph o f le ft eye o f patient V I-6 , showing preserved RPE in the macular region 
w ith  an extremely hypopigmented area along the vascular arcade, w h ich  extends to the periphery.
In addition, 85 LCA patients in whom the c.2991+1655A>G mutat ion was previously 
excluded4 were screened for the p.Arg151X mutation. The c.2991+1655A>G and 
p.Arg151X mutat ions were not detected in addit ional CRD or LCA probands. The novel 
p.Arg151X mutation was also excluded in 182 alleles of ethnically matched control 
subjects. Usually, the combination of a hypomorphic change and a truncating change 
would lead to a LCA phenotype. Since the phenotypes in VI-3 and VI-4 were much
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less seve re  th a n  ty p ic a l LCA, w e  h ypo thes ized  th a t th e  p.A rg151X m u ta tio n  shou ld  
have a h ypom o rph ic  cha ra c te r. T he re fo re , us ing  RT-PCR w e  ana lyzed  CEP290 mRNA  
in p e rip h e ra l b lood  lym phocy te s  o f th e  a ffe c te d  c h ild re n  (V I-3 , V I-4 , and V I-6) 
and s ix  c o n tro l in d iv id ua ls . A lth o u g h  sp lice  s ite  and e xon ic  s p lic e  e n h a n ce r s ite  
p re d ic tio n  s o f tw a re 19- 20 d id  no t p re d ic t an e ffe c t on the  s p lic in g  p rocess , w e  id e n tif ie d  
th re e  d iffe re n t RT-PCR p ro d u c ts  in h e te ro zygous  c a r r ie rs  o f p .A rg151X w h en  using  
a fo rw a rd  p r im e r in exon 5 and a re ve rse  p r im e r in exon 10 (F igure 4). One p ro d u c t 
re p re sen te d  n o rm a lly  s p lice d  m RNA, in w h ic h  o n ly  a m in im a l fra c tio n  o f th e  m u ta ted  
T -a lle le  w a s  p re sen t (F igu re  4C). The second  PCR p ro d u c t (282 bp) la cked  exon 7, 
and th e  th ird  p ro d u c t (261 bp) la cked  exons 7 and 8 (F igu re  4). The rem ova l o f exon 7 
o r exons 7 and 8 does  no t d is ru p t th e  open  re ad in g  fram e . These  a lte rn a tiv e ly  sp lice d  
p ro d u c ts  w e re  no t d e te c te d  in s ix  c o n tro l in d iv id ua ls . It w a s  a lso no t p re se n t in 
hum an re tina  cD N A  (da ta  no t show n ). In pa tie n ts  as w e ll as c o n tro l in d iv id ua ls , 
w e  fo und  a w e a k - in te n s ity  PCR p ro d u c t la c k in g  exon 6.
H om ozygos ity  m app ing  in th e  d is ta n tly  re la te d  RP p a tie n t (V-1; F igure 1) re vea led  
seve ra l hom ozygous  segm en ts  (Co llin  et al., m a n u sc r ip t in p repa ra tio n ). Sequence  
ana lys is  o f MERTK, a know n  RP gene lo ca te d  w ith in  th e  p a tie n t's  la rg e s t hom ozygous  
re g ion , re vea led  a hom ozygous  fra m e s h ift m u ta tio n  (c.1179dup, p .Leu394SerfsX3). 
Th is  m u ta tio n  w a s  id e n tif ie d  h e te ro zygous ly  in th e  m os t s e ve re ly  a ffe c te d  (LCA) 
p a tie n t (V I-6 ) and w a s  no t id e n tif ie d  in th e  m ore m ild ly  a ffe c te d  (EOSRD) pa tie n ts  
(V I-3  and V I-4 ; F igure 1).
DiSCUSSiON
Using  lin kage  a na lys is  in a fa m ily  w ith  one p roband  a ffe c te d  by LCA and he r tw o  
cou s in s  a ffe c te d  by EOSRD, w e  lo ca lized  th e  g ene tic  d e fe c t on 12q21 and d e te c te d  
com pound  h e te ro zygous  m u ta tio n s  in CEP290 (c.2991+1655A>G and c.451C>T, 
p.A rg151X). The in tro n ic  m u ta tio n  is know n  as th e  m os t p re va le n t LC A -caus ing  
m u ta tio n  in CEP290,4, 5 The nonsense  m u ta tio n  p.A rg151X has no t been desc r ib ed  
be fo re . The p heno type  o f th e  LCA p a tie n t w a s  com pa ra b le  to  th e  CEP290-LCA 
pa tie n ts  p re v io u s ly  d e s c r ib e d 4, 5 and c on s is te d  o f n ys tagm us , h igh  h ype rop ia  (+4.5 D), 
n ig h t b lin dness , re du ce d  v isu a l a cu ity  from  b ir th  (20/250), fu n du s  a bno rm a lit ie s , and  
n o n re c o rd a b le  e le c tro p h y s io lo g ic a l re sponses . The p heno typ e s  o f the  tw o  a ffe c te d  
cou s in s  w e re  c om pa ra b le , b u t less seve re , w ith  m in im a l m easu rab le  s co to p ic  
re spon se s  on ERG and a m ore fu n c tio n a l v isu a l a cu ity . Lorenz e t a l.21 co ine d  th e  name  
e a r ly -o n se t seve re  ro d -c o n e  d y s tro p h y  to  d is tin g u ish  b e tw e e n  tru e  LCA and re la tiv e ly
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a  400 bp
B .
c .
F IG U R E  4 . CEP290 cDNA analysis of the e ffec t of the c.4510>T varian t on splic ing.
(See appendix for color figure)
A. Agarose (3%) gel electrophoresis showing three major PCR products in  carriers o f p.Arg151X  
and one major product in  the six con tro l individuals. B. Agarose gel electrophoresis showing 
GUSB as the reference gene product. C -E . PCR sequences o f cD N A  o f patient V I-3  (CEP290 
c.451C>T/c.2991+1655A>G), showing (0) m RNA containing all exons, but showing a low  peak 
fo r the m utant heterozygous T  at position 451 (arrow). (D) m RNA missing exon 7, and (E) mRNA  
missing exons 7 and 8. *Low-in tensity p roduct could not be amplified fo r sequence analysis. 
Based on the size, it  could contain the CEP290 m R NA  lacking exon 8 only, w h ich should 
be 315 bp; tlow -in tens ity  product ~200 bp was analyzed by sequence analysis and appeared 
to  be the CEP290 m R NA  lacking exon 6 only (192 bp). Since CEP290 lacking exon 6 is present 
in  patients as well as con tro l individuals, it  appears to  be a norm al splice variant.
D
E
less seve re  pheno typ e s  as, fo r  e xam p le , obse rved  in p a tie n ts  c a rry in g  m u ta tio n s  
in RPE65. C om parab ly , w e  dec id e d  th a t th e  c la s s if ic a tio n  EOSRD w o u ld  be a m ore  
a p p ro p r ia te  d e s c r ip tio n  o f th e  pheno type  o f th e  tw o  a ffe c te d  cous in s . T h a t w e  found  
a rem nan t o f rod fu n c tio n  a t th e  age o f 2 ye a rs  in th e se  tw o  p a tie n ts  sugge s ts  th a t  
CEP290-associated LCA is o f th e  c o n e - ro d  type  as obse rved  by P e rra u lt e t a l.5 On the  
o th e r hand , v isu a l a cu ity  and c o lo r v is io n  w e re  re la t iv e ly  w e ll p rese rved , sugges tin g
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the opposite. An interesting finding was the marbled appearance of the fundi, 
which seemed to disappear w ith age, in patient VI-3. A  similar appearance of the 
fundus was seen in two other patients carrying mutations in CEP290 (L. Ingeborgh 
van den Born, personal observation). Perrault et al.5 showed a similar fundus as 
well and called it "wh ite  dots ." The etiology of this fundus abnormali ty remains 
unclear, but tapeta l reflexes can be pathognomonic for certa in diseases, as has 
been observed in carr iers of RPGR mutat ions.22 The marbled appearance of the 
fundus may be pathognomonic for the CEP290-associated phenotype.
In contrast to the previously described CEP290-associated phenotype, we  determined  
a visual acuity that is remarkably high compared w ith most patients carrying 
mutations in CEP290, especially in patient VI-3 (20/40 at age 11). A  well-preserved  
visual acuity has been reported previously in 4 patients of the 77 CEP290-LCA patients 
who have been described cl in ically (18 patients from Yzer et al., manuscript in 
preparation).4- 5 10 Three patients carr ied the c.2991+1655A>G variant homozygously 
and had visual acuities of 20/80 and 20/150 at age>404 and 20/50 at age 20.10 One 
patient carr ied the c.2991+1655A>G mutation together w ith a c.5668G>T (p.Gly1890X) 
nonsense mutation and had a visual acuity of 20/50 at age 19.10 In most patients, 
however, the visual acuity ranged from no vision at birth to a maximum of 20/400, 
as shown in 47 patients by Perrault et al.5 and in the 18 patients evaluated by Yzer 
et al. (manuscript in preparation). We hypothesize that the mild phenotype in the 
two cousins described in this study can be explained by the fact that they carry  
two mutations w ith  a relatively mild effect on the protein. First, the c.2991+1655A>G 
mutat ion affects only part of the mRNA; part of the wild-type mRNA remains present 
as shown by den Hollander et al.4 Second, the allele carrying the p.Arg151X mutation 
is differentially spliced, lacking exon 7 or exons 7 and 8, but remain in frame.
The low peak of the mutated T nucleotide in the mRNA (Figure 4) shows that most of 
the differentially spliced CEP290 results from the mutated allele. Usually, the presence 
of a premature termination codon (PTC) leads to nonsense-mediated mRNA decay, 
a process that results in the degradation of nonsense-contain ing mRNAs.23-25 
We suggest that the dif ferent splice products are the result of nonsense-associated 
altered splic ing (NAS), a putative correction mechanism that recognizes an exon with 
a PTC, and excludes that exon from the mature mRNA.26-29 One form of NAS is due to 
the disruption of an exonic splice enhancer (ESE) by a mutation. Since the ESE finder 
program20 does not predict a disruption of an ESE, NAS is likely to occur specif ically  
due to the nonsense character of the p.Arg151X mutation. The precise mechanism is 
not well understood yet.30 Exons 3 to 17 of the CEP290 protein are predicted to encode 
a coiled-coil domain of 506 amino acids. The protein sequences lacking the 18 or 25
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am ino a c id s  e n coded  by exon 7 o r by exons 7 and 8 are s till p re d ic te d  to  encode  
a c o ile d -c o il dom a in  th a t is on ly  s lig h tly  s h o r te r th a n  th e  w ild - ty p e  c o ile d -c o il dom a in  
T he re fo re , w e  h ypo thes ize  th a t th e  a lte red  s p lice d  p ro d u c ts  en code  a s tab le  p ro te in  
w ith  re s id u a l fu n c tio n , re su lt in g  in a re la t iv e ly  m ild  pheno type . B ecause  o f te c h n ic a l 
lim ita tio n s , it is d if f ic u lt  to  q u a n tify  th e  am oun t o f m u ta n t m RNA th a t is s u b je c te d  to  
NAS. S ince  th e  m u ta n t sp lice  p ro d u c ts  a re sm a lle r th a n  th e  w ild - ty p e  p ro d u c t, th e y  
w il l be am p lif ie d  m ore  e ff ic ie n t ly . In a d d itio n , w e  c a n n o t be c e rta in  th a t th e  ana lys is  
o f lym phob la s t m RNA is re p re sen ta tiv e  o f th e  in v ivo  s itu a tio n  in th e  re tin a s  o f these  
pa tien ts .
The th re e  p a tie n ts  in th is  s tu d y  s h ow ed  an in tra fa m ilia l p h en o typ ic  v a r ia b ility  th a t  
led to  d iffe re n t c lin ic a l d ia gnoses . In tra fa m ilia l v a r ia b ility  has been re po rte d  be fo re  
in a fa m ily  w ith  fo u r p a tie n ts  c a rry in g  hom ozygous  c.2991+1655A>G m u ta tio n s .4 
S ince  th e  am oun t o f w ild - ty p e  CEP290 p ro d u c t, q u a n tif ie d  in lym phob la s t RNA, w a s  
com pa ra b le  in all p a tie n ts  o f th a t fa m ily  (da ta  no t show n ), a n o th e r v a r ia n t in o the r  
gene (s ) m ay in flu e n ce  th e  pheno type  and th e  in tra fa m ilia l v a r ia b ility . In th e  fam ily  
d e sc r ib e d  in th is  s tudy, the  in tra fa m ilia l v a r ia b ility  b e tw e e n  the  p roband  and her 
tw o  c ou s in s  m ay be e xp la in e d  by th e  he te ro zygous  p .Leu394SerfsX3 m u ta tion  
in the  MERTK gene , w h ic h  w a s  p re se n t in the  LCA p a tie n t (V I-6 ) and ab sen t in the  
tw o  EOSRD p a tie n ts  (V I-3  and V I-4). MERTK is a s so c ia te d  w ith  au to som a l re ce ss ive  
RP31-33 and is s tro n g ly  exp re ssed  in th e  RPE and m ac ro phage s , w h e re  it p la ys  a ro le  
in the  RPE phag o cy to s is  p ro ce ss .34 CEP290 is lo ca lized  in th e  c on n e c tin g  c ilia  o f 
p h o to re ce p to rs  and is sugges ted  to  p lay  a ro le  in m ic ro tu b u le -a s so c ia te d  p ro te in  
t ra n s p o r t in the  c ilia .2- 3- 35 In v ie w  o f th e  d iffe re n c e  in fu n c tio n  and lo ca liza tion , 
a phys ica l in te ra c tio n  be tw een  the se  p ro te in s  seem s un like ly. M o reove r, one MERTK 
p .Leu394SerfsX3 m u ta tio n  and one CEP290 c.2991+1655A>G m u ta tio n  to g e th e r  do 
no t lead to  sym p tom s  o f re tin a l d y s tro p h y  (in in d iv id ua l V-4). In a dd itio n , hum an  
and m u rin e  c a r r ie rs  o f h e te ro zygous  p a th ogen ic  MERTK m u ta tio n s  do no t show  
s ig ns  o f re tin a l d y s tro p h y  as w e ll. H owever, c u ltu re d  RPE ce lls  from  the  RCS ra ts  
th a t c a r ry  a hom ozygous  tru n c a t in g  d e le tio n  in MERTK  in v itro  p h ago cy to se  on ly  
a fe w  p h o to re ce p to r o u te r segm en ts , in c o n tra s t to  w ild - ty p e  ce lls , in w h ic h  m any  
phagosom es appear.36 T he re fo re , RPE ce lls  w ith  on ly  50% o f the  am oun t o f fu n c tio n a l 
MER ty ro s in e  k inase  re ce p to r m ay have a lo w e r tu rn o v e r  o f p h o to re ce p to r ou te r  
s egm en t p h a g o cy to s is , w h ic h  does no t have a m easu rab le  p a th ogen ic  e ffe c t in 
o th e rw is e  h ea lth y  in d iv id ua ls , bu t cou ld  have a c um u la tiv e  (o r m od ify in g ) e ffe c t 
in p a tie n ts  in w h om  th e  p ro d u c tio n  o f p h o to re ce p to r o u te r segm en ts  is d is tu rbed , 
in th is  case  by tw o  p a th ogen ic  m u ta tio n s  in CEP290. The phenom enon  o f m od ifie r  
a lle le s  has been d e sc r ib e d  m ore  o fte n  -  fo r  exam p le , t r i- a l le l ic  m u ta tio n s  re su ltin g
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in a more severe phenotype in Bardet-Biedl patients and a modif ier RPGRIP1L allele 
that is suggested to result in a more severe retinal phenotype in cil iopathies.37, 38 
Nevertheless, it remains speculative whether the MERTK mutat ion functions  
as a modif ier allele. The a priori chance for an individual to carry a pathogenic  
mutat ion in a retinal dystrophy gene is ~10%, assuming that there are 67 autosomal 
recessive retinal dystrophy genes that all account for a similar proportion of cases, 
as calculated by Rivolta et al.39 in 2002. Currently, 44 nonsyndromic autosomal 
recessive retinal dystrophy genes have been identified (http:/ /www.sph.uth.tmc.edu/ 
retnet) that account for ~50% of cases, indicating that the calculation of Rivolta et 
al.39 could be realistic. Therefore, we estimate that 10% of retinal dystrophy patients 
are expected to carry a heterozygous mutat ion in a second gene. Eventually, the 
identif ication of combinations of mutat ions in more than one retinal dystrophy gene 
by next-generation sequencing, together w ith  a precise description of phenotypes, 
may uncover the unknown influences of addit ional heterozygous mutations.
In conclusion, we found a novel nonsense mutation in exon 7 of CEP290 that causes 
a milder phenotype than expected for an early nonsense mutation, most likely due 
to nonsense-associated altered splicing. Furthermore, we  detected a heterozygous  
MERTK mutation in the most severely affected patient that may have a deteriorating 
effect on the phenotype. In th is study, we extended the phenotypic spectrum of 
CEP290-associated diseases at the mildest end.
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SUPPLEMENTAL DATA
S U P P L E M E N T A L  T A B L E  1. Primers used for sequence analysis of MERTK, 
mutation-specif ic PCR of the CEP290 c.2991+1655A>G mutation, PCR for c.451C>T 
restriction fragment length polymorphism analysis and cDNA PCRs of the CEP290 mRNA.
Size Annealing
Primer Sequence 5' - 3' (bp) PCR mix temperature
MERTK
exon 1 forward 
exon 1 reverse
G CCACTCGGCACTCACTG 
AGAGGCCCCTGCTTCCTC
258 GC rich PCR 
System
58° C
exon 2 forward 
exon 2 reverse
CCTAAGAAGTTGGGAACCTAC
CTGGGCTACAGAATGATACTC
586 3 mM MgCl2 58° C
exon 3 forward 
exon 3 reverse
AGTTGAAGAAGTTTCCATCC 
ATTTAACACAG G CCCTAAAAC
241 3 mM MgCl2 58° C
exon 4 forward 
exon 4 reverse
GGCTCTGTCTCTGTTTTCAG
GCCAAACTTTTGATCCTGTC
294 3 mM MgCl2 58° C
exon 5 forward 
exon 5 reverse
AGAATTGTAGTGAACAGCAGC
GCAAGCTCATGCTGTACC
217 3 mM MgCl2 58° C
exon 6 forward 
exon 6 reverse
GGTAGCTGTAGCCTGTCATC 
AAT C CTTAAACC CACAGAGAG
247 3 mM MgCl2 58° C
exon 7 forward 
exon 7 reverse
CCTGACATTCCCACCAC
GGAAGGGTTTGTTGAATCAC
302 3 mM MgCl2 58° C
exon 8 forward 
exon 8 reverse
AAAACCAAACACTTGAAAACC
ACCAGCAAGTTGAAAGGAG
292 3 mM MgCl2 58° C
exon 9 forward 
exon 9 reverse
CAGTTTGCCCAGACCTC
CAGGTTACTTTCTGGCAATC
282 3 mM MgCl2 58° C
exon 10 forward 
exon 10 reverse
TGTTACAAGCCAGTGTTTCTC 
AACAG GAAAG G CATAATCAC
294 3 mM MgCl2 58° C
exon 11 forward 
exon 11 reverse
GAAGCTCTGTAGCATCCTTG 
TGATCCTT CTTTGTT CTCAAC
235 3 mM MgCl2 58° C
exon 12 forward 
exon 12 reverse
TTATCAAGTGAAAGAAAACACG
TGTATGTGCTAGGCATTGAAG
371 3 mM MgCl2 58° C
exon 13 forward 
exon 13 reverse
CACTGTAGCATTTCTGTGGTC 
ACCCAATACTGAAG CAACTG
209 3 mM MgCl2 58° C
exon 14 forward 
exon 14 reverse
ACCCACTCCCCTTAATTG 
CACAGAG CAGATCAG CAG
211 3 mM MgCl2 58° C
exon 15 forward 
exon 15 reverse
CGAGGGCTTTTCTGGTC
TTAGATGATTTGGTTGTCCTG
259 3 mM MgCl2 58° C
exon 16 forward 
exon 16 reverse
AACTGCTTGCAAGTTTTCC
AGGTCCTCTCACTAACCCTG
247 3 mM MgCl2 58° C
exon 17 forward 
exon 17 reverse
GACCAGTAATTTAAGGCATTG
GTCATTTCTTTCAATATGCCC
285 3 mM MgCl2 58° C
exon 18 forward 
exon 18 reverse
AAAG T C CATT CAGG CTTTG 
CTGTGTTTCCGAGGTCAG
279 3 mM MgCl2 58° C
exon 19 forward 
exon 19 reverse
AATGAATG CTGATTAAAATGTG 
ACAATTGGATTCTCCTACAGC
688 3 mM MgCl2 58° C
*, Roche, Woerden, Netherlands
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CEP290, ARMS PCRt (c.2991+1655A>G)
Primer Sequence 5' - 3'
Size Annealing
(bp) PCR mix temperature
c.2991+1655A>G 
wildtype forward ACCGCACCTGGCCCCAGTTGTAATTGTGGA
c.2991+1655A>G 
mutant forward ACCGCACCTGGCCCCAGTTGTAATTGTGGg 137
1.5 mM 
MgCl2 60° C
c.2991+1655A>G
reverse AGTAAGGAGGATGTAAGACTGGAGATAGAG
t, Amplification-refractory mutation system (ARMS) PCR;
CEP290, RFLP exon 7 t (c.451C>T, p.Arg151X)
exon 7 forward 
exon 7 reverse
CATTTT CTACTTTGTTAG AGAGG ATTT 
GAAGACTCCAGTCCTGG TTAAAA
578 1.5 mM MgCl2
t, restriction fragment length polymorphism analysis
CEP290, cDNA primers
exon 5 forward TAATGAAACTGGAAAATGAACTGG
exon 9 reverse CACTGTCTTCCCCTCTTCTTG 336 3 mM MgCl2 56° C
exon 10 reverse TGAACTTCAATTTTCTCATTAGCTTC 433
CHARTER 4 A NOVEL NONSENSE MUTATION IN CEP290 INDUCES EXON SKIPPING AND LEADS TO A RELATIVELY MILD RETINAL PHENOTYPE
REFERENCES
1. Frank V, den Hollander AI, Bruchle NO, et al. Mutations of the CEP290 gene encoding 
a centrosomal protein cause Meckel-Gruber syndrome. Hum Mutat. 2008;29:45-52.
2. Sayer JA, Otto EA, O'Toole JF, et al. The centrosomal protein nephrocystin-6 is mutated 
in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006;38:674-681.
3. Valente EM, Silhavy JL, Brancati F, et al. Mutations in CEP290, which encodes a centrosomal 
protein, cause pleiotropic forms of Joubert syndrome. Nat Genet. 2006;38:623-625.
4. den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene 
are a frequent cause of Leber congenital amaurosis. Am J Hum Genet. 2006;79:556-561.
5. Perrault I, Delphin N, Hanein S, et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital 
amaurosis and delineation of the associated phenotype. Hum Mutat. 2007;28:416.
6. Helou J, Otto EA, Attanasio M, et al. Mutation analysis of NPHP6/CEP290 in patients with Joubert 
syndrome and Senior-Loken syndrome. J Med Genet. 2007;44:657-663.
7. Leitch CC, Zaghloul NA, Davis EE, et al. Hypomorphic mutations in syndromic encephalocele 
genes are associated with Bardet-Biedl syndrome. Nat Genet. 2008;40:443-448.
8. Vallespin E, Lopez-Martinez MA, Cantalapiedra D, et al. Frequency of CEP290 c.2991+1655A>G 
mutation in 175 Spanish families affected with Leber congenital amaurosis and early-onset 
retinitis pigmentosa. Mol Vis. 2007;13:2160-2162.
9. den Hollander AI, Roepman R, Koenekoop RK, Cremers FPM. Leber congenital amaurosis: 
genes, proteins and disease mechanisms. Prog Retin Eye Res. 2008;27:391-419.
10. Cideciyan AV, Aleman TS, Jacobson SG, et al. Centrosomal-ciliary gene CEP290/NPHP6 
mutations result in blindness with unexpected sparing of photoreceptors and visual brain: 
implications for therapy of Leber congenital amaurosis. Hum Mutat. 2007;28:1074-1083.
11. Hanein S, Perrault I, Gerber S, et al. Leber congenital amaurosis: comprehensive survey of the 
genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations 
as a strategy for molecular diagnosis. Hum Mutat. 2004;23:306-317.
12. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV Standard for full-field 
clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69-77.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human 
nucleated cells. Nucleic Acids Res. 1988;16:1215.
14. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: 
a unified multipoint approach. Am J Hum Genet. 1996;58:1347-1363.
15. Hoffmann K, Lindner TH. EasyLINKAGE-Plus-automated linkage analyses using large-scale 
SNP data. Bioinformatics. 2005;21:3565-3567.
16. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using 
high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 
2005;65:6071-6079.
97
17. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. 
Methods Mol Biol. 2000;132:365-386.
18. Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations.
Curr Protoc Hum Genet. 2001;Chapter 9:Unit 9.8.
19. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection 
in Genie. J Comput Biol. 1997;4:311-323.
20. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify 
exonic splicing enhancers. Nucleic Acids Res. 2003;31:3568-3571.
21. Lorenz B, Gyurus P, Preising M, et al. Early-onset severe rod-cone dystrophy in young children 
with RPE65 mutations. Invest Ophthalmol Vis Sci. 2000;41:2735-2742.
22. van Osch L, van Schooneveld M, Bleeker-Wagemakers EM. Golden tapetal reflex in male 
patients with X-linked retinitis pigmentosa. Case report and practical implications. Ophthalmic 
Paediatr Genet. 1990;11:287-291.
23. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes: 
when nonsense affects RNA abundance. Trends Biochem Sci. 1998;23:198-199.
24. Cheng J, Belgrader P, Zhou X, Maquat LE. Introns are cis effectors of the nonsense- 
codon-mediated reduction in nuclear mRNA abundance. Mol Cell Biol. 1994;14:6317-6325.
25. Zhang J, Sun X, Qian Y, Maquat LE. Intron function in the nonsense-mediated decay 
of beta-globin mRNA: indications that pre-mRNA splicing in the nucleus can influence 
mRNA translation in the cytoplasm. RNA. 1998;4:801-815.
26. Dietz HC, Valle D, Francomano CA, Kendzior Jr. RJ, Pyeritz RE, Cutting GR. The skipping of 
constitutive exons in vivo induced by nonsense mutations. Science. 1993;259:680-683.
27. Valentine CR. The association of nonsense codons with exon skipping. Mutat Res. 1998;411:87-117.
28. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: 
exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285-298.
29. Wang J, Chang YF, Hamilton JI, Wilkinson MF. Nonsense-associated altered splicing:
a frame-dependent response distinct from nonsense-mediated decay. Mol Cell. 2002;10:951-957.
30. Maquat LE. NASty effects on fibrillin pre-mRNA splicing: another case of ESE does it, but 
proposals for translation-dependent splice site choice live on. Genes Dev. 2002;16:1743-1753.
31. Gal A, Li Y, Thompson DA, et al. Mutations in MERTK, the human orthologue of the RCS rat 
retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet. 2000;26:270-271.
32. Tada A, Wada Y, Sato H, et al. Screening of the MERTK gene for mutations in Japanese 
patients with autosomal recessive retinitis pigmentosa. Mol Vis. 2006;12:441-444.
33. Tschernutter M, Jenkins SA, Waseem NH, et al. Clinical characterisation of a family with 
retinal dystrophy caused by mutation in the Mertk gene. Br J Ophthalmol. 2006;90:718-723.
34. D'Cruz PM, Yasumura D, Weir J, et al. Mutation of the receptor tyrosine kinase gene 
Mertk in the retinal dystrophic RCS rat. Hum Mol Genet. 2000;9:645-651.
CHARTER 4 A NOVEL NONSENSE MUTATION IN CEP290 INDUCES EXON SKIPPING AND LEADS TO A RELATIVELY MILD RETINAL PHENOTYPE
35. Chang B, Khanna H, Hawes N, et al. In-frame deletion in a novel centrosomal/ciliary protein 
CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration 
in the rd16 mouse. Hum Mol Genet. 2006;15:1847-1857.
36. Edwards RB, Szamier RB. Defective phagocytosis of isolated rod outer segments by RCS 
rat retinal pigment epithelium in culture. Science. 1977;197:1001-1003.
37. Badano JL, Kim JC, Hoskins BE, et al. Heterozygous mutations in BBS1, BBS2 and BBS6 have
a potential epistatic effect on Bardet-Biedl patients with two mutations at a second BBS locus. 
Hum Mol Genet. 2003;12:1651-1659.
38. Khanna H, Davis EE, Murga-Zamalloa CA, et al. A common allele in RPGRIP1L is a modifier 
of retinal degeneration in ciliopathies. Nat Genet. 2009;41:739-745.
39. Rivolta C, Sharon D, DeAngelis MM, Dryja TP. Retinitis pigmentosa and allied diseases: 
numerous diseases, genes, and inheritance patterns. Hum Mol Genet. 2002;11:1219-1227.
99
Ill
Adapted from : American Journal o f Human Genetics. 2008 Nov;83(5):594-603.
< I < W'J
I I I
Rob W.J. Collin,1-2-7 Karin W. Littink,1-3-7 B. Jeroen Klevering,4 
L. Ingeborgh van den Born,3 Robert K. Koenekoop,5 Marijke N. Zonneveld,13 
Ellen A.W. Blokland,1 Tim M. Strom,6 Carel B. Hoyng,4 Anneke I. den Hollander1-2-4 
and Frans PM. Cremers1-2
1 Department o f Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands;2 Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands;3 The Rotterdam Eye Hospital, Rotterdam, The Netherlands;
4 Department o f Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands;5 McGill Ocular Genetics Laboratory, Montreal Children’s Hospital Research Institute, 
M cGill University Health Centre, Montreal, Canada;6 Institute o f Human Genetics, Helmholtz Zentrum 
München, German Research Center for Environmental Health, Neuherberg, Germany.
7 These two authors contributed equally to this work.
I l l

a b s t r a c t
In patients w ith  autosomal-recessive retinitis pigmentosa (arRP), homozygosity 
mapping was performed for detection of regions harboring genes that might be 
causative for RP. In one affected sib pair, a shared homozygous region of 5.0 Mb was  
identified on chromosome 6, w ith in the RP25 locus. One of the genes residing in this 
interval was the retina-expressed gene EGFL11. Several genes resembling EGFL11 
were predicted just centromeric of EGFL11. Extensive long-range RT-PCR, combined  
with  5'- and 3'- RACE analysis, resulted in the identi fication of a 10-kb transcript,  
starting w ith the annotated exons of EGFL11 and spanning 44 exons and 2 Mb of 
genomic DNA. The transcrip t is predicted to encode a 3165-amino acids extracellular 
protein containing 28 EGF-like and five Laminin A G-like domains. Interestingly, 
the second part of the protein was found to be the human ortholog of Drosophila 
eyes shut (eys), also known as spacemaker, a protein essential for photoreceptor  
morphology. Mutation analysis in the sib pair homozygous at RP25 revealed 
a nonsense mutation (p.Tyr3156X) segregating w ith RP The same mutation was  
identified homozygously in three arRP siblings of an unrelated family. A  frameshift  
mutat ion (pPro2238ProfsX16) was found in an isolated RP patient. In conclusion,  
we identif ied a gene, coined eyes shut homolog (EYS), consisting of EGFL11 and 
the human ortholog of Drosophila eys, wh ich is mutated in patients w ith  arRP With  
a size of 2 Mb, it is one of the largest human genes, and it is by far the largest retinal 
dystrophy gene. The discovery of EYS might shed light on a cri tical component of 
photoreceptor morphogenesis.
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iNTRoDUCTioN
Retinitis pigmentosa (RP [M IM 268000]) is made up of a clinically and genetically 
heterogeneous group of diseases characterized by night blindness and constriction 
of the visual field, leading to severe visual impairment due to progressive degeneration 
of photoreceptors and, often, blindness. To date, 21 genes have been described as 
causing autosomal-recessive RP (arRP) and five loci have been identified for which  
the causative gene is still unidentified (RetNet web resource). Genes that cause arRP 
encode proteins that exert their function in different pathways within the retina, such 
as the phototransduction cascade (CNGA1, CNGB1, PDE6A, PDE6B, RGR, RHO, SAG 
[M IM *123825, *600724, *180071, +180072, *600342, +180380, and *181031, respectively]) 
or vitamin A metabolism (ABCA4, LRAT, RLBP1, RPE65[M IM *601691, +604863, *180090, 
and +180069, respectively]). Others encode proteins that have a structural or signaling 
function (CRB1, RP1, TULP1, USH2A [M IM +604210, *603937, *602280, and +608400, 
respectively]), play a role in transcriptional regulation (NR2E3, NRL [M IM *604485 and 
+162080, respectively]), or play a role in phagocytosis of the RPE (MERTK [M IM +604705]), 
or their exact role still awaits discovery (CERKL, PRCD, PROM1 [M IM *608381, *610598, 
and *604365, respectively]).1 USH2A is the most frequently mutated gene, causing ~7% 
of arRP, whereas most other genes account for only 1-2% of arRP cases.1 Altogether, 
these 21 known genes are estimated to account for 50% of arRP cases, indicating that 
more genes await discovery. Mutations at the RP25 locus [MIM #602772] might also 
represent a signif icant cause of arRP, given that 10%-25% of Spanish arRP families 
were previously shown to map to this locus.2, 3 Previous studies have excluded mutations 
in 60 genes at the RP25 locus.4-14 Recently, the RP25 locus was significantly reduced 
by linkage studies in additional Spanish families and the identification of a 100-200 kb 
deletion in one of the linked families, but the causative gene has not yet been identified.2, 7 
Homozygosity mapping has proven to be an effective approach in the search for genes15' 
17 and in the discovery of mutations in known arRP genes.18
The purpose of this study was to identify retinal dystrophy genes, utilizing homozygosity 
mapping with SNP microarray technology. Genome-wide homozygosity mapping in 
a large series of outbred arRP patients revealed a region on chromosome 6q12-q11.1 
that was homozygous in two affected siblings and was fully situated within the previously 
defined RP25 locus.3 We characterized an exceptionally large gene variant in this 
region, and we found it to be specifically expressed in the retina. Sequence analysis 
revealed a homozygous nonsense mutation in these siblings, segregating with RP in the 
family. Subsequently, the same mutation was detected in an unrelated family with arRP, 
whereas another mutation was identified in an isolated RP patient.
103
s u b j e c t s  a n d  m e t h o d s
S u b je c t s  a n d  c l i n i c a l  e v a lu a t io n
Five patients from three families (II-1 and II-3 from family A, II-3 and II-6 from family  
B, and II-1 from family C) received the RP diagnosis several years ago through  
ophthalmologic examination. The examination included evaluation of best-corrected  
visual acuity and sli t-lamp biomicroscopy, fo llowed by indirect ophthalmoscopy  
and fundus photography after pupillary dilatation. The size and the extent of the 
visual-f ield defects were assessed w ith Goldmann kinetic perimetry (targets V-4e, 
II-4e, and I-4e to I-1e; for all patients) and Humphrey static perimetry (30-2; only for 
patient II-3 in family A). Finally, an electroretinogram (ERG) was recorded in all five 
patients, in accordance w ith the protocol of the International Society for Clinical 
Electrophysiology of Vision (ISCEV).19 After the nature of this phenotype-genotype 
study was explained, an informed consent adhering to the tenets of the Declaration 
of Helsinki was obtained from all patients and from the unaffected siblings of family 
A and B. Blood samples from these individuals were then collected for future 
molecular-genetics testing. The initial results of the molecular-genetics analysis 
warranted further ophthalmologic investigation in the supposedly unaffected  
individual II-4 from family B. This investigation included all of the elements of the 
earlier ophthalmologic examination of the affected individuals, w ith the exception 
of the visual-f ield assessment. Furthermore, 142 probands w ith  RP and indications  
of a recessive mode of inheritance part ic ipated in th is study. Control DNA samples 
from 276 unrelated Dutch individuals were used.
H o m o z y g o s i t y  m a p p in g  a n d  m u ta t io n  a n a ly s is
Genomic DNA was isolated from lymphocytes by standard salt ing-out procedures.20 
DNA samples of 145 RP patients, main ly of Dutch origin, were  genotyped on either 
the GeneChip Mapping 250K NspI array, contain ing 262,000 SNPs, or the GeneChip 
Genome-Wide Human SNP Array 5.0, w h ich  contains 500,568 polymorphic SNPs 
in addition to 420,000 nonpolymorphic probes for the detection of germline copy- 
number varia t ions (Affymetrix). Array experiments were  performed accord ing to 
protocols provided by the manufacturer. The 250K SNP genotypes were  analyzed 
w ith  the software package CNAG.21 Data from the 5.0 array were  genotyped w ith  
Genotype Console software (Affymetr ix), whereas regions of homozygosity were  
calcu lated w ith  Partek Genomics Solution (Partek). All 41 coding exons and three  
noncoding exons of EYS were PCR amplif ied and analyzed in sense and antisense  
direct ions w ith  a dye-termination chemis try (BigDye Terminator, vers ion 3 on a 3730 
DNA analyzer; Applied Biosystems). Primers for PCR and sequencing of the
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44 exons are given in Table S1; PCR condit ions are available upon request.
A  subset of 131 RP patients, mainly from The Netherlands, and a control panel 
of 276 ethn ica l ly matched unrelated and unaffected indiv iduals were  screened for 
the p.Tyr3156X mutation w ith  the amplif ica t ion-re frac tory mutation system (ARMS; 
primers listed in Table S2).
C h a r a c te r i z a t io n  o f  th e  g e n e t ic  c o m p o s i t i o n  o f  EY S
For characterization of the expression of predicted genes encoding EGF-like and/or 
Laminin A G-like domains (NT_007299.33, NT_007299.34, NT_007299.35, NT_007299.37 
and ENST00000237253) in retina, several primers were designed, corresponding to the 
exons of these gene predictions. Long-range PCRs were performed on human retina 
Marathon-Ready cDNA (Clontech) w ith  the Advantage cDNA PCR Kit (Clontech), 
in accordance w ith the manufacturer's protocol. Nested PCR reactions w ith the 
use of a number of these primer combinations resulted in the amplif ication of PCR 
products representing parts of a transcr ip t expressed in retina. PCR products were  
purified on Nucleospin Plasmid Quick Pure columns (Macherey-Nagel) and either  
direct ly sequenced or cloned in the pCR4-TOPO vector w ith the use of the TOPO 
TA Cloning Kit (Invitrogen) for sequencing w ith T7 and T3 sequencing primers as 
described above. Primer sequences are listed in Table S3. To characterize the 5'- 
and 3'- untranslated regions (UTR) of the detected transcrip ts , rapid amplif ication 
of cDNA ends (5'- and 3'- RACE, Clontech) was performed, in accordance with  
the manufacturer's protocol, using the Advantage cDNA PCR kit and human retina 
Marathon-Ready cDNA (Clontech) as a template.
R T -P C R  a n a ly s is  f o r  d e te r m in in g  t i s s u e  d is t r i b u t io n  o f  E Y S
Total RNA from human placenta, adult brain, testis, kidney, and retina and from 
feta l heart, skeletal muscle, liver, and lung was obta ined from Clontech. For cDNA  
synthesis, 2 ^g of tota l RNA was incubated w ith  5 ng/^ l of random hexamers  
(pd(N)6, Pharmacia) and 0.3 mM dNTPs (Invitrogen Life Sciences). Subsequently, 
cDNA was synthesized w ith  the M -MLV Reverse Transcriptase kit (Invitrogen Life 
Sciences), w ith  a final concentrat ion of 10 mM DTT, 11 U Reverse Transcr iptase, 
and 0.33 U RNAguard (American Biosc iences) per reaction. For detecting the 
distr ibution patterns of human EYS in various human tissues, RT-PCR was carried  
out w ith  Advantage Polymerase (Clontech), w ith  the use of various primer pairs 
equally distr ibuted along the transcrip t. As a contro l, b-act in (ACTB) was  amplif ied.  
To verify that the amplif ied products indeed corresponded to the EYS transcrip t,
PCR products were  purif ied and sequenced as described above. Primer sequences  
are listed in Table S4.
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B io i n f o r m a t i c  a n a ly s is
Genes and g e n e -p re d ic t io n  tra c k s  w e re  de rive d  from  the  UCSC Genom e W o rk in g  
D ra ft, M a rc h  2006 a ssem b ly  (hg18). For id e n tif ic a t io n  o f h om o logous  p ro te in s  o f 
hum an and D rosophila  eys, p ro te in  b la s t and tb la s tn  w e re  run unde r d e fa u lt se ttin g s  
(BLAST w e b  re sou rce ). C onse rved  fu n c tio n a l d om a in s  w ith in  p ro te in s  w e re  sea rched  
w ith  e ith e r th e  w e b -b a se d  to o l SM AR T22, 23 o r P fam .24 P re d ic t io n  o f am ino acid  
re s id u e s  th a t m igh t be s u b je c t to  O -linked  g ly co sy la tio n  w a s  c a rr ie d  ou t w ith  the  
NetO G lyc 3.1 Serve r.25
RESULTS
H o m o z y g o s i t y  m a p p in g
In ou r s e a rc h  fo r  re tin a l d ys tro p h y  genes, hom ozygos ity  m app ing  w a s  c on du c te d  
in a la rge  s e r ie s  o f p a tie n ts  w ith  RP. G enom e -w ide  SNP geno typ ing  re vea led  tw o  
sha red  hom ozygous  re g ion s  >  5 M b  in tw o  a ffe c te d  s ib lin g s  d ia gnosed  w ith  RP. The  
la rg e s t hom ozygous  reg ion  (19.3 M b ) w a s  lo ca te d  on ch rom osom e  2 b e tw e e n  SN P_A -  
1816491 and SNP_A-2053763, w h e re a s  th e  second  reg ion , o f 5.0 M b , w a s  lo ca te d  at 
ch rom osom e  6q12-q11.1 b e tw een  SNP_A-2144407 and SNP_A-1833968. The reg ion  
on ch rom osom e  6 o ve r la p ped  w ith  a w e ll-k n o w n  and pub lish ed  lo cu s  fo r arRP, 
nam e ly  RP25,3 fo r  w h ic h  th e  c a u sa tiv e  gene has no t y e t been id e n tif ie d  (F igure 1A). 
The re fo re , a s ea rch  fo r  can d id a te  genes re s id in g  w ith in  th is  hom ozygous  in te rv a l w a s  
c on d u c te d . W ith in  th e  hom ozygous  re g ion  sha red  w ith  th e  RP25 lo cus , five  genes are  
know n  to  re s ide  (F igu re  1A), o f w h ic h  EGFL11 w a s  fo u nd  to  be exp re ssed  in th e  eye, 
a c c o rd in g  to  th e  U n igene  d a tabase . RT-PCR ana lys is  con firm ed  abundan t e xp ress ion  
o f th is  gene in hum an re tina  (data no t show n ).
I d e n t i f i c a t io n  o f  E Y S  e x o n s
The EGFL11 gene is made up o f 12 exons and en code s  a p ro te in  w ith  seve ra l EGF- 
like  dom a ins . S equence  a na lys is  o f th e  anno ta te d  EGFL11 gene in one o f th e  tw o  
a ffe c te d  s ib lin g s  d id no t re vea l any c a u sa tiv e  sequen ce  va r ia n ts . C en trom e ric  to  
EGFL11, s eve ra l o th e r genes e n cod ing  EGF-like d om a in s  w e re  p re d ic te d , in c lu d ing  
NT_007299.37, ENST00000237253, NT_007299.35, NT_007299.34, and NT_007299.33.
To te s t th e  h ypo th es is  th a t e xons o f th e se  g e n e -p re d ic t io n  tra c k s  w e re  p a rt o f 
a lo n ge r iso fo rm  o f th e  EGFL11 gene , e x ten s ive  lo n g -ra nge  RT-PCR e xpe rim en ts  
w e re  p e rfo rm ed , com b ined  w ith  5 '- and 3 '- RACE e xpe r im en ts  us ing  hum an re tina  
cD N A  as a tem p la te . In te re s tin g ly , th e se  ana lyse s  show ed  th a t in a dd itio n  to  
a tra n s c r ip t c o rre sp o n d in g  to  th e  anno ta te d  EGFL11 gene , a second  tra n s c r ip t
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F IG U R E  1. Genomic structu re , cDNA fragments, and protein domains of EYS.
(See appendix for color figure)
A. Upper panel: the RP25 chromosomal region at 6p12.1-q133, the 5.0 M b  homozygous region  
identified in fam ily A , and the five known genes w ith in  the homozygous region. Exons 1 and 2 
o f KHDRBS2 reside in  the critica l region. In  the middle, the exon predictions are depicted on
the basis o f RefSeq (in blue), Genescan (in black), and Ensembl (in red), w ith  the use o f the M arch  
2006 UCSC genome bu ild  (hg18). Below the genomic-exon annotation is the exon structure  
o f human EYS (exons drawn to scale; in tron  sizes can be found in  the top panel). The complete 
nucleotide sequence o f human EYS cD N A  is presented in  Figure S2. For details o f the exon- 
in tron  structure, see Table S5. The 5’- and 3’- UTRs are indicated in black boxes; the colors 
o f the prote in-coding exons correspond w ith  those o f the prote in domains in  (B). Lower panel: 
reverse-transcription PCR fragments o f human EYS w ith  retina R NA and EYS-specific primers  
(arrowheads) or 5’- and 3’- RACE adaptor primers (squares). The 5’-UTR , the open reading 
frame, and the 3’-UTR  altogether measure 10,475 nucleotides (see Table S5). Exon 42 (63 bp) 
is alternatively spliced in retina R N A  (see Figure 2). For details o f RT-PCR studies, see Figure S1.
B. Protein-domain structure o f EYS and its Drosophila o rtho log (GenBank ID  ABH07112.1).
Note the conspicuous conservation o f the order o f EGF-like and Lam in in A  G-like domains 
between human and Drosophila. The p.Pro2238ProfsX16 frameshift muta tion truncates several 
EGF-like and Lam in in A  G-like domains, whereas the carboxy-term inal p.Tyr3156X mutation  
truncates the last ten amino acids o f human EYS. Abbreviations are as follows: EGF, epidermal 
grow th factor domain; cbEGF, calcium -binding EGF-like domain; EGF-like, EGF-like domain; 
LamG, Lam in in A  G-like domain. The asterisk denotes glycosaminoglycan (GAG) attachment 
sites predicted by Husain and coworkers.26 Two putative O-glycosylation sites are predicted in 
the human prote in (Thr1268 and Thr1424). Detailed characteristics o f the human EYS protein  
domains are presented in Figure S2
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was present, containing several exons of these gene predictions. This larger 
transcr ip t started at the previously annotated EGFL11 gene and extended up to 
the final exon of NT_007299.33 (Figure 1A). In total, this extended variant of EGFL11 
spans almost 2 Mb of genomic DNA and contains 44 exons, of wh ich several had 
not previously been predicted by gene-predict ion programs. The transcr ip t contains 
10,475 nucleotides, including the 3' untranslated region and poly-A tail. A  detailed 
overv iew of the identif ication and characterization of the transcr ip t is presented in 
Figure S1. The protein encoded by this transcr ip t is made up of 3165 amino acids 
and is predicted to contain a signal peptide for secretion into the extracellu lar  
environment. In addition, the protein harbors 28 EGF-like and 5 Laminin A  G-like 
domains (Figure 1B). Subsequently, BLAST analyses were performed for the 
identif ication of potential orthologs of this human protein in lower species. These 
analyses led us to discover that the second part of this protein is homologous to 
Drosophila eyes shu t (eys), also known as spacemaker, a protein essential for 
photoreceptor development and morphology in the insect eye.26, 27
The domain organization of eys is comparable to that of the human eys homolog 
protein, w ith 14 EGF-like and four Laminin A  G-like domains posit ioned in a similar 
order (Figure 1B). Initially, the Drosophila eys protein was described as a proteo­
glycan related to agrin and perlecan.26 However, w ith the sequence of the Drosophila  
protein used as input in a BLAST search for human orthologs, eys homolog protein, 
rather than agrin  and perlecan, was found to be the closest relative. In addition, the 
signaling molecules Notch-1 and -2 and the Crumbs-1 and -2 homolog proteins were  
identified as relatives of Drosophila eys (data not shown). These analyses show that 
the gene identified in this study is the true ortholog of Drosophila eys. Therefore,  
we propose to name the human gene eyes shu t hom olog (EYS).
T is s u e  d is t r i b u t io n  o f  E Y S  m R N A
For study of the tissue distribution of human EYS, RT-PCR analysis was performed 
on cDNA from various tissues, including retina. In total, five primer pairs were used, 
distr ibuted along the transcrip t. All five primer pairs that were used showed either 
specif ic or enriched expression of EYS in retina, although for one primer pair (exons 
41-44), weak PCR products were also observed in the other tissues (Figure 2). This 
primer pair also amplif ied two fragments, and sequence analysis showed that the 
fragments represent alternatively spliced mRNA products of the EYS gene, either 
lacking or containing exon 42 (63 bp). Together, these results show that this gene is 
abundantly expressed in retina and support the hypothesis that the encoded protein 
plays an important role in vision.
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F IG U R E  2 . Tissue d is tribu tion of EYS.
RT-PCR analysis was performed on tota l R N A  from  various tissues. The expression o f EYS was 
determ ined w ith  the use o f several p rim er pairs d istributed along the transcript (see Table S4). 
The weak PCR product detected w ith  primers from  exon 41 to exon 44 is indicated by an asterisk 
and represents a transcrip t resulting from  alternative splicing. ACTB (lower panel) was used as 
a control.
M u t a t io n  a n a ly s is
After this transcr ip t was identified, the SNP data were reanalyzed in an attempt 
to identify RP patients who carry homozygous regions (threshold was set at >200 
consecutive homozygous SNP calls) encompassing this new gene. On the basis of 
these data, ten arRP patients, including one of the affected individuals of the family  
described above (Figure 3A, family A), were selected for further mutation analysis 
of this gene. Sequence analysis of all 44 exons and flanking intronic sequences of 
the human EYS gene revealed a homozygous mutation, c.9468T>A, in the last exon 
(Figure 3B), present in the proband of family A. At the protein level, this mutation 
results in premature termination of the encoded protein at position 3156 (p.Tyr3156X). 
The mutation was confirmed to be homozygously present in his affected sibling and 
either absent or heterozygously present in four unaffected siblings (Figure 3A, 
family A). For detecting whether this mutation occurs more frequently in arRP 
patients, alle le-specif ic PCR was conducted on another group of 131 unrelated 
probands affected with RP, resulting in the identification of a second proband carrying 
this mutation. The mutation was also homozygously present in her affected siblings,
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bu t no t in he r fo u r  u n a ffe c te d  fa m ily  m em be rs  (F igu re  3A, fa m ily  B). M ic ro s a te llite  
and SNP ana lys is  in th e  reg ion  w ith in  and su rro u nd in g  th e  EYS gene re vea le d  th a t 
p.Tyr3156X w a s  p re sen t a t th e  sam e hap lo type  in bo th  fam ilie s , sugge s tin g  a fo u n d e r  
e ffe c t. The p.Tyr3156X m u ta tio n  w a s  e xc lu d ed  from  552 a lle le s  o f e th n ic a lly  m a tched  
co n tro l in d iv id ua ls . The nonsense  m u ta tio n  d e sc r ib ed  he re  re su lts  in th e  absence  
o f th e  te n  C -te rm ina l am ino a c id s  o f the  hum an EYS p ro te in . S equence  com pa rison  
o f th e  C -te rm ina l am ino a c id s  o f th e  hum an EYS p ro te in  and va r io u s  v e r te b ra te  and  
in v e rte b ra te  o r th o lo g s  re vea led  th a t som e o f th e  am ino a c id s  th a t a re a bsen t in 
th e  hum an m u ta n t EYS p ro te in  are w e ll c on se rved , even up to  zeb ra fish , and th u s  
m ay be c ru c ia l fo r  p rope r fu n c tio n  o f th e  EYS p ro te in  in v e r te b ra te s  (F igure 3C). 
S equence  ana lys is  in th e  o the r n ine  p a tie n ts  w h o s e  D N A  w a s  hom ozygous  a t the  
re g ion  h a rb o r in g  th e  EYS gene re vea led  a se cond  m u ta tio n , nam e ly  a hom ozygous  
1-bp de le tio n  in exon 33 (c.6714delT; F igure 3B). A t th e  p ro te in  leve l, th is  m u ta tio n  is 
p re d ic te d  to  re su lt in a fra m e s h ift and p rem a tu re  te rm in a tio n  (p .P ro2238P rofsX16) of 
EYS. G iven th a t p rem a tu re  tru n c a t io n  is p re d ic te d  to  o c c u r w ith in  th e  se cond  Lam in in  
A  G -like  dom a in , th e  m u tan t p ro te in  w il l la c k  s ix  EGF-like and th re e  Lam in in  A  G -like  
dom a ins  (F igu re  1B).
F iG U R E  3 . Mutation analysis of EYS in Rp patients. (See appendix for color figure)
A . Family A
Q-
1-1
-O
I-2
à 5 è ò ò ù
11-1 II-2 II-3 II-4 II-5 II-6 
M1/M1 M1/+ M1/M1 M1/+ +/+ M1/+
a . Pedi grees o f three families w ith  individuals affected w ith  RP. Below the individuals, genotypes 
are presented for either the p.Tyr3156X change (M1, families A  and B) or the p.Pro2238ProfsX16 
change (M2, fam ily C) detected to segregate w ith  the disease. M 1 /M 1  and M 2 /M 2  represent 
homozygous mutants; M 1 /+  indicates heterozygous carriers, whereas +/+ indicates individuals 
carrying two w ild -type  alleles.
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B. Upper panel: partia l sequence 
o f the EYS gene showing the nonsense 
c.9486T>A change, in  an affected 
ind iv idua l (fam ily A, II-1) and an 
unaffected sibling (fam ily A , II-5).
The m utation replaces a tyrosine  
residue by a te rm ina tion codon  
(p.Tyr3156X). Preceding amino acids 
are indicated above the sequence trace. 
Lower panel: partial sequence o f the 
EYS gene showing the c.6714delT 
change, in an affected individual 
(fam ily C, II-1) and a control 
individual. The m utation results 
in  a frame shift and, eventually, in  
premature te rm ina tion o f the protein  
(p.Pro2238ProfsX16). A m ino  acids are 
indicated above the sequence trace.
Asr Val X 
A A T G T T T A A G A
p.Tyr3156X
(M1) Asn Val Tyr Asp 
A A T G T T T A T G A
Wildtype
Thr Pro Ser Gin
A C C C C A T C A C A
p.Pro2238ProfsX16
(M2)
B
c .
Human
Chimpanzee
Horse
Chicken
Zebrafish
Drosophila
IELIK-LE 
IELIK-LE 
KIELIK-SE 
jKKIQL K-GE 
?0C r E 
IISDFSTYQ
p.Tyr3156X
♦
v y d g d e q n Sv t —
VY DG DE QN gV T---
GDEQ N-------
GDHR N-------
VYiG^E---------------
|g s c d l h g @ e p l t v
c. Sequence comparison o f the 25 most C -term inal amino acids o f the human EYS protein  
and several vertebrate and invertebrate orthologs. Residues identical in  all sequences are 
white on a black background, whereas sim ilar amino acids are white on a gray background. 
Residues that are present in at least three o f the six proteins are indicated in black on a light 
gray background. Residues constitu ting the most C -term inal Lam in in  A  G-like domain  
in  the Drosophila prote in are underlined. Accession numbers o f the prote in sequences 
used fo r sequence comparison are as follows: chimpanzee, XM_527426.2 (RefSeq); horse, 
XM_001918159.1 (RefSeq); chicken, XM_426198.2 (RefSeq); zebrafish, BX005106.5 (EMBL); 
Drosophila, ABH07112.1 (GenBank).
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TABLE 1. Clinical characteristics of patients w ith mutations in EYS
iD Age*(yrs) Sex
Family A
ii-1 61
Age
of
onset
(yrs)
12
in itia l
symptom
Night
blindness
and
photophobia
Visual
acuity
OD OS
20/100 20/40
1-3 57 F 28 Night
blindness
and
photophobia
20/50 20/80
Family B
ii-3 53 45
-4 52 F 46
II-6 49 F 42
Night
blindness
Night
blindness
Night
blindness
20/20 20/20
20/25 20/20
20/20 20/20
Family C
II-2 48 13 Night
blindness
20/50 20/40
Goldmann
Ophthalmoscopy Kinetic
Perimetry
Pallor of the optic Constricted
disc, attenuated visual fields
retinal vasculature, (50-80
bone spicules in degrees).
midperiphery and Marked
atrophic lesion in decrease of
the posterior pole. the central 
visual field 
(I-4e not 
observed)
Mild attenuation Large
of the retinal central
vessels and RPE scotomas
alterations in the without
central macula. constriction 
of the 
peripheral 
visual field.
Normal aspect Constricted
of the optic disc, visual fields
attenuated retinal (50-60
vasculature and 
bone spicules in 
midperiphery.
degrees)
Normal aspect 
of the optic disc, 
attenuated retinal 
vessels and bone 
spicules in the 
nasal fundus.
NP
Mild pallor of the Severely
optic disc, severely constricted
attenuated visual fields,
vasculature and with some
bone spicules residual
throughout entire visual field
retina. temporally.
Pallor of the optic Severely
disc, attenuated constricted
vasculature, (<5 degrees)
RPE alterations 
in the central 
macula, extensive 
bone spicule 
pigmentation 
throughout entire 
retina.
visual fields
Rod
ERG
Pheno- 
cone type
NR NR RP
CRD
NR NR RP
RP
NR NR RP
NR NR RP
F
F
’ Current age; M , male; F, female; RP, re tin itis  pigmentosa; CRD, cone-rod dystrophy; RPE, retinal 
pigment epithelium; NP, no t performed; ERG, electroretinogram; ¿, decreased; ¿¿, severely 
decreased; NR, non-recordable
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time from flash onset, 20 ms/unit time from flash onset, 20 ms/unit
F IG U R E  4 . Clinical characteristics of RP patients w ith  a homozygous p.Tyr3156X mutation in EYS. 
(See appendix for color figure)
A. Fundus photograph o f the righ t eye o f patient II-1 o f fam ily A , showing m ild  pallor o f the optic  
disc, a peripapillary crescent, attenuated retinal vessels, and bone-spicule pigmentations. A n  area 
o f sharply demarcated chorioretinal atrophy is located nasal to the fovea, w ith  sim ilar atrophic 
lesions along the vascular arcades, conflating to diffuse atrophy in  the m idperiphery.
B. Fundus photograph o f the posterior pole and nasal peripheral retina o f the righ t eye o f patient 
II-6  o f fam ily B, showing m ild  pallor o f the optic disc, severely attenuated vessels, pronounced  
atrophic changes in the (m id) periphery that spare the posterior pole, and extensive bone spicules 
in  the peripheral retina.
C. Scotopic and photopic ERG o f the righ t eye o f patient II-3  o f fam ily A  and a norm al subject. 
Scotopic m ixed response (ISCEV measurement; 2500 mcds/m2) had a b-wave amplitude
o f 274 |iV  (normal > 195 |iV , mean 424 |iV ). The b-wave amplitude o f the photopic response 
(ISCEV measurement; 2500 mcds/m2) was 58.8 | iV  (normal > 69 |iV , mean 79 |iV).
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C l in i c a l  c h a r a c t e r i s t i c s
C lin ica l e xam ina tio n  o f th e  a ffe c te d  in d iv id ua ls  o f fa m ilie s  A , B, and C show ed  th a t 
a ll p a tie n ts , w ith  th e  e xcep tio n  o f p a tie n t II-3 o f fa m ily  A , d is p la yed  c h a ra c te r is t ic  RP 
ab n o rm a lit ie s , in c lu d in g  n ig h t b lin d ne ss  as th e  in it ia l sym p tom , re tin a l b o n e -sp icu le  
p igm en ta tio n s  and a tte n ua te d  re tin a l ve sse ls  (F igu res 4A  and 4B), c o n s tr ic t io n  o f the  
v isu a l fie ld s , and a n o n -re co rd a b le  ERG o r ERG re sponses  in a ro d -c o ne  pa tte rn .
A  p o s te r io r  su b ca p su la r c a ta ra c t cou ld  be ob se rved  in p a tie n t II-1 o f fa m ily  A  (age 53) 
and in p a tie n t II-1 o f fa m ily  C (age 39). P a tie n t II-3  o f fa m ily  A  a lso dem ons tra te d  
a p h o to re ce p to r d ys tro phy , bu t in th is  p a tie n t, the  cones  w e re  m ore se ve re ly  a ffe c te d  
th a n  w e re  the  rods  (co n e -ro d  p a tte rn ; F igure 4C). Th is  is a lso re fle c te d  by th e  cen tra l 
sco tom as  on the  k in e tic  v isua l fie ld . Fundus abno rm a lit ie s  in c lu ded  cen tra l abno rm a ­
lit ie s  at th e  leve l o f the  RPE and m ode ra te  a tte nua tio n  o f the  re tina l vesse ls . The c lin ica l 
c h a ra c te r is t ic s  o f the  pa tien ts  in fam ilie s  A , B, and C are sum m arized in Table 1.
DiSCUSSiON
In th e  p re se n t s tudy, w e  d e sc r ib e  an e x tended  tra n s c r ip t o f th e  EGFL11 gene, 
con ta in in g  33 a s -y e t-u n c h a ra c te r iz e d  exons d ow n s tre am  o f th e  p re v io u s ly  anno ta ted  
gene. The re su lt in g  t ra n s c r ip t is m ore  th a n  10 kb in s ize and is a b u ndan tly  exp ressed  
in hum an re tin a . The p ro te in  e n coded  by th is  gene is p re d ic te d  to  c on ta in  28 EGF-like  
and five  Lam in in  A  G -like  dom a ins . In te re s tin g ly , th e  second  p a rt o f th e  p ro te in  w a s  
fo u nd  to  be h om o logous  to  th e  Drosophila  eys p ro te in . T he re fo re , w e  nam e the  
c o rre sp o n d in g  hum an gene eyes shu t hom olog (EYS). In tw o  u n re la te d  fa m ilie s , the  
sam e hom ozygous  nonsense  m u ta tio n  (p.Tyr3156X) w a s  id e n tif ie d  as seg re g a tin g  w ith  
arRP, w h e re a s  in an is o la te d  p a tie n t, a hom ozygous  fra m e s h ift m u ta tio n  w a s  id e n tif ie d  
(p .P ro2238P rofsX16). The p a tie n ts  o f all th re e  fa m ilie s  d is p la y  ty p ic a l s ig ns  o f RP, w ith  
n ig h t b lin dness , fu n d u s  a b n o rm a lit ie s  ( in c lu d in g  b o n e -s p icu le  p igm en ta tio n s  and 
n a rro w in g  o f th e  re tin a l vesse ls ), c o n s tr ic t io n  o f th e  v isua l fie ld s , and e v id e n ce  o f 
cone - and ro d -p h o to re c e p to r  a b n o rm a lit ie s  on th e  ERG. A lth o u g h  a ll a ffe c te d  
in d iv id u a ls  sha re  a s im ila r m o le cu la r d e fe c t, th e re  a re , n e ve rth e le s s , d if fe re n c e s  in 
th e  ensu ing  p h o to re ce p to r d ys tro phy . A lth o u g h  th e  a ffe c te d  in d iv id ua l o f fa m ily  C is 
th e  yo u n g e s t o f a ll p a tie n ts  d e sc r ib e d  in th is  s tudy, she is th e  o n ly  one w h o  is le ga lly  
b lind , a re su lt o f he r s e ve re ly  c o n s tr ic te d  v isu a l fie ld s . The pheno type  o f fa m ily  A , on 
th e  o th e r hand , show s  a m ore  p rom in en t in vo lvem en t o f cone  d e g e n e ra tio n  com pa red  
to  th e  o th e r fam ilie s . T h is  is re fle c te d  by th e  m ode ra te  to  seve re  im pa irm en t o f the  
v isu a l a c u ity  (see Table 1), th e  cone  and m ixed ro d -c o ne  re spon se s  o f the  ERG, and  
th e  p ho tophob ia  as an e a rly  sym p tom . In p a tie n t II-3, e spe c ia lly , the  ERG show s
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relatively more impairment of the cone-photoreceptor system compared to the rod- 
photoreceptor system. The visual fields in th is patient are not constric ted, as in the 
other patients, but show bilateral central scotomas, also indicative of cone-rod  
dystrophy (CRD). Her elder brother (II-1) also shows central fundus lesions, but his 
ERG (at age 60) no longer shows either cone nor rod activity. We do not know whether  
a cone-rod pattern of deterioration was present in the earlier stages of his disease. 
Family B, finally, has a relatively late onset of a classic form of RP, w ith preservation 
of central vision. In this regard, the phenotype in this family is relatively mild compared 
to many forms of arRP. In two patients, cataracts were observed at a relatively young 
age. The development of cataracts, however, is often seen in patients affected by RP 
at an early age and is not exclusively present in patients w ith RP due to EYS 
mutations. It appears that in th is type of photoreceptor dystrophy, like in many forms 
of inherited retinal diseases, other modifying facto rs besides the genetic defect in 
EYS exert their influence on the phenotypic outcome and explain the intra- and 
interfamilial variability.
The frameshif t mutat ion identif ied in the isolated RP patient (family C) results in the 
absence of 927 amino acids that altogether form six EGF-like and three Laminin A  G- 
like domains. As a result of the absence of these functionally important domains, 
the truncated protein w il l probably have little or no residual function. Alternatively, 
the mRNA is degraded via a mechanism called nonsense mediated decay.28 
Premature termination of the EYS protein due to the nonsense mutation in families A 
and B results only in the absence of the ten C-terminal amino acids that apparently  
fulfill a crucial function. Although the C-terminal amino acids of Drosophila eys are 
not highly conserved compared to the human protein, several residues of this 
segment are conserved in vertebrate species, including zebrafish. These results may 
indicate that during evolution of the vertebrate eye, the C-terminal part of EYS 
became essential for proper functioning of the entire protein.
The EYS gene is located on chromosome 6q 12 and resides w ith in  the 15 Mb RP25 
locus.2- 3 Recently, a ~100 kb clone from a ti l ing-path array located w ith in  the RP25 
interval w as  found to be dele ted in all affected members of a Spanish family linked 
to RP25,7 suggesting that genes residing w ith in  th is deletion might be underly ing RP 
in famil ies linked to RP25. On the basis of the array-CGH data, the tota l length of the 
dele tion was predic ted to be 100-200 kb in size, spanning EYS exons 14-19. 
Altogether, these data support our conc lusion that EYS is the gene responsib le for 
RP in famil ies that link to the RP25 locus. The prevalence of EYS mutations remains 
to be established, because we have thus far only fu lly analyzed the presence
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of mutations in the 44 exons and flanking intronic sequences of EYS in ten patients 
w ith  arRP. The human EYS prote in is composed of 3165 amino acids and has 
a number of remarkable features. The fi rst part of the prote in corresponds to the 
previously annotated EGFL11 protein, w h ich  seems not to be present in Drosophila. 
The second part of human EYS is the ortholog of the Drosophila  eys protein. 
Whereas the domain organization is sim ilar between human and Drosophila eys, 
other features are not conserved. In both proteins, a less conserved region of the 
protein, located between the first series of EGF-like domains and the C-terminal end 
(with both EGF-like and Laminin A  G-like domains), is present. In Drosophila eys, 
mult ip le sites for the a ttachment of g lycosaminoglycan side chains are predic ted in 
th is region, and indeed, the protein is heavily glycosylated in the insect eye.26 
The consensus for such an a ttachment is composed of a serine residue d irect ly  
fo l lowed by a glycine residue, w ith  either a second ser ine-g lycine tandem or 
a series of acid ic amino acids in close proxim ity.29 Several of these serine-glycine  
clusters are found in Drosophila eys, but, remarkably, they are not conserved in 
the human ortholog. Apparently, extensive glycosylation is not required for proper  
func t ion ing of the human eys homolog protein in the retina.
Drosophila eys is an extracellular matrix protein that occupies the interrhabdomeral 
space.26- 27 The generation of the interrhabdomeral space has been a crit ical event 
in the transit ion of compound eyes from a closed to an open system. In insects with 
a ''fused rhabdomer' ' conf iguration, such as bees, photoreceptors 1-6 with in one 
ommatidium behave as one photosensitive system and collect light from the same 
area. In contrast, in insects w ith an open system, such as flies, photoreceptors 1-6 
detect light from dif ferent areas in the visual field, because they are isolated from 
each other. Consequently, flies have an improved angular sensitivity, allowing the 
detection of smaller moving objects. Both mutant Drosophila  lines eys and prom inin  
(prom) showed a failure of interrhabdomeral space separation.27 Drosophila  prom, 
a pentaspan transmembrane protein, is present throughout rhabdomer biogenesis  
and, at the time of eclosion, is selectively localized to the stalk membrane and the tips 
of the rhabdomer microvilli. There is evidence that eys binds to prom  in orchestrating  
the open-rhabdomer configuration. Interestingly, Drosophila  crumbs, a single-span 
transmembrane protein consisting of 30 extracellular EGF-like and four Laminin 
A G-like domains, is also expressed at the stalk membrane.
Wha t function can be attributed to Eys, Prom, and Crumbs in mammalian 
photoreceptors? In the mouse embryonic eye, Prom1 is located between the 
progenitors of the photoreceptor and retinal pigment epithelium (RPE) cells, whereas
CHARTER 5A IDENTIfICATION Of EYS THAT IS MUTATED IN PATIENTS WITH RP
in adult murine retina, Proml was found at the microvil li of the RPE cells and in the 
rod outer segment (ROS) layer, w ith  a high concentration in the plasmamembrane 
evaginations.30 Mutat ions in human PROM1 are associated w ith  arRP30, 31 or macular  
degeneration.32 Crumbs homolog 1 (Crb1) is expressed in mouse Müller cells, at the 
outer limiting membrane opposing photoreceptor cell inner segments, the functional 
equivalent of the Drosophila photoreceptor stalk.33 Loss-of-function mutations in 
human CRB1 result in Leber congenital amaurosis or arRP34-36
We hypothesize three d if fe rent func t ions for human EYS. First, th rough an 
in teraction w ith  PROM1, EYS could be involved in ROS disc morphogenesis.
Second, EYS might in teract direct ly or indirect ly w ith  the extracel lu lar domain of 
CRB1 or its homolog CRB2 and in this w ay  form a cri t ica l component of Mül le r cell- 
photoreceptor cell and photoreceptor ce l l-photoreceptor cell interactions. Third, 
remin iscent of the function of its Drosophila ortholog, EYS might be sequestered  
in the extracel lu lar matrix, also known as the subretinal space, between the 
(developing) photoreceptors and RPE.
In conclusion, we  have identif ied the human ortholog of Drosophila eyes shut, a 3165- 
amino acids extracellular protein that is encoded by one of the largest human genes 
described thus far. The 2 Mb size of th is gene, wh ich we have coined eyes shut 
homolog (EYS), is a little shorter of that of the dystrophin gene mutated in X-linked 
Duchenne and Becker muscular dystrophies, wh ich spans 2.2 Mb.37- 38 EYS is mutated 
in six patients of three families w ith arRP and, on the basis of previous linkage 
studies, is probably an important cause of inherited retinal blindness. On the basis 
of the function of its Drosophila counterpart (eys) and interactor (prom), it probably 
serves an important function in photoreceptor morphogenesis.
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A C C E S S IO N  N U M B E R S
For ou r hum an cD N A  encod ing  the  hum an o rtho log  o f Drosophila eys, an access ion  
num be r w a s  reques ted  a t th e  EM BL N u c le o tid e  Sequence  D a tabase  and w as  
p rov id e d ; nam e ly, FM209056. A f te r  a re qu e s t to  th e  Human Gene N om enc la tu re  
C om m ittee  w a s  s ubm itte d , th e  hum an gene is n ow  o ff ic ia lly  nam ed eyes shut 
homolog, a b b re v ia te d  EYS.
A C K N O W L E D G M E N T S
The a u th o rs  th a n k  C h ris te l Beum er, Sy lv ia van B ee rsum , D iana C rem ers , Irm a Lopez, 
Saskia  van de r V e lde -V isse r, and E rw in  van W ijk  fo r  e x c e lle n t te c h n ic a l a ss is ta n ce  
and Jayne  H eh ir-K w a  fo r da ta  ana lys is . W e  a lso  th a n k  all o f the  p a rt ic ip a t in g  RP 
pa tie n ts  and th e ir  fam ilie s . Th is  s tu d y  w a s  f in a n c ia lly  s u ppo rte d  by: th e  D utch  
O rgan isa tio n  fo r  S c ie n tif ic  R esea rch  (g ra n t 916.56.160 to  A .I.d .H .), th e  Founda tion  
F igh ting  B lin dne ss  USA (g ra n t BR -GE-0606-0349-RAD to  A .I.d .H .), S tich tin g  
W e te n s c h a p p e li jk  O nde rzoek O ogz iekenhu is  R o tte rdam  (g ra n t 2005-13 to  L.I.v.d.B., 
A .I.d .H ., and F.P.M.C.), Fonds de la re c h e rc h e  'e n  s a n te ' Q uebec (to R.K.K), th e  
Founda tion  F igh ting  B lin dness -C anada  (to R.K.K and F.P.M.C), To ron to  Dom in ion  
f in a n c ia l g roup  (to R.K.K), A lgem ene  N ede rla ndse  V e ren ig in g  te r  V oo rkom ing  van  
B lin dhe id  (to F.P.M.C.), Lande lijke  S tich tin g  v o o r B linden  en S lech tz ie n den  (to F.P.M.C.), 
R o tte rdam se  V e re n ig in g  B lin d enbe la ngen  (to F.P.M.C.), S tich tin g  B lin denhu lp  (to  
F.P.M.C.), and S tich tin g  O nde rs teun ing  O oghee lkunde  's -G ra venhage  (to F.P.M.C.).
SUPPLEMENTAL DATA
S U P P L E M E N T A L  T A B L E  S1. Primers used fo r genomic sequence analysis of human EYS
Exon Forward (5' > 3') Reverse (5' > 3')
Amplicon
length
(basepairs)
1 TTATGTCAGCCTGCACATGG GTAGTTGTGTTCAGCTAGGC 286
2 AG CTAAAG GCAGGATACTGG ATGGAAAGCAGGGAATGAGG 315
3 GAAGACTCATTCTAGGTTAGTC CACTGCAAAGATAGTGTCACC 472
4A CTTAAAACACCATTTTG CAG C ATGTGTCCCAACACTCAGCC 498
4B ACTTCTACAGAGATTGCTGG AGATTCCTGGCAGAACTGC 376
4C GTGGTCCATCACCTTGTCC TAGAGACGGGGTTTCACCG 486
5 AGAATTGAGGGAAAACTGATGG CATAAAAG AG TT CAG TATATATACC 322
6 TCTATGCTCATTTCTTCTTTC CTTC AAAATAAGTAGACCGTTCTTGTTCG 403
7 TTCTCCAG GTAAG AACC CATT C TTAAG TAAAAG TTAG G GTTAAAACCAG 311
8 TTGG AATAATGTTAATAG G CTTTT C TGG CTAAGATTAATAAGAG CATTTG 285
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9
10
11
12
13
14
15
16
17-1
19
20
21
22
23
24
25
26A
26B
26C
26D
26E
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44A
44B
44C
Amplicon
Forward (5' > 3') Reverse (5' > 3') length
(basepairs)
GGCTTTTGAACATGGATATGAC AGATTTCCTAGGATGTAGTTGGTG 559
GGAACTTATTTTGTGGCAGATG GACTGTTGAGAATTTGTTTACGAAG 427
G G TTT CAT CTTAG TAGACAGAGAGGC CATTGTTACCATGAAACAGTTCG 368
TGCACCCCACAACTATCTTC AATTG CCCAAAGAAG CAATC 570
TTCAGATGTCATCCTAAGTGG CAGACAAGAGACAGAAGTG C 293
GGATATTTTCATTGTTGCTTTGC TGAATCCAATAAGTGAACAGTTTG 655
GAGATATCAAAATGGCCAGGAG ATCCCAAGGACACTGAGCAC 273
CACCACATACTATTAGTTCAAG ATTTTAG GAGGCCATCATCC 447
ATTCTTTAGACTACCACTGATTC ACATAATGAGCACATGTGTGC 551
AGCAG AACAAAATTTTG CAAGG CATCTGGCAG ATTATTT CAGG 425
AGAGAGGTCTTCATTTCTTGG AGCTCTTGTTTTATGAAAGAGC 395
AAACCCAGGAATAAACTCTGC GGAAGAAATGACTCTGAAACC 322
GTCAAACAAGTTTGCACATCAG GAAAGCAAAACATGGGAGTG 531
AACTCATTGTCACCCCAAGG TCCTGATGAAAGCCTAAGTGC 486
AATGGCACCACGGATAAGAG GAGGAATGCCGAGAAAAGTG 572
GAGCTATCCAATATGTCTATGG G CAGAAAATATG CTTTTACCAC 378
TTATCCCAGTGCCAAAGTGG AGTAATGACTGCCTGTTTAG C 525
ACTGTTGCTTTATCTGCTACC GAACATGTTGCACATGTTTGG 434
TACTGAGGCTTCAAGCAACC GTGGGTCCCATAGTTATGCC 555
ATCCATTGTCCCTTCACAAAC TACAGACATGGAGGAAGACG 439
GATTTTTCAGAAGTCACCACC CTGATTACAATGAGGCTGTTC 410
AAAGAGGCAGGAAAGAGACG AGGAAGAGACATCCTGGTGG 443
ACTTCATGTCTCTCCAAAGTG ATTGTTAGGGATAGCCTTTGC 273
TG CTTCTGGCTTTGTTTTATTG TG GAAAAACAGACTGACATTG G 521
TGCATACCCTGACCAGTTTG CGTAGGAATGTGAAGCAAAAAC 335
GTTAAACCTTGATCAGTATTGG ACAGCTGTTTCTTGTTTGTGC 475
TGCTTCATGCACTGGTCTGG GTGTTACCTTTTCAAATGAATGC 552
CTAATAGCACTCCTACCAACC TCTGTAGTCCCAACTACTTGG 465
CTTGAAAATGTCCACACTTGG TTTCTGGTGCTTTGTTGAGAG 405
AACTAG CCAACAATAG CAACC CTCTCAGAGGACAATACTGC 447
AGTGGAAAGCACACAGCTAC TTGATCAGTCAAGTGCTATCC 458
TTAGTTGCTCAATGCTGAAGG CAATTAGAGTGTCCCTGAGG 410
CAGCCAGTTGCACATATACC GTGAACTTCGTGGATGTAGG 438
AGCAGAGAATTGAGTGGTATC G AAAG CAAT CCATATAGCTGG 410
TCTCTGCGCATTTCTGTATTC ATGTGCATCTGTTTGTGTTCC 438
AAATTGACAAGTTAG CATCAGG AAGTACTAGTCTATCTGTGAAG 432
GAACTGCAGGACAGATGTAC C CTAATT CTAAG CTCCAAT C C 323
TTGATGTACTCACCTACAAGC ACGCATACACTTGCAGTGAC 444
CACAATTGTGCTCAAGATCTG TACATTTGAGCCACCTTTTGC 511
TGAACCTGTAGGTTTTCAAGG TGAACTGGAGGTTTCTCATTC 422
TTCTTACAGTTGCCTGTGTAC_________ TTTATGTGGATCAATATCCTCG______________424
TTCTGTTGTAATAAATGGCACC ACAATCAGAACCTTCAGTGAC 394
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SUPPLEMENTAL TABLE S2. ARMS-primers used for screening c.9468T>A, p.Tyr3156X
ARMS
primer Forward (5' > 3') Reverse (5' > 3')
Amplicon 
length
wildtype
combi- CAGTCTAATTCTTTCCGAGGATATTGATCC 
nation
TATGTAACCTCATTTTGTTCATCTCCATAA 249
mutant tgaACTAATTAAATTAGAAGGATACAATGTTTAA GGTAATATAGTAAACAGTTGATTCCCCGTA 169 combi­
nation
S U P P L E M E N T A L  T A B L E  S 3 . Primers used fo r cDNA sequence analysis of human EYS
Number* Exon Forward (5' > 3') Reverse (5' > 3') Comment
race
AP CCATCCTAATACGACTCACTATAGGGC adaptorprimer
(Clontech)
RACE nested
NAP ACTCACTATAGGGCTCGAGCGGC adaptorprimer
(Clontech)
1 4 GTG GTCCATCACCTTGTCC
2 4 TGAGGGTTGTGGATGCCATTCTTCCAC 5' RACE nested PCR
3 11 GAGTGAAGAAGACAGTCAGGAATATCGG
4 11 GTTTTCTCAGATGGGCTGGCAACATG Nested PCR
5 12 GCTACAGTTACAATTGTGCG
6 13 TGCAGGGATGTGAAGCACACTCATC 5' RACE PCR
7 17 CCTTTCCTGCCAGGATTATGGTGACTG Nested PCR
8 17 GCAGGAAAGGAAGAGGCAGTCTTTCAC Nested PCR
9 2 CD AG GATCTGTCTTCATTG GTG
10 41 CACCACTGTAGCAGAGGAGCAACCTG 3' RACE PCR
11 41 GGAACCACTGGAATCTACTGTGAAC 3' RACE nested PCR
12 41 GAAATG CAG GTTG CTCCTCTGCTACAG
13 41 ACAGTGGTGTGGAGGGTCATGTTCAG Nested PCR
14 44 TACATTTGAGCCACCTTTTGC
*, numbers corresponding to primers in  Supplemental Figure S1. AP, adaptor primer; NAP, nested 
adaptor primer; RACE, Rapid Am plifica tion  o f cD N A  Ends.
CHARTER 5A IDENTIflCATION Of EYS THAT IS MUTATED IN PATIENTS WITH RP
SUPPLEMENTAL TABLE S4. Primers used for RT-PCR of human EYS
Exon forward (5' > 3') Reverse (5' > 3')
9-12 ctaattcatcaacacctctg  c gctacagttacaattgtgcg
16-19 tgtacatctggatggactgg gcagttgtatccatcagtcc
21-26 gttcatgtgatgcagatggg agtaatgactgcctgtttagc
29-37 aggatctgtcttcattggtg cagtgctgagtggttgtttg
41-44 accctccacaccactgtagc gccttctgcaccaactcttc
ACTB gggacgacatggagaaaatc cagaggcgtacagggatagc
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su p p le m e n ta l TABLE s5. primers used for cD N A  sequence analysis of human EYS
Exon/intron Exon size in nucleotides
intron size in 
nucleotides
1 43 67.243
2 115 143.785
3 135 252
4 945 3.956
5 114 85.227
6 194 2.569
7 128 17.978
8 115 30.769
9 160 9.281
10 140 8.892
11 167 38.861
12 257 238.136
13 114 59.911
14 122 51.668
15 122 33.050
16 260 9.984
17 97 184
18 108 15.271
19 146 63.875
2 O 172 934
21 79 8.068
22 200 187.133
32 125 8.588
42 116 24.109
52 193 1.128
62 1.767 150.871
27 191 2.897
82 92 47.334
2 CD 151 80.403
30 113 76.146
31 33
CN 148.590
23 147 15.365
33 154 67.155
34 109 14.472
35 21
CN 120.025
36 173 57.814
37 183 16.966
38 167 809
39 145 9.925
40 175 15.373
41 173 20.486
42 63 15.233
43 162 4.719
44 1.689
Subtotals: 10.475 1.975.435
Total size human EYS: 1.985.910
C H A P T E R  5 A  I D E N T I F I c A T I o N  o f  EYS T H A T  i s  m u t a t e d  I N  p A T I E N T s  w i T H  R p
s u p p l e m e n t a l  f i g u r e  s 1 .  Details of RT-pcR study of EYS.
(See appendix for color figure)
Primer sequences are listed in Supplemental Table S1. A P  (filled square) and N A P  (open square) 
denote R A C E  adaptor and nested adaptor primers, respectively. Filled and open arrowheads 
represent regular and nested RT-PCR primers. Dashed line denote primary RT-PCR products.
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101
151
201
251
301
351
401
451
501
551
601
651
701
751
801
851
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001
051
LDFYRDCWFL
INLMNVSETS
VMASGPSPCP
HCQPPFSGKY
KNCSEIIGQC
LLFWKRGICP
SNDVMCICSP
TEKNCEKAlg|
VYLIHQHLCY
FFLAANCTED
RYLCFLRWAG
CWNVDYCLG
SRKNGTTSTH
GVNTKIDTSG NQAVPQICPL QIQLGDILVT SSEPSLQFPE 
FVGCVQNTTT EDQLLFGCRL KGMHTVNSKW LSVGTHYFIT 
LGLRLNVTVK QQFCQESLSS EFCSGHGKCL SEAWSKTYSC 
CQELDACSFK PCKNNGSCIN KRENWDEQAY ECVCHPPFTG 
QPHVCFHGNC SNITSNSFIC ECDEQFSGPF CEVSAKPCVS 
NSSSAYTYEC PKGSSSQNGE TDVSEFSLVP CQNGTDCIKI 
IFTDLLCKSI QTSCESFPLR NNATCKKCEK DYPCSCISGF
CGVTFHGICQ DKGPAQFEYV WQLGFAGSEG EKCQGVIDAY 
ATYVNDPEDN NSSCWFPHEG TKEICANGCS CLSEEDSQEY 
NMYLENTTDD QENECQHEAV CKDEINRPRC SCSLSYIGRL 
NHSISVHGLC LALSHNCNCS GLQRYERNIC EIDTEDCKSA 
LRGYFFRKCV PGFKGTQCEI ¡31
¡EE I 
NLCDLLHNPC 
DYGDCEDMVN
NECDSDPCMN GGLCHESTIP GQFVCLCPPL YTGQFCHQRY 
RNNSTCLALV DANQHCICRE EFEGKNCEID VKDCLFLSCQ 
NFRCICRPGF SGSLCBlH E B g g g g B S E B j g g a H  
¡LDVNKC KISPCLDEEN CVYRTDGYNC LCAPGYTGIN 
TNANDCLSNPc e : iJ|
CLHGRYTELI NEYPCSCDAD GTSTQCfÏKI NDCTSIPCMN EGFCQKSAHG
1101
1151
1201
1251
1301
1351
1401
1451
1501
1551
1601
1651
1701
1751
1801
1851
1901
1951
2001
2051
2101
2151
2201
2251
FTCICPRGYT GAYCEKSIDN CAEPELNSVI 
PGFSGQFCEI 
ECIPNSCVHE
QRTDPISTQT 
KHDILPTTGL 
LNFGIRDPAQ 
DFIFPTQSLL 
IAASISATPV 
ISKQVTILNS 
ELSQTCATCS 
GAQTITSGHS 
LSSNLDVNLC 
LLKIRQYGIT 
QIYPDVTLKT 
ALSIQTSSSM 
FPTASRHLPF 
' PQNNISLE
YTIPPSE0LV
ATLRISTPLE
IVQDKTSVSH
FENCQTVALS
VSRGAQEDIE
SALHRFSTKA
MTEIKSSREF
FSSATEITPS
LDKTCLSIVP
MGPTEVLNQE
YSEITHANDF
SVIRPDWPYF
TRSLTLSSLE
SSFPSIKATR
SYLLQELIVT
MPIRTSAATL
ATPgTSVIRS
EYSADSLISR
FNPSEYQAIT
SDQVLHSKQS
VAFTEVPSLF
SQTISSDLMN
SLLDMEKSKG
KNNLPPLTGS
TDYMTSLKKE
SILAPQRLMI
SIGLLCGDEI
IPAIMDTYPV
RELSAKHSLL
GFFFPDRRAR
IPGADIELNR
REHWRLLSPS
EASSNQRLTN
HFYETFWMNS
PSKKSAKRTI
SDLTSKMTTD
SHTLFKLHPS
VPDFSEVTTN
VKTSSEWSKW
SDFSCVRYYG
FQTFSSYGLL LHVKQDSNLV DGFFIQLFIE
I PGHTFDCRCL 
@NEL 
RRITCLTPIF 
DQGPKQTGIV 
SSADVSSSRF 
TPFIMSSLMS 
QSLLSRGFLL 
MSPIFPAKVI 
IKSQAADSLR 
AILASWYALM 
LSSSLEESIT 
ELSVSENILK 
DSSLDFELNL 
VAFYTVSATP 
ELQPSVQYQE 
DSYLEFQNVA
H£t l k yhfy(|
:FKSIN TTVRVDNt : YTLLIRQELD PCNAELTILG
PSKAVKNYHI NNCRSQGFML SPTASFVDAS DVTQGVDTMW 
SVCQQDVCHN GGTCHAIFLS SGIVSFQCDC PLHFTGRFCE 
NGNSYLELPF LKFVLEKEHN 
LHLFLVEGRP SVKYGCGNSQ NILTVSANYS INTNAFTPIT IRYTTPVGSP 
GVVCMIEMTA DGKPPVQKKD TEISHASQAY FESMFLGHIP ANVQIHKKAG
2301
2351
2401
2451
2501
2551
2601
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2701
2751
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3101
3151
IIDEARHGKN 
QFASCENNPC 
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ISDNENLFCE 
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M j1i.il,M ulti
HHLCRNNGTC 
GTDIVCLCPY 
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CPRLYSGKLC
INITQPRFSG
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GNGATCVPKS i 
AYSRISDISJI
EPLNLSLG VHTVHLGKFF QEGWLKVDDH KNKSIIAPGR LVG1
YVGGYSEYTP DLLPNGADFK NGFQGCIFTL QVRTE
SVYCNCTTGW 
LGTTGIYCEQ 
A5FH : H |
I ASPCSLMKCG 
HCSRGATCIS 
; EALSISDPSF
NGGTCIESGT ; 
LPHGYTCFCP 1 
RSNELSWMSF i
RGLGNPEGHP
KGSFCTETVS
ALILIVILEK
IQLQFQPLAAl
NAGRSVGQCH i 
TCDPEHDPPH 1 
PKPAERKVKK I
NLVNPMAIEN EPVGFQGCIR QVIINNQ .
RCLPDWAGNT 
NKTSFSTAKF
GYNTCRNGGE
DQSFSYSCLC
tTTISLNFSTT-
LTEFGAKGGS NVGDCDGTAC 
CNQSVSCLNN LCLHQSLCIP 
MGNSYIKYID PNYRMRNLH 
KTEGLIVWMG ME©MEENDFLBSB@jHMH6gBiHK IAVNLGERlg
CTVNGTTFSC
TLGWVGRYCE
yPMSYNNGTF CCNKWHHVW IQNQTLIKAY INNSLILSED IDPHKNFVA]
EGYNVYDGDE QNEVT
Protein motifs :
SUPPLEMENTAL FIGURE S2. Detailed characteristics of the human EYS protein domains. (See appendix for color figure)
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ABSTRACT
AiM. To determine the prevalence of mutations in the EYS gene in a cohort of 
patients affected by autosomal recess ive  retinitis pigmentosa (RP) and to describe 
the associated phenotype.
METHODS. D N A  of 245 RP patients w a s  selected for mutation analysis. All 
coding exons of EYS were  screened  for mutations by polymerase chain reaction 
amplification and sequence  analysis. All 12 patients carrying mutations in EYS were 
re-examined, wh ich  included Goldmann kinetic perimetry, electroretinography, 
and high-resolution spectral-domain optical coherence tomography (OCT).
R E S U L T S .  Nine novel truncating mutations and one previously described mutation 
in EYS were  identified in 11 families. In addition, 18 m issense  ch an ge s  of uncertain 
pathogenicity were found. Patients carrying mutations in EYS demonstrated classic 
RP with night b lindness as the initial symptom, followed by gradual constriction of the 
visual field and a decline of visual acuity later in life. The onset of symptoms typically 
occurred between the second  and fourth decade of life. The fundus displayed bone 
sp icu les  increasing in density with age and generalized atrophy of the retinal pigment 
epithelium and choriocapillaris with relative sparing of the posterior pole until later 
in the d isease process, w hen  atrophic macular ch an ge s  occurred.
CONCLUSiONS. Mutations in EYS account for approximately 5 %  of autosomal 
recess ive  RP patients in a cohort of patients consist ing predominantly of patients 
of western European ancestry. The EYS-assoc iated  RP phenotype is typical and 
fairly hom ogeneous  in most patients.
CHARTER 5B MUTATIONS IN EYS ACCOUNT fOR ~5% Of ARRP AND CAUSE fAIRLY HOMOGENEOUS PHENOTYPE
INTRODUCTION
Retinitis pigmentosa (RP; M I M  268000) is a clinically and genetically heterogeneous 
group of inherited retinal d isorders characterized by photoreceptor degeneration. 
The rod and cone system may be equally affected in RP, but in most patients, rod 
dysfunction precedes  cone dysfunction, resulting in the typical symptoms of night 
blindness, followed by loss of the (mid)peripheral visual field. In many patients, the 
cones  in the central retina also become affected, resulting in loss of visual acuity 
in the later s tages  of the disease. Ophthalmoscopic abnormalities include a w axy  
pallor of the optic disc, attenuation of retinal vesse ls, and peripheral bone spicule 
pigmentations as  well a s  atrophy of the retinal pigment epithelium (RPE). All modes 
of Mende lian inheritance, including digenic inheritance, have been observed in R P 1- 2 
Clinical findings may vary between patients carrying causative mutations in different 
genes, and a degree of clinical heterogeneity even may be observed in patients 
carrying different or even identical causative mutations within one specific RP gene.1 
Until recently, mutations in 25 genes  have been associated with autosomal recessive 
RP (arRP; http://www.sph.uth.tmc.edu/Retnet/). Together, these genes  account for 
approximately 5 0 %  of arRP cases. The most frequently mutated gene is the USH2A 
gene ( M IM  +608400), accounting for approximately 7 %  of arRP cases, w h e re a s  most 
other genes  contribute to only 1 %  to 2 %  of arRP ca se s .1- 3- 4 Recently, a new  gene, 
eyes shut homolog (EYS), w a s  identified at the RP25 locus.5, 6 The EYS gene is one 
of the largest genes  ever identified and, based on current knowledge, the largest 
gene that is expressed in the human eye. The human EYS protein is localized at the 
outer segm ents  of the photoreceptor layer, but its function in human retina remains 
largely unknown.6 In Drosophila, the eys protein plays a critical role in creating 
the space  between the rhabdomeres, a structure comparable with the human 
photoreceptor.7 Therefore, the human EYS protein may be essential for the integrity 
of the outer segment. To date, a total of eight truncating mutations have been 
detected in EYS in eight different arRP families.5, 6 The presence of mutations 
in families from different ancestral origins, the identification of several indepen­
dent mutations, and the enormous size of the gene have led to the hypothesis that 
mutations in EYS may be a major cause  of RP  Moreover, by linkage analysis,
14%  to 2 5 %  of Span ish  arRP families were  show n  to map to the RP25 interval.8, 9
This study attempted to determine the percentage of arRP that can be ascribed 
to mutations in the EYS gene in a cohort of patients mainly of western European 
ancestry. In addition, a detailed clinical description of the RP patients carrying 
mutations in EYS is provided.
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PATIENTS AND METHODS
S u b j e c t s
Blood sam p les  were  collected of 245 patients w ho  were d iagnosed with RP based 
on ophthalmic examination at The Rotterdam Eye Hospital (by LIvdB), the Radboud 
University Nijmegen Med ica l  Centre (by B J K  and CBH), or The McGill University 
Health Centre in Montreal (by RKK). Som e pedigrees show ed  a pattern compatible 
with a recess ive  mode of inheritance (43%); the other patients were  considered 
isolated ca se s  (57%). In 18%  of cases, known mutations in arRP genes were excluded 
with the arrayed-primer extension microarray for arRP genes  (Asper Ophthalmics, 
Tartu, Estonia). In addition, 36 probands affected by an autosomal recess ive  form 
of cone- rod  dystrophy and negative for known ABCA4  mutations were  enrolled in 
this study. After explaining the nature of this genotype-phenotype study, informed 
consent adhering to the tenets of the Declaration of Helsinki w a s  obtained from all 
patients and unaffected family members w h o  participated in the molecular study. 
Blood sam p les  of the affected and unaffected family members were collected for 
segregation analysis of the genetic defect.
M u t a t io n  a n a ly s i s
Genomic D N A  w a s  isolated from lymphocytes by a standard salting-out procedure.10 
All 41 coding and three non-cod ing  exons  of EYS (FM209056) w e re  amplified by 
po lymerase chain reaction (PCR) using the conditions descr ibed by Collin et 
al.5 Purified PCR products of the coding exons  w ere  analyzed in either s e n se  or 
antisense direction using dye termination chemistry (B igDye Terminator, version 1.1, 
on a 3730 D N A  analyzer; Applied B iosystems, Inc., Foster City, CA). All sequence  
variants  that w e re  identified were  confirmed with independent PCR reactions 
and w ere  analyzed in sen se  and ant isense direction. To determine whether some 
variants  are com m on polymorphisms, the m is sen se  ch a n ge s  that were  found 
in combination with another m is sen se  or truncating c h a n ge s  w ere  sc reened  
in D N A  sam p le s  of 180 unrelated and unaffected ethnically matched subjects 
us ing restriction fragment length ana lys is  or allele-specific PCR.11 Furthermore, 
all patients w h o  carried only one truncating mutation in EYS w e re  sc reened  for 
the p re sence  of heterozygous  deletions of exon 12 or exons  15 through 19, wh ich 
previously  w ere  published by A bd  El-Aziz et al.6 by us ing primers downstream  and 
upstream of the reported breakpoints. The pathogenicity of the m is sen se  ch an ge s  
w a s  evaluated for evolutionary conservat ion using the B L O S U M 6 2  sco re ,12 by splice 
site prediction,13 by the sea rch  for exonic splice enhancers ,14 and by ana lys is  of the
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biophysica l properties of the side cha in s  of the amino acid substitutions (Project 
Hope; http://www.cmbi.ru.nl/hope/). Furthermore, becau se  prom1 is known to 
interact with eys in Drosophila,7 the PROM1 gene (NM_006017) w a s  sc reened  in 
D N A  of patients w h o  carried a heterozygous  truncating mutation w ithout a second  
allele to test the hypothes is  of d igenic inheritance. Primers w ere  des igned  by 
ExonPrimer (software des igned  by T.M. Strom, Helmholtz Center Mun ich,  Mun ich, 
Germany).
C l in i c a l  e v a lu a t io n
After approval of the institutional review board w a s  obtained, 12 patients w ho  
carried hom ozygous  or com pound  heterozygous  mutations in EYS w e re  clinically 
re-evaluated at The Rotterdam Eye Hospital (by LIvdB), the Department of 
Ophthalmology at the Radboud University Nijmegen M ed ica l  Centre (by BJK), 
or the Department of Ophthalmology at McGill University Health Centre in Montreal, 
Canada  (by RKK). Clinical evaluation included best-corrected visual acuity and 
slit-lamp b iomicroscopy, followed by o ph tha lm oscopy  after pupillary dilatation. 
Additional examinat ions included fundus  photography, Goldmann kinetic perimetry 
(targets V-4e, II-4e, and I-4e to I-1e) to a s s e s s  the size and extent of the v isual field 
and spectra l-domain optical coherence  tom ography  (OCT; Spectralis, Heidelberg 
Engineering, Heidelberg, Germany) to visualize the in vivo retinal architecture. 
E lectroretinograms w ere  recorded accord ing  to the protocol of the International 
Soc iety  for Clinical E lectrophysio logy of V is ion.15 W h e n  available, the medical 
history w a s  reviewed for a longitudinal evaluation of the EYS -as so c ia ted  RP 
phenotype.
RESULTS
M u t a t io n  a n a l y s i s
Sequence analysis of all 41 coding exons of the EYS gene led to the identification of
10 pathogenic variants in 11 different families (Table 1). In 5 families (families B, C, D,
J, and K), the truncating mutations conclusively were causative for RP, because they 
were present on both alleles either homozygously or compound heterozygously and 
segregated in the RP family (Figure 1). In 1 family (Figure 1, family A), the mutation in EYS 
w a s  causative for only two siblings who  carry the frameshift mutation homozygously, 
whe reas  one affected sibling carries the mutation heterozygously and two affected 
siblings do not carry the EYS mutation. In three families (families G, H, and L), the 
truncating mutation w a s  found in combination with a m issense change (Table 1).
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TABLE 1. Retinitis pigmentosa patients carrying truncating mutation(s) in EYS
Allele 1 Allele 2
Confirme 
by segre­
Patient Inheritance Country Mutation Effect Mutation Effect
gation
analysis
A  ii-1 AR C anada c.1644delG p.Q 548Q fsX60 c.1644delG p.Q 548Q fsX60 P a rtia lly
B II-2 Iso la ted N e th e r la n d s c.1673G >A p.W 558X c.2811C >A p.C937X Yes
C II-6 AR N e th e r la n d s c.4350_4356del7 p. K1450 KfsX3 c .8710_8717del8 p .T 2904KfsX4 Yes
D II-1 Iso la ted N e th e r la n d s c.4350_4356del7 p. K1450 KfsX3 c .4350_4356del7 p.K1450KfsX3 Yes
E Isolated N e th e r la n d s c.4350_4356del7 p.K1450KfsX3 NI N A
F II-9» AR N e th e r la n d s c.4350_4356del7 p. K1450 KfsX3 NI N o
G Iso la ted
S o u th -K o re a
/U S A
c.4712C>G p.S1571X c.6557G > A p.G2186E N A
H Iso la ted C ura g a o c.6794delC p.P2265Q fsX46 c .2500G > A p.V834I N A
J  II-1 Iso la ted N e th e r la n d s c.6714delT p. P2238 P fsX16 c .6714delT p.P2238PfsX16 Yes
K II-2 AR N e th e r la n d s c.6799_6800delCA p.Q 2267EfsX15 AlCeld080_68997.6c sX1Ef762.Q2p. Yes
L II-2 Iso la ted N e th e r la n d s c.7095T>G p.Y2365X c.9047T>A p.I3016N Yes
AR, autosomal recessive; fsX#, frameshift that leads to stopcodon # amino acids downstream; 
N A , no family members available; N I, not identified; X, stopcodon. Nucleotide and amino 
acid numbering refer to EYS c D N A  sequence FM209056. *, mutation in EYS  is not causative 
in this patient.
Two of the m issense  change s  (family G, p.G2186E; and family L, p.I3016N) affect amino 
acids that are conserved in most of the Laminin A  G-like domains in EYS (Figure 2), 
and therefore are likely to play a crucial role in this domain. Furthermore, these two 
ch an ge s  lead to the substitution of amino acids that evolutionarily are not related, 
and therefore have a negative B L O S U M 6 2  score.12- 14 The third m issense  change
(family H, p.V834I) affects an amino acid that is not conserved between the epidermal 
growth factor (EGF)-like domains of EYS (Figure 2) and has  a B L O S U M 6 2  score  of
3, indicating that a valine commonly is replaced by a isoleucine during evolution.
For family L, segregation of the mutations with the d isease w a s  confirmed. For the
other two patients carrying m issense  variants, no family members were available
for segregation analysis. In two families (families E and F), only one heterozygous
truncating mutation w a s  detected (Table 1).
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F IG U R E  1. Pedigrees of the families that were available for mutation analysis. Pedigrees of 
6 families (families B, C, D, J, K, and L) showing segregation of the mutation with the disease. In 
family A, the mutations are causative in only 2 of 5 patients, and in family F, the mutation is not 
causative, as shown by the common haplotypes on both alleles in patient II-9 and her unaffected 
siblings II-1 and II-3. Plus signs indicate a wild-type allele, square boxes indicate men, circles 
denote women, and affected individuals are pointed out by a black symbol. The probands are 
indicated with an arrow.
For patient E, no second  allele could be identified and no family members were 
available for segregation analysis. Surprisingly, in family F, the other affected sibling 
(II-4) did not carry the mutation (Figure 1). Moreover, haplotype analysis  around the 
EYS locus revealed the presence of the same second  allele in patient II-9 and two 
of her unaffected siblings (II-1 and II-3) w ho  also carry the p.K1450KfsX3 mutation 
(Figure 1), suggest ing  that this mutation in EYS is not causative for RP in this family.
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F IG U R E  2. Alignment of analogous protein domains within human EYs.
Alignment of analogous domains within the human EYS protein showing amino acids that are 
conserved throughout the domains that may be essential for a normal function of the domain. 
Black boxes with white letters denote identical amino acids, conserved amino acids are presented 
as grey with white letters, and a block of similar amino acids is presented as a grey box with 
black letters. Sequences were adapted from Collin et al5 and aligned by Vector N T I version 10 
(Invitrogen, Carlsbad, CA). Am ino acid position of the first shown amino acid is indicated per 
domain. *, part of domain not shown; EGF, epidermal growth factor
In two patients in w hom  no truncating mutations could be identified and who 
were  therefore not included in the overview of EYS RP patients (14613, 28692), more 
than one heterozygous m issense  change  w a s  found (Table 2). In patient 14613, the 
p.T1424A change  is predicted to affect one of the two predicted glycosylation sites.16 
The other two ch an ge s  (p.T1993A and p.T2831I) both concern a residue in a Laminin 
A  G-like domain that is not conserved between the EYS Laminin A  G-like domains 
and have a B L O S U M 6 2  score  of 0 and -1, respectively. In the other patient (28692), 
the p.T1993A allele again w a s  found in combination with another heterozygous 
m issense  variant (p.I1232F), but this change  also is not conserved  between the EYS 
EGF-like domains and has a B L O S U M 6 2  score  of 0. Be cau se  no family members were 
available, it could not be determined whether these variants are present on separate 
alleles and whether they segregate with the disease. All seven m issense  changes  
mentioned above were not present in 180 ethnically matched control individuals.
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TABLE 2. Heterozygous m issense  changes in EYS identified in retinitis pigmentosa patients
Change Effect
Prevalence in 
RP-patients
BLO SU M  
62 score Proof of pathogenicity/non-pathogenicity
Probably pathogenic
c.2500G>A
c.6557G>A
c.9047T>A
p.V834I 
p.G2186E 
p. 13016N
1/245
1/245
1/245
3
-2
-3
Excluded in 180 control subjects, but not conserved  
throughout EYS EGF dom ains (Figure 2). H ow ever, found in 
com bination w ith  truncating mutation (p.P2265QfsX46)
Excluded in 180 control subjects, conserved  throughout 
EYS Lam G dom ains (Figure 2), found in com bination w ith 
nonsense mutation (p.S1571X)
Excluded in 180 control subjects, conserved  throughout 
EYS Lam G dom ains (Figure 2), found in com bination w ith 
nonsense mutation (p.Y2365X); segregation  w ith  d isease 
confirm ed
Unknown pathogenicity
c.977G>A p.S326N 1/245 1 Found in patient from consangu ineous m arriage, so 
heterozygous change perhaps non-significant
c.1145A>T p. N 3821 1/245 -3 Resid ue not conserved  throughout EYS EGF-like domains 
Not in functional dom ain, but rem oval of cyste ine  in
c.1382G>A p.C461Y 1/245 -2 extracellu lar domain might d isrupt se co n d a ry  structure or 
protein interaction
c.3489T>A p.N1163K 1/245 0 Conserved  residue (D or N) in cb EG F  dom ains (figure 2) 
Excluded in 180 control subjects, but not conserved  residue
c.3694A>T p. 11232F§ 1/245 0 in EGF-like domain. H ow ever, found in com bination w ith 
other m issense varian t
c.4531T>C p.S1511P 1/245 -1 Not in functional domain
Excluded in 180 control subjects, predicted to disrupt
c.4270A>G p.T1424A* 1/245 0 glycosylation site, found in com bination w ith  other m issense 
varian ts
c.4985A>T p.D1662V 1/245 -3 Not in functional domain
c.5110A>T p. 11704L 1/245 2 Not in functional domain
c.5401G>A p.A1801T 1/245 0 Not in functional domain
c.5510G>C p.W1837S 1/245 -3 Not in functional domain
Excluded in 180 control subjects, but non-conserved  residue
c.5977A>G p.T1993A* § 3/245 0 in Lam G domain. H ow ever, found in com bination w ith  other 
m issense varian ts
Not in functional dom ain, but is p redicted  to form disulphide
c.6188G>T p.C2063F 1/245 -2 bond w ith  cyste ine  at position 2037 (P ro je c t Hope), and thus 
m ay disrupt seco n d ary  structure or protein interaction
c.6452A>G p.N2151S 1/245 1 Not in functional domain
c.6964A>G p. 12321V 1/245 3 Not in functional domain
c.7597A>G p.K2533E 1/245 1 Resid ue not conserved  in Lam G domain
c.7751C>G p.T2584S 2/245 1 Resid ue not conserved  in Lam G domain 
Excluded in 180 control subjects, but not conserved
c.8492C>T p.T28311* 2/245 -1 residue in Lam G domain. H ow ever, found in one patient in 
com bination w ith  tw o  other m issense varian ts
Non-pathogenic
c.5244A>C p. L1748F 0/245 0 Found in unaffected  fam ily m em bers, w h ile  not p resent in 
affected  fam ily m em bers
c.7666A>T p.S2556C 43/245 -1 Frequently p resent in control individuals, both homozygously 
as heterozygously
c.7796A>G p.H2599R 4/245 0 Found in unaffected  fam ily m em bers, w h ile  not p resent in affected  fam ily m em bers
*, p.T1993A, p.T2831I and p.T1424A were all detected in one patient (14613); §, p.T1993A and 
p.I1232F were detected in one patient (28692); family members were not available for segregation 
analysis. LamG, Laminin A  G-like domain; cbEGF, calcium-binding EGF domain
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Furthermore, 18 heterozygous m issense  ch an ge s  w ere identified that w ere present 
w ithout a second  allele. Table 2 conta ins further information about these changes, 
enabling speculation about their pathogenicity.
Three m issense  ch an ge s  should be considered benign, because  they w ere  found 
hom ozygously  in control subjects, or w ere detected in unaffected fam ily members, 
w h e re a s they w ere not present in the respective affected fam ily members. In 
addition, 11 silent ch an ge s  (i.e., nucleotide ch an ge s that do not affect the amino 
acid) and m any intronic variants w ere identified that are likely to be non-pathogenic, 
because  none of the variants introduce or abolish a splice site or sp lice enhancer 
site (data not shown). Abd El-Aziz et al.6 describe a deletion in EYS of exon 12 and 
a deletion of exons 15 through 19. In an attempt to find the second  allele in the 
patients w ho  carry one heterozygous stop or fram eshift mutation, a breakpoint­
spanning PCR ana lysis w a s  conducted to search  for the deletions in a heterozygous 
state. These  deletions, as well as the other mutations described by Abd El-Aziz et 
al.,6 w ere  not identified in this study. Furthermore, these patients w ere screened  for 
mutations in PROM1, because  this gene is known to interact with spacemaker/eyes 
shut(eys) in the eye of Drosophila.1 No mutations, however, w ere found in the coding 
exons of PROM1. B e cau se  mutations in EYS have been found previously in a patient 
affected by cone-rod  dystrophy,5 36 patients affected by cone-rod  dystrophy also were 
screened  for mutations in EYS, but no mutations w ere identified in this patient group.
F IG U R E  3. Graph showing changes in visual acuity with age in patients carrying mutations in EYS.
The graph shows the change in visual acuity (y-axis) related to the age in years (x-axis). Symbols 
indicate the moments of assessment of the visual acuity. Improvement of visual acuity in patient 
D II-1 was the result of successful treatment of cystoid macula edema with Octreotide, and in 
patient C II-6  visual improvement was the result of cataract extraction
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c l i n i c a l  c h a r a c t e r i s t i c s
Clinical evaluation of 12 patients carrying pathogenic mutations in EYS  show ed 
typical RP sym ptom s of night b lindness a s the initial symptom and progressive  
constriction of the v isual fields. Table 3 sh o w s  an overview  of the clinical features of 
the patients w ho  carry probable causative mutation(s) in EYS. The median age of first 
sym ptom s w a s  19 yea rs  (range, 14-62 years), including one patient (patient E; Table 3) 
w ith an age of onset of 62, w h ich  deviates from the others. For those patients with an 
extended period of clinical follow-up, the decline of v isual acuity over the years 
is depicted in Figure 3. Th is figure su gg e sts  that visual acuity starts to decrease  after 
the age of 30 yea rs  and drops to le ss than 20/200 near the age of 60 years. Posterior 
subcap su la r cataracts w ere  seen  in 11 of 12 patients and w ere  encountered at 
a relatively young age (>26 years).
O phthalm oscopy show ed  optic d isc pallor in all patients, with multiple nerve head 
drusen in one patient. Retinal v e sse ls  w ere  attenuated, and profound atrophy 
of the RPE, choriocapillaris, and outer retina at the (m id)peripheral retina w a s 
observed  in all patients. In the later sta ge s of the d isease, the m acular region and 
som etim es the fovea also becam e affected. In the periphery, variable am ounts of 
intraretinal pigm entations w ere observed  (Figure 4). One patient had fibrous Coats­
like le sions on the inferior quadrants. The high-resolution OCT im ages show ed 
a relative preservation of the retinal layers in the central m acula in all patients 
and marked atrophy of the chorioretinal layers more (m id)peripherally (Figure 5). 
Reduction of retinal th ickne ss resulting from the lo ss of neuroretinal t issue  is show n 
in Figure 6. In a patient with end-stage RP, OCT even dem onstrated a complete lo ss 
of photoreceptors, RPE, and choriocap illaris peripheral to the macula (Figure 7).
The profound lo ss of the normal retinal layers enabled visualization of the entire 
choriocap illaris and even the sclera  in som e patients. Interestingly, cellular-sized 
hyperreflective structures w ere  seen  at variable depths, varying from the nerve 
fiber layer to the RPE (Figure 8). Electroretinography re spo n se s  at the age of last 
examination w ere nonrecordable or show ed  severe lo ss of signal in a rod -cone  
pattern for all patients.
139
Family
ID ID
Age
(yrs) Sex
Age
of
onset
V isual acuity 
(current age)
OD OS Lens status
Goldmann
perimetry
A II-1 63 M 8 2/400 2/400 N S  and P SC  
cataract
5 degree visual field with 
V4e target
B II-2 64 M 36 20/200 LP+ P S C  cataract
OD: Central visual field<5 
degrees, two peripheral islands. 
OS: small peripheral island
II-4 73 F 21 20/63 20/50
P SC
cataract; 
extraction 
at a ge  73 yrs 
(OU)
Severely constricted visual 
fields (<10 degrees)
C
II-6 69 F 14 H M H M
P SC
cataract; 
extraction 
at a ge  54  yrs 
(OU)
No longer possible. At age 40: 
central visual field < 10 degrees
D II-1 25 M 17 20/20 20/25 Clear
Intact periphery with V-4e, III-4e, 
mid peripheral sensitivity loss 
with paracentral scotoma
E - 64 F 62 20/32 20/25
OD: Posterior
cortical
cataract
Constricted visual fields up 
to 30 degrees
G - 36 F 22 20/25 20/25
M ild  P SC  
cataract
Constricted visual fields 
up to 15 degrees
H - 26 M 13 20/32 20/40 M ild  P SC  
cataract
Constriction up to 20 degrees 
nasally, 70-80 degrees temporally. 
OS: Relative central scotoma
J II-1 42 M 22 20/25 20/25 P SC  cataract
Mildly constricted visual fields 
at V-4e, marked constriction of 
visual fields (<20 degrees) at all 
other intensities
K
II-2 39 M 15 20/50 20/40 P SC  cataract
Marked decrease in visual 
fields (<30 degrees) with 
a small temporal islands
II-3 36 F 17 20/32 20/32
OD: ant/post 
polar and 
cap su la r  
opacification
OS: P SC  
cataract
Marked decrease of visual 
field (<20-30 degrees) with 
residual temporal peninsulas
L II-2 66 F 35 20/100 CF P SC  cataract
Constricted visual fields 
(<30-40 degrees), small 
paracentral scotomas. 
Loss of sensitivity OS>OD
T A B L E  3. Clinical chai acteristics of retinitis pigmentosa patients carrying mutations in EYS.
§, current age; *, recorded elsewhere; 1, isolated rod response; +, single flash cone response; 50­
100 microvolt; ¿ ¿ ,  10-50 microvolt (normal values rod response: ~114 uV, cone response: ~194uV, 
according to ISC E V  with Dawson Trick Litzkow (DTL) electrodes; ant, anterior; CF, counting
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Fundoscopy OCT vo
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n ERG
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Optic disc pallor, narrow vesse ls and 
peripapillary atrophy. Extensive and diffuse 
choroidal show  and choroidal sclerosis, with 
RPE loss and bone spicule pigmentation.
Extensive remodeling and severe loss 
of retinal layers. NR N R
Optic nerve head drusen, severely attenuated 
vessels, atrophic macular region with foveal 
island, relatively preserved RPE midperipheral, 
atrophic RPE far periphery with bone-spicules 
and pavingstone-like degenerations.
Severe epiretinal fibrosis. Mild abnormalities 
in fovea, marked atrophy of the more 
peripherally located chorioretinal layers.
NR U
Attenuated retinal vasculature, generalized 
atrophy with macular sparing, extensive 
bone spicules throughout periphery.
Complete loss of photoreceptors, RPE and 
choriocapillaris peripheral to the macula.
NR N R
Very pale, w axy optic disc. Severely attenuated 
retinal vasculature, extensive chorioretinal atrophy 
with minimal residual RPE at macular region. 
Profound (mid)peripheral pigmentations.
Irregular loss of photoreceptors in the central 
macula. Severely atrophic retina especially 
peripheral to the macula. All retinal layers 
appear to be affected. Focal increased 
reflectivity in deep layers of neuroretina, 
possibly RPE cells.
NR N R
Pink optic disc, moderately attenuated vesse ls, 
cystoid maculopathy, in (mid)periphery RPE 
atrophy with som e bone-sp icules and som e 
drusen-like deposits.
Virtually normal anatomic aspect of the foveal 
photoreceptors, with exception of cystoid 
macular edema. Mild epiretinal fibrosis.
a a
Pallor of the optic disc, attenuated retinal 
vasculature, preserved RPE posterior pole, 
(mid)periphery RPE atrophy with bone-spicules, 
inferior quadrants (OU) fibrotic lesions resembling 
old Coats'-like vasculopathy.
NP a a
Pink optic disc, severely attenuated vesse ls  
with sheathing, preserved RPE macular region, 
(mid)periphery pronounced RPE atrophy with 
bone-spicules and som e drusen-like deposits.
Normal aspect of foveal anatomy. Chorioretinal 
atrophy in periphery. Clearly visible choroidal 
vessels. Hyperreflective structures in variable 
depths in the nerve fiber layer.
a 4
Mild pallor optic disc, ve sse ls  near normal caliber, 
preserved RPE posterior pole with mild epiretinal 
membrane, RPE changes in macula with three 
intraretinal crystals. OD (mid)periphery atrophic 
with bone-spicules.
Deepened foveal dimple, almost no outer and 
inner segments in macular region. In right fovea 
irregular hyperreflective structure. Outside the 
macular region generalized atrophy of the 
retinal layers and RPE.
N R * N R *
W axy pallor of the optic disc, attenuated retinal 
vasculature, generalized chorioretinal atrophy, mild 
bone spicule pigmentation clustered in periphery.
Relative normal aspect of the fovea. Atrophy 
of predominantly the deeper layers of the retina 
in the periphery. Loss of choriocapillaris.
N R N R
Pink, w axy optic disc. Moderately attenuated 
retinal vasculature, generalized chorioretinal 
atrophy with macular sparing, and classic bone 
spicules in periphery.
Relative sparing of foveal photoreceptors, 
generalized atrophy of deep retinal layers and 
choriocapillaris. Deep choroidal vesse ls clearly 
visible. Highly irregular hyperreflective 
structures in retina, possible proliferating 
and migrating RPE cells.
N R N R
W axy optic disc with temporal pallor, 
attenuated retinal vasculature, extensive 
chorioretinal atrophy few  bone spicules 
in periphery.
Relative good aspect of central macula and 
sparing of foveal cones. Severe atrophy of 
(mid)peripheral retina, with clearly visible larger 
choroidal vessels. Bone spicules in nerve fiber 
layer with obscuration of deeper layers.
N R N R
Pink optic disc. Mild to moderate attenuation of 
retinal vasculature, marked chorioretinal atrophy 
extending into the posterior pole. Clustered bone 
spicule pigmentation in periphery.
Foveal contour present, nevertheless loss of 
cone outer segments in fovea. Chorioretinal 
atrophy throughout retina with exception of 
central macula. Increased visibility of the large 
choroidal vesse ls and even sclera due to 
atrophy of the overlying layers
N R N R
fingers; ERG, electroretínogram; F, female; H M , hand movements; ID, identification number; LP+, 
positive for light perception; M , male; NP, not performed; NR, non-recordable; NS, nuclear sclerosis; 
OCT, optical coherence tomography; OD, right eye; OS, left eye; OU, both eyes; post, posterior; PSC, 
posterior subcapsular; RPE, retinal pigment epithelium.
141
F iG U R E  4. Fundus photographs
of patients carrying mutations in EYS.
(See appendix for color figure)
A. Fundus photograph of the central 
retina of the right eye of patient 
CII-6 showing the fundus in an 
end-stage of the disease. The fundus 
is characterized by a very pale, 
waxy optic disc, severely attenuated 
retinal vasculature, and extensive 
chorioretinal atrophy with minimal 
residual retinal pigment epithelium 
at the macular region.
B. Fundus photograph of the temporal peripheral retina of patient C  II-6 showing heavy irregular 
pigmentations in the (mid)peripheral retina.
C. Fundus photograph of the central retina of the right eye of patient K II-2  showing a pink, waxy 
optic disc, moderately attenuated retinal vessels, and generalized chorioretinal atrophy with 
macular sparing.
D. Fundus photograph of the upper temporal peripheral retina of patient K II-2  showing classic 
bone spicules in periphery. The red telangiectatic-like vessels at the temporal retina (Figure 
4C, 4D) are not visible with higher resolution and on fluorescein angiography, and therefore 
seem to be artifacts.
A F iG U R E  5. Illustration of macular changes by
spectral-domain optical coherence tomography.
A. In the healthy, the outer retina constantly shows 
four highly reflective stripes, representing the 
photoreceptor outer segment/retinal pigment 
epithelium complex and the choriocapillary layer.
B. In the earlier stages of retinitis pigmentosa resulting 
from mutations in EYS, the high reflective outer 
retinal layers are disorganized and lost peripheral 
to the macula. Frequently, a transition zone may
be observed containing a more central margin 
of photoreceptor outer segment/retinal pigment 
epithelium loss (arrows) and a more peripheral 
boundary of total photoreceptor loss (arrowheads), 
as shown in the right eye of patient KII-3.
C. Optical coherence tomography image of the right 
eye of patient LII-2 showing a late-stage of EYS- 
related retinitis pigmentosa, total outer retinal loss, 
and subretinal clump formation at the fovea.
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DiSCUSSiON
This study identified 11 families carrying pathogenic mutations in EYS, a gene that 
recently w a s  found to be mutated in patients with a rR P 5- 6 One mutation previously 
w a s  identified in a Dutch family;5 the other nine mutations are novel. In one family 
(family E) with a homozygous  frameshift mutation in EYS, haplotype analys is  revealed 
that the EYS mutation cannot be causative in that family. Previously, mutations in 
EYS were identified in three of 10 patients from the same cohort. Consequently, the 
molecular cause  w a s  identified in 13 arRP families, wh ich  brings the prevalence of 
EYS mutations in the total cohort of 255 patients to approximately 5%. Of the 25 genes 
known to cause  arRP, only four are known to be responsible for more than 3 %  of 
c a se s  (USH2A [7%],3- 4 ABCA4  [ 5 % - 6 % ] , 17 PDE6B [ 4 % - 5 % ] , 18- 19 and PDE6A [ 3 % - 4 % ] 20 ), 
w h e re a s  the other genes  account for only 1 -2%  of patients or less.1 The prevalence 
of approximately 5 %  of EYS mutations in the cohort a llows for the conclus ion that 
mutations in EYS may be one of the major c a u se s  of arRP
M o s t  patients carrying mutations in EYS demonstrate the typical RP symptoms 
of night b lindness and progress ive constriction of the visual field. The age of first 
symptoms varied from 14 to 62 years, with a mean age of 19 years. A  late onset with 
mild symptoms has  been described previously for patients carrying mutations in EYS,
F IG U R E  6. Graph
showing retinal thickness 
of f/S-associated retinitis 
pigmentosa patients 
compared with that of 
normal individuals.
Retinal thickness across the horizontal meridian with up to 2500 |im of eccentricity from the 
fovea of 6 patients with autosomal recessive retinitis pigmentosa resulting from mutations in EYS 
(CII-4 and CII-6, JII-1, K II-2 and KII-3, and LII-2; assessed by T.T.) compared with age-matched 
normal individuals (gray band, ± 2 standard deviations from the mean). Box, mean ± standard 
deviation; line in box, median; point in box, mean; whisker, range; nas, microns nasal to the fovea.
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as  well as  phenotypic variability in patients carrying identical mutations.5 M o s t  of the 
mutations described in this study have a truncating effect on the protein and likely are 
to result in degradation of the mRNA.
Patients carrying a m issense  change, wh ich  would be expected to result in the 
mildest phenotype, are not specifically affected more mildly. Therefore, a correlation 
between the genotype and the severity of the phenotype cannot be determined. 
Be cau se  the age varied in the patients, different stages  of the d isease could be 
studied. For most patients, visual acuity w a s  preserved until the fourth decade. 
Overall, the fundi of all patients were  remarkably similar, with generalized and 
profound chorioretinal atrophy, sparing of the macular region, and bone spicule 
pigmentations. The high-resolution OCT images show ed  areas of hyperreflectivity, 
presumably RPE cells, that appear to be located at different levels in the neuroretina 
(Figure 8). These OCT data may very well represent migration of RPE cells to the 
inner retinal layers. Su ch  a p rocess  already w a s  suggested  in earlier histopathologic 
studies on bone spicule pigmentation that show ed  a migration of RPE into the neural 
retina.21 Moreover, the severe atrophy of the neuroretinal layers enhanced the 
penetrating depth of the OCT, enabling visualization of the larger choroidal vesse ls  
and sometimes even the sclera (Figure 7).
Posterior subcapsu la r  cataracts were  present at an early age, varying from second 
to fourth decade, in most of the patients (92%), ranging from mild to severe and 
varying with age. In one patient, visual acuity improved noticeably from hand 
movements to counting f ingers after cataract extraction at age 54 years.
F IG U R E  7. Appearance of the peripheral choroid on spectral-domain optical coherence 
tomography images.
A. In a healthy eye, the choroidal visibility is limited by melanin of the retinal pigment epithelium. 
Beneath the choriocapillary layer, large choroidal vessels (black asterisks) may be observed.
B. In autosomal recessive retinitis pigmentosa caused by mutations in EYS, loss of retinal pigment 
epithelium results in a dramatically increased visibility of the sclera (white asterisks), as shown 
in the left eye of patient CII-6. Choroidal vessels cannot be detected any more because of 
complete atrophy of the choroid. Note the scleral emissary channel (arrow).
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A B
F IG U R E  8. Spectral-domain optical coherence tomography image of the equatorial retina 
in f/S-associated autosomal recessive retinitis pigmentosa.
Considerable retinal thinning and disorganization with loss of the typical structure can be observed. 
At variable retinal levels, highly reflective structures could be observed (arrows) that could occur as 
single dots in the left eye of patient KII-3 or as clusters in (B) the right eye of patient KII-2. These 
changes were colocated with funduscopically visible pigment changes, suggesting transretinal retinal 
pigment epithelium migration.
The high prevalence of cataracts in EYS-assoc iated  RP again demonstrates the 
importance of regular follow-up of patients with inherited retinal disease, because 
the benefits of cataract surgery in RP patients have been demonstrated even in the 
presence of relative minor lens opacifications.22
Previously described mutations or deletions in EYS resulted in premature truncation 
of the protein.5, 6 Interestingly, 18 m issense  variants were  found as  well. Of particular 
interest are the three m issense  change s  (p.V834I, p.G2186E, p.I3016N) that probably 
are causative in v iew of their p resence in combination with a truncating mutation. 
Four of the m issense  change s  were found in combination with one or two other 
m issense  variants. One variant (p.T1424A) is predicted to affect a putative glyco- 
sylation site, and therefore may be pathogenic. The residues of the other three 
variants (p.I1232F, p.T1993A, and p.T2831I) are not conserved throughout the EYS 
EGF-like and Laminin A  G-like domains, respectively, and their pathogenicity remains 
unclear. Of special interest as  well is the p.N1163K change, because  this particular 
residue in the calc ium-binding EGF domain is a conserved residue involved in calcium 
binding (Figure 2).23 A lso  of interest are two m issense  ch an ge s  (p.C461Y and p.C2063F) 
that are not part of a specific domain, but concern the change  of a cysteine residue. 
Extracellular cysteine residues are known to form disulfide bonds, which are important 
for the seconda ry  structure of the protein and for protein—protein interaction.24 
Specifically, the cysteine residue at position 2063 is predicted to form a disulfide 
bond with the cysteine residue at position 2037. Therefore, these m issense  changes
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may have a pathogenic character. Patients in w hom  a change  w a s  identified on 
only one allele may carry an additional intronic mutation or a heterozygous deletion 
on the other allele, wh ich  cannot be detected by PCR-based  mutation screening 
of the exons. Alternatively, in case  of a m issense  change, the variant could be 
a nonpathogenic rare variant. In patients with only one clear protein-truncating 
mutation, PROM1 w a s  screened for mutations because  it has  been show n  to interact 
with eys in Drosophila,1 but no mutations were  found.
Interestingly, the p.K1450KfsX3 mutation w a s  detected in five patients, all originating 
from the western part of The Netherlands. M a rke r  analysis  show ed  a common 
haplotype for markers at 1 M b  of the frameshift mutation for two families and partially 
the same haplotype for the other two families (data not shown), indicating that this 
may be a founder mutation in the w e st  of The Netherlands.
In conclusion, this study described nine novel mutations in the EYS gene together 
with a number of possible pathogenic m issense  changes. The EYS-assoc iated  
RP phenotype is fairly typical with severe atrophy of the neuroretina in the 
(mid)periphery. Be cau se  mutations in EYS contribute to a significant proportion 
of RP patients (approximately 5%), routine diagnostic screen ing on a genotyping chip 
is important. By  adding the mutations identified in EYS by this study and others to the 
arRP genotyping microarray (Asper Ophthalmics, Tartu, Estonia), the efficiency of this 
d iagnostic tool can be improved significantly. The identification of the genetic cause 
a llows a more precise genetic counsel ing and, in the future, will be of importance 
w hen  gene-specif ic or mutation-specific therapies become available.25- 26
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a b s t r a c t
p U R p o s E. To characterize the role of EYS, a recently identified retinal d isease 
gene, in families with inherited retinal degenerations in the Israeli and Palestinian 
populations.
METHoDS. Clinical and molecular ana lyses  included family history, ocular 
examination, full-field electroretinography (ERG), perimetry, autozygosity mapping, 
mutation detection, and estimation of the mutation age.
RESULTS. W e  performed autozygosity mapping in 171 con sangu ineou s  Israeli and 
Palestinian families with inherited retinal degenerations. Large hom ozygous  regions 
harboring the EYS gene were identified in 15 of the families. EYS mutation analysis 
in the 15 index cases, followed by genotyping of specific mutations in additional 121 
c a se s  with inherited retinal degenerations, revealed five novel null mutations, two 
of wh ich  are founder mutations, in 10 Israeli and Palestinian families with autosomal 
recess ive  retinitis pigmentosa (arRP). The most common mutation w e  identified w a s  
a founder mutation in the M o ro cc a n  Jew ish  sub-population. Using the EST IAGE 
program, w e  estimate that the age of the most recent common ancestor is 26 
generations. The retinal phenotype in most patients w a s  a typical yet relatively severe 
RP, with an early age of onset and non-recordable ERGs upon presentation.
CoNCLUSioNS. Our results demonstrate that EYS is currently the most 
commonly mutated arRP gene in the Israeli population, mainly due to founder 
mutations. EYS mutations were  associated with an RP phenotype in all patients, and 
w e  predict that the gene plays only a minor role in caus ing  other retinal phenotypes.
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iNTRoDUCTioN
Retinitis pigmentosa (RP), with a worldw ide prevalence of about 1:3,500,1-3 is a group 
of hereditary degenerative d isea se s  of the retina and is considered one of the most 
heterogeneous genetic d iseases  in humans. The disease appears with different modes 
of inheritance, including autosomal recess ive  (50-60%), autosomal dominant (30­
40%), or X-l inked (5-15%).4 A  total of 25 genes  have so far been described to cause 
non-syndromic autosomal recess ive  RP (arRP) and four additional loci have been 
identified by linkage studies (RetNet database; http://www.sph.uth.tmc.edu/RetNet/). 
In 1998, homozygosity mapping led to the identification of the RP25 locus in Spanish 
families.5 Subsequent  linkage ana lyses  show ed  that additional families with arRP 
from var ious origins, including Pakistani6 and Chinese,7 were linked to the RP25 locus. 
Extensive fine mapping and sequenc ing  efforts in the RP25 region led to a refinement 
of the linked region,8 and eventually to the identification of the causative gene 
simultaneously by two groups that used different gene hunting strategies.9, 10 Abd  El- 
Aziz and co-workers  used a multi-step analysis  in wh ich they excluded 60 of the 110 
genes  in the RP25 region, refining the locus to a 2.67 c M  region, and identified a large 
genomic deletion in one of the linked families.10 Collin and co-workers, on the other 
hand, applied homozygosity mapping in non -consangu ineous  families, using genome- 
wide single nucleotide polymorphism (SN P )  genotyping.9 The RP25 gene identified 
by both studies, termed EYS (eyes shut homolog), s p an s  almost 2 M b  of genomic 
sequence  and includes 44 exons coding for a 10,475 nucleotide transcript. The gene 
is abundantly  expressed in the human retina9, 10 and the protein is localized to the 
outer segm ents  of the photoreceptor cells.10 The retinal function of the EYS protein 
is still unknown. It is a large protein, com posed  of 3165 amino acids, containing 
a signal peptide, 28 EGF-like and 5 Laminin A  G-like domains. The human EYS 
protein is a homolog of the Drosophila eyes shut (spacemaker) protein, wh ich  is an 
extracellular matrix protein essential for photoreceptor development and morphology 
of the insect eye.11, 12 Eight EYS mutations, all of wh ich are null, have been reported 
to date, in eight arRP families.9, 10 M o s t  patients with EYS mutations had the clinical 
d iagnos is  of RP with an autosomal recess ive  inheritance pattern,9, 10 but interestingly, 
one patient had a cone-rod pattern of photoreceptor loss.9
In a study aimed to estimate the prevalence of RP in the Israeli Jew ish  population, 
341,175 individuals aged 17-20 years  were  screened  for visual acuity problems, 
and those w h o  had a visual acuity lower than 20/25 were further examined by 
an ophthalmologist. The prevalence in this study w a s  estimated as 1:4,610.13 Since 
many RP patients in this age group have relatively preserved visual acuities, this
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num ber is probably an underestimation. The Israeli and Palestinian populations serve 
a s important genetic so u rce s  for identifying autosom al recessive  d isease  genes 
since  the Jew ish  population w a s  divided into isolated ethnic groups during history, 
leading to relatively high inbreeding levels, and because  the M uslim  population is 
enriched with con san gu in eou s marriages. A  study conducted in sch o o ls  for the blind 
in the W e st Bank  and Gaza in 1992 concluded that 44 -85%  of the affected children 
(depending on location) w ere the offspring of a con san gu in eou s m arriage.14
Only limited information is currently available on the genetic cau se s of non-syndrom ic 
RP in the Israeli and Palestinian populations, with only a few  mutations reported thus far 
in the CERKL, CRB1, NR2E3, RDH12, TULP1, and USH2A genes.15-19 A s  part of our genetic 
analysis of Israeli and Palestinian families with autosomal recessive retinal degenerations, 
w e used autozygosity mapping as the major mapping tool and identified families with arRP 
linked to the EYS region. Sequence  ana lysis revealed five novel null mutations, two 
of w h ich  w ere  founder mutations, in 10 fam ilies w ith arRP. The phenotype of most 
affected individuals w a s  typical for a rRP although som e clinical variation w a s  evident.
m e t h o d s
P a t ie n t  r e c ru itm e n t
The tenets of the Declaration of Helsinki w ere  followed and informed consent w a s 
obtained from all patients w ho  participated in this study prior to donation of a blood 
sample. Blood sam p les for D N A  ana lysis w ere obtained from the index patient as 
well a s other affected and unaffected family members.
G e n e t ic  a n a l y s i s
Genom ic D N A  w a s  extracted from peripheral blood sam p les of index c a se s  and their 
family m em bers using the FlexiGene D N A  kit (Q IAGEN). W ho le  genom e S N P  analysis 
w a s  performed using the GeneChip Human M app ing  10K Xba  142 2.0 m icroarray 
(Affymetrix). Prim ers for the screen ing  of EYS  by PCR amplification have been 
reported previously.9 PCR w a s  performed in a volume of 25 ^l reaction with 35 cycles. 
Mutation ana lysis w a s  performed by direct sequenc ing  of purified PCR products.
G e n o t y p in g  o f  s p e c i f i c  m u ta t io n s
Two mutations, c.403delA,406G>T,410_424del15 (exon 4) and c.4361_4362CC>AG (exon 
26) w ere  genotyped using the restriction enzym es DdeI and MnlI, respectively. For the 
genotyping a ssa y  of the c.3715G>T (exon 25) mutation, w e  designed  allele-specific
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prim ers to d istinguish between the mutant and normal alleles (primer seq uence s 
available on request) and used the NlaIII enzyme for restriction analysis. The 
c.1211_1212insA (exon 8) and c.8218_8219delCA (exon 43) mutations w ere screened  
by sequenc ing  analysis. The possib le effect of sequence  ch an ge s on the splicing 
of the corre spond ing exon w a s  estimated using Sp lice Site Prediction by Neural 
Netw ork at http://www.fruitfly.org/.
E s t im a t io n  o f m u ta t io n  a g e
W e  used the E ST IA G E  program 20 to calculate the age (in generations) of the most 
recent com m on ancestor of patients carrying the c.403delA,406G>T,410_424del15 
mutation. E ST IA G E  is a likelihood-based method w h ich  u se s  multi locus marker data 
from patients carrying the sam e mutation, assum ing they descended  from a common 
ancestor w ho  introduced the mutation. An  estimate of the number of generations 
s ince  the most recent com m on ancestor is obtained from the size of the haplotype 
shared  by the individuals on each side of the d isease  locus. The method u se s  the 
haplotype information in patients carrying the mutation and in controls to identify 
the most likely positions of recom bination events on the ancestral haplotype. This 
method w a s  reported to be efficient for a very small number of affected individuals in 
rare d isease s. W e  used S N P  genotyping data from 36 m arkers on eight ch rom osom es 
carrying the mutation and 46 population-m atched control chrom osom es. Allele 
frequencies w ere  calculated based on the control population.
C l in ic a l  e v a lu a t io n
Complete ophthalm ic exam inations w ere  perform ed includ ing refraction, v isual 
acuity, b iom icro scop ic  slit lamp exam ination, and fundoscopy. Be st corrected visual 
acuity w a s  m easured  in each  eye separate ly  using an ET D R S  chart, and presented 
a s  a decim al ratio. In patients with v isual acuity low er than 20/400, the d istance  at 
w h ich  finge rs could be reliably counted w a s  recorded. Retinal im aging included 
color fundus photographs, optical coherence  tom ography (OCT) and fundus 
autofluorescence  (FAF). Retinal function w a s  evaluated a ccord ing  to the level of 
patient cooperation by full-field e lectroretinography (ERG), Goldm ann kinetic and/or 
Hum phrey static perimetry a s p reviously  described .21 Briefly, full-field ERG s w ere 
recorded using corneal e lectrodes and a com puterized system  (U TAS 3000, LKC, 
M D ). In the dark-adapted state, rod re sp o n se s  to a dim blue flash (W ratten 47b) 
and mixed cone-rod  re sp o n se s  to a white flash (2.35 cd se c / m 2) w ere  acquired.
Cone re sp o n se s  to 30 Hz fla she s of white light (9.4 cd-sec/m 2) w ere  acquired under 
a background  light of 21 cd/m2. All ERG re sp o n se s  w ere  filtered at 0.3-500 Hz and 
s igna l averag ing  w a s  used.
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r e s u l t s
A u t o z y g o s i t y  m a p p in g  a n d  E Y S  m u ta t io n  a n a l y s i s
W e  recruited 712 Israeli and Palestinian families with hereditary non-syndromic 
retinal disease, 307 (including 121 with RP and 43 with Leber congenital amaurosis  
[LCA]) of wh ich  w ere  consanguineous. A iming to identify the causative gene in the 
con sangu ineou s  families, w e  used the 10K Affymetrix S N P  microarray system for 
autozygosity mapping in patients from 171 of the families (82 with RP, 28 with LCA, 
and 61 with cone-dominated diseases). Autozygosity analysis  revealed 18 patients 
from 15 different families (Table 1) w h o  had a large homozygous  region harboring 
the recently identified EYS gene and fulfilled two criteria: the genetic size of the 
hom ozygous  region w a s  at least 10 c M  and it w a s  among the 10 largest homozygous 
regions in the affected individual (Table 1). Interestingly, patients from three of the 
families (MOL0318, MOL0501, and MOL0662; Figure 1) were  of M o ro cc a n  Jewish  
ancestry and shared a large region covered by 44 consecutive homozygous  S N P  
markers. Sequence  analysis  of the 44 EYS exons and exon-intron boundaries in the 
15 above-mentioned index c a se s  revealed two novel homozygous  null mutations 
in four families (Table 1 and Figure 2). Patients from the three above-mentioned 
M o ro cc a n  Jew ish  families were  homozygous  for a novel complex frameshift mutation 
c.403delA,406G>T,410_424del15 (hereafter referred to as p.Thr135LeufsX25) in exon
4, wh ich  c a u se s  a premature stopcodon at position 160 due to a single base pair 
deletion followed by a 15-bp deletion (Figure 2A). In addition, an isolated case  from 
a con sangu ineou s  Palestinian Musl im  family (MOL0410; Figure 1 and Table 1) w a s  
hom ozygous  for a novel nonsense  mutation, c.4361_4362CC>AG (p.Ser1454X), in exon 
26 of the EYS gene (Figure 2D).
Aiming to a s s e s s  the frequency of these mutations among patients from the 
corresponding sub-populations, w e  screened a set of 56 Jew ish  families with RP 
from North-African ancestry (from M orocco ,  Libya, Tunisia, and Algeria) for the 
p.Thr135LeufsX25 mutation and 47 Musl im  families with RP for the p.Ser1454X 
mutation. The analysis revealed four additional index patients w ho  were either 
hom ozygous  (MOL0792 II:2 and MOL0806 III:7) or heterozygous (TB59 III:1 and 
MOL0626 III:1; Figure 1 and Table 1) or for the p.Thr135LeufsX25 mutation. Screening 
of the complete EYS gene revealed novel heterozygous null mutations in the two latter 
patients. Patient MOL0626 III:1 (from M o ro cc a n  Jew ish  ancestry) w a s  heterozygous 
for a frameshift mutation (c.1211_1212insA, p.Asn404LysfsX2; Table 1 and Figure 2B), 
in exon 8. No additional family members were available to confirm the compound 
heterozygous state.
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Aiming to evaluate the frequency of the c.1211_1212insA mutation in North African 
Jew ish  RP patients, w e  sequenced  exon 8 in 47 additional index RP patients, but 
none of them carried the c.1211_1212insA mutation or any other mutation in this 
exon. Patient TB59 III:1 w a s  heterozygous for a novel frameshift mutation (c.8218_ 
8219delCA, p.His2740TyrfsX27; Figure 2E), in exon 43. Segregation analysis in family 
TB59 (Figure 1) revealed that the p.Thr135LeufsX25 mutation w a s  on the maternal 
allele (of M o ro c c a n  Jew ish  ancestry) and the c.8218_8219delCA mutation w a s  
on the paternal allele (of Iraqi Jew ish  ancestry). W e  therefore evaluated the
F iG U R E  1. israeli and Palestinian families with EYS mutations.
Numbers above the pedigrees indicate the family serial number, numbers within symbols represent 
the number of siblings, numbers below symbols indicate the generation and individual numbers, 
arrows represent index cases, and a double horizontal line designates consanguinity with an 
indication of the consanguinity level (e.g. 2:2 designates first cousin marriages). For each recruited 
individual, the EYS genotype is depicted below the individual symbol. M1, p.Thr135LeufsX25; M2, 
p.Ser1454X; M3, p.Asn404LysfsX2; M4, p.His2740TyrfsX27; M5, p.Glu1239X.
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frequency of the c.8218_8219delCA mutation in 31 Oriental Jew ish  RP patients (mainly 
from Iran, Iraq, and A fghan istan) and identified two no n -consangu ineous patients 
from Iraqi Jew ish  origin w ho  w ere either hom ozygous (M OL0640 II:1) or heterozygous 
(TB24 III:2) for the mutation. All the alleles carrying the c.8218_8219delCA mutation 
w ere  from an Iraqi Jew ish  origin and shared  an identical haplotype within EYS, 
indicating a founder mutation.
Sequenc in g  ana lysis of the remaining exons in TB24 III:2 revealed yet another 
novel nonsen se  mutation (c.3715G>T, p.Glu1239X), in exon 25 (Table 1 and Figure 2C). 
The mutation could not be identified in any of 31 additional RP patients from Oriental 
Jew ish  origin. In addition, w e identified 29 sequence  ch an ge s  in our genetic screen, 
of w h ich  14 w ere  non-synonym ous ch an ge s w h ich  are known polym orphism s in the 
S N P  database. None of these sequence  ch an ge s  is likely to be pathogenic.
H a p lo t y p e  a n a l y s i s  a n d  e s t im a t io n  o f m u ta t io n  a g e
The most com m on EYS  mutation identified in this study w a s  the p.Thr135LeufsX25 
mutation identified in 7 RP families, all of M o ro cc a n  Jew ish  ancestry, indicating 
a founder effect. Sc reen ing  of normal individuals of M o ro cc a n  origin revealed 
that one out of 94 control individuals w a s  heterozygous. Haplotype ana lysis  of four 
patients w ho  w ere hom ozygous for this mutation revealed a shared  hom ozygous 
region com posed  of nine S N P  m arkers covering 3.2 M b  or 2.1 c M  (Supplem entary 
Figure 1). The shared  hom ozygous region in three of these patients from 
con san gu in eou s fam ilies is much larger, harboring 44 m arkers along a region of 17 
M b  (6.3 cM). Two p ieces of evidence su gge st  that the mutation is relatively young: 
the relatively large size of the shared  hom ozygous region and the fact that the 
mutation w a s  found only in M o ro cc a n  Je w s  and not in Je w s  originating from 
ne ighboring countries (Algeria, Libya, and Tunisia). A im ing to estimate the mutation 
age, w e  used genotyping data from 36 S N P  m arkers (8 w ithin the EYS  gene 
and 28 flanking it) on eight ch rom osom es carrying the mutation (M OL0318 II:13, 
M O L0318 III:2, MOL0501 II:1, and M OL0662 IV:1) and 46 population-m atched control 
chrom osom es. The data set w a s  analyzed using the E ST IA G E  software and the 
num ber of generations s ince  the most recent com m on ancestor w a s  estimated 
a s 26 (95%, confidence interval of 12-56 generations) or 650 y ea rs  (based on a mean 
generation time of 25 years).
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G M H T V N S K W L S V  S G F T E K N C E K A I D
132 133 134 135 136 137 138 139 140 141 142 143 398 399 400 401 402 403 404 405 406 407 408 409 410
c.406G>T Mutant
G L L C G D E l  R R I T  C A A S I S A T P V V S R
1232 1233 1234 1235 1237 1238 1239 1240 1241 1242 1243 1244 1245 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463
Mutant
V R K K T H  I Q  L Q F Q  
2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746
Mutant
V R K K T
2735 2736 2737 2738 2739
F iG U R E  2. The chromatograms of the five novel EYS mutations. (See appendix for color figure)
For each mutation, the wild-type (wt) sequence is depicted with the homozygous or heterozygous 
sequences when available. The mutation location is indicated by either an arrow (for a nucleotide 
change) or a horizontal line (for a sequence change affecting more than a single nucleotide).
A. c. 403delA,406G>T,410_424del15; p.Thr135LeufsX25 (exon 4).
B. c.1211_1212insA; p.Asn404LysfsX2 (exon 8). C. c.3715G>T; p.Glu1239X (exon 25).
D. c.4361_4362CC>AG; p.Ser1454X (exon 26). E. c.8218_8219delCA; p.His2740TyrfsX27 (exon 43).
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T A B L E  1. Data regarding patients screened for mutations in the EYS gene
Patient ID*
Inheritance pattern and 
clinical diagnosist
Level of 
consanguinity! Origin
MÜL0139-1
MÜL0139-2
arRP
2:1
2:1
Moroccan Jew
MÜL0144-1 arRP 3:2 Oriental Jew
MÜL0161-1 sSTGD 2:2 Israeli Muslim
MÜL0260-1 sRP 2:2 Israeli Muslim
MÜL0264-1 sRP 2:2 Israeli Muslim
CO 
CO 
c
o
c
o
cô
cô
cô
ci
o
o
o
o
o
o
o
o
S
E
E
S
arRP
2:2
2:2
none
none
Moroccan Jew
MÜL0399-1 sLCA 2:2 Oriental Jew
MÜL0400-1 sRP 2:2 Ashkenazi Jew
MOL0410 II:1 sRP 2:2 Palestinian Muslim
MOL0501 II:1 arRP 2:2 Moroccan Jew
MÜL0615-1 sLCA 2:2 Israeli Muslim
M0L0626 III:1 arRP none Moroccan Jew
MÜL0631-1 arRP 2:2 Moroccan Jew
MOL0640 II:1 sRP- sector none Iraqi Jew
MÜL0652-1 arRP 2:2 Israeli Muslim
M0L0662 IV:1 sRP 2:2 Moroccan Jew
MÜL0788-1 sRP 2:2 Ashkenazi Jew
M0L0792 II:2 sRP 2:2 Moroccan Jew
M0L0806 III:7 arRP 2:1 Moroccan Jew
TB24 III:2 sRP none Moroccan/ Iraqi Jew
TB59 III:1 sRP none Iraqi Jew
*, In bold are patients in whom EYS mutations were identified. ^ e  corresponding family trees 
are shown in Figure 1. t, arRP, autosomal recessive retinitis pigmentosa; sRP, simplex retinitis 
pigmentosa; sSTGD, simplex Stargardt disease; sLCA, simplex Leber congenital amaurosis. t, 
Level of consanguinity is measured by the number of generations separating the spouse from the
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Number of 
consecutive 
homozygous SNPs
size of homozygous 
region (in Mb and cM)§
Rank among 
homozygous regions 
(based on genetic size)
Mutation 1 
Mutation 2| 1
169
332
50 Mb; 39 cM 
90 Mb; 70 cM
2nd
1st none
113 33 Mb; 27 cM 2nd none
236 60 Mb; 43 cM 1st none
277 72 Mb; 53 cM 1st none
118 34 Mb; 16 cM 4th none
243 65 Mb; 72 cM
200 55 Mb; 49 cM 1st p.Thr135LeufsX25
9 3.2Mb; 1.5 cM 1st p.Thr135LeufsX25
NP NP
396 103 Mb; 80 cM 1st none
107 30 Mb; 13 cM 3rd none
122 37 Mb; 20 cM 5th
p.Ser1454X
p.Ser1454X
175 44 Mb; 24 cM 1st
p.Thr135LeufsX25
p.Thr135LeufsX25
157 42 Mb; 20 cM 1st none
NP NP NP
p.Thr135LeufsX25
p.Asn404LysfsX2
254 70 Mb; 71 cM 1st none
NP NP NP
p.His2740TyrfsX27
p.His2740TyrfsX27
102 28 Mb; 18 cM 4th none
60 20 Mb; 10 cM 7th
p.Thr135LeufsX25
p.Thr135LeufsX25
69 24 Mb; 12 cM 9th none
NP NP NP
p.Thr135LeufsX25
p.Thr135LeufsX25
NP NP NP
p.Thr135LeufsX25
p.Thr135LeufsX25
NP NP NP
p.Glu1239X
p.His2740TyrfsX27
NP NP NP
p.Thr135LeufsX25
p.His2740TyrfsX27
common ancestor (e.g. 2:2 designates first cousins, 2:1 designates marriage between an uncle and 
his niece). § Data are based on 10K SN P  analysis (see Materials and Methods). 11, The predicted 
effect of the mutation on the protein sequence is presented. See Supplementary Table for 
additional information. NP, not performed
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F IG U R E  3. Fundus imaging and visual fields. (See appendix for color figure)
Representative fundus images and Goldman visual fields of the left eyes of patient TB24 III:2 
(panels A-D) at age 63 and patient M O L0501 II:3 (panels E-H) at age 52 are shown. The typical 
funduscopic findings of RP are present, including bone spicule-like pigmentation, pallor of 
the optic discs, and narrowing of blood vessels (A,E). Macular involvement is evident also on 
autofluorescence imaging (B,F) and OCT, with retinal thinning and atrophy (D,H). Note more 
severe foveal atrophy in patient M O L0501 II:3 which correlates with the lower visual acuity 
of this patient (Table 2). Visual fields are markedly constricted in both patients (C,G).
o c u l a r  p h e n o t y p e  a s s o c ia t e d  w i t h  E Y S  m u ta t io n s
W e  clinically examined 15 patients with EYS mutations and performed ERG testing 
in 11 of them (Table 2). All patients with EYS mutations show ed  characteristic 
manifestations of RP, with a relatively severe course  of disease. Night vision, visual 
fields, and ERG re sponses  were markedly impaired already at early ages. Both myopic 
and hyperopic refractive errors were present. Fundus appearance w a s  typical for 
RP  including bone spicule-l ike pigmentation, pallor of the optic discs, and narrowing 
of blood vesse ls. Representative fundus m osa ic s  of the left eyes of patient TB24 
III:2 at age 63 and patient MOL0501 II:3 at age 52 are show n  in Figures 3A  and 3E, 
respectively.
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T A B L E  2. clin ica l data of patients carrying EYS mutations
patient iD
e
g
CO 
<0
age
of
onset
age of 
diagnosis Refraction visual acuity FFERG
MÜL0318 III:1
M
19
19 NA NA
Extinguished
Extinguished
MÜL031811:9
F
51
12 36 Myopia
CF 2m 
CF 2m
Extinguished
Extinguished
MÜL0318 II:9
F
38
-3.50/-1.00x35°
-5.00/-0.50x160°
0.3
0.15
NP
MÜL0318 II:11
M
32
8 32
-4.50/-1.00x35°
-6.00/-0.50x170°
0.15
0.15
NP
MÜL031811:13
F
36
22 36 NA NA
Extinguished
Extinguished
MÜL0318 III:2
M
21
19 NA NA
Extinguished
NP
MÜL0318 III:5
F
19
18 18 NA
0.7
0.7
NP
Extinguished
MÜL0410 II:1
M
21
21
-2.0/-0.25x35°
-2.0/-1.0x140°
0.5
0.8
Extinguished
Extinguished
MÜL0501 II-1
F
33
33 NA
1
5 
.1 
2 
0 
0.
Extinguished
Extinguished
MÜL0626 III:1
F
50
50 50 NA
.4 
.4 
0. 
0.
Extinguished
Extinguished
MÜL0640 II:1
M
47
20 NA
0.5
0.6
27; 53/97; 8, 36 
29; 31/81; 7, 36
MÜL0662 IV: 1
M
41
41 NA
0.15
0.15
NP
MÜL0792 II:2
M
57
57
-0.75/-3.00x40°
-2.50/-1.50x50°
.5m 
1m
™ 
lI 
CF 
CF
NP
TB24 F
37 40
-0.75/-0.25x18° 0.5 Extinguished
III:2 55 +0.25/-1.5x132° 0.4 Extinguished
TB59
III:1
F
19
15 19
+3.50/-
0.75x160°
+4.25/-0.50x44°
0.8
0.8
Extinguished
Extinguished
*, Full Field Electroretinogram including the following responses: rod response b-wave amplitude 
(in |iV, normal > 200|iV); mixed cone-rod a/b wave (in |iV, normal a-wave > 90|iV, normal b-wave 
> 400|iV); cone response (in |iV, normal > 60|iV), implicit time (in msec, normal < 33 msec). CF, 
counting fingers; F, female; FFERG, full-field electroretinogram; M , male; m, meter; NA , Not available; 
NP, not performed. First line (2nd -6th column) indicates the right eye, second line indicates the left eye.
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M a cu la r  involvement is evident also on FAF imaging (Figures 3 B and 3F) and OCT, 
with retinal thinning and atrophy (Figures 3D and 3H). Visual fields in these two 
patients are markedly constricted (Figures 3C and 3G). In almost all patients for whom  
ERG data w ere  available (ages between 19-51 years), both scotopic and photopic full- 
field ERG re sponses  were extinguished, indicating severe retinal involvement (Table 
2). Only in one patient (MOL0640 III:1) scotopic as  well as photopic ERG re sponses  
were  measurable, although also severely reduced. This patient initially presented 
with sector RP -  based on funduscopic and visual field f indings 
-  at the age of 25 wh ich  later progressed  to w idespread, generalized retinal 
involvement. The mean 30 Hz cone flicker ERG amplitude measured at our centre on 
the first ERG test performed in each patient w a s  significantly lower in the EYS group 
as  compared to pooled, first test-ERG amplitudes in RP patients in our population 
(Figure 4). The EYS group included 11 patients with a mean age of 34 years  and mean 
± SD  amplitude of 0.65 ^V ± 2.17. The control RP group included 240 patients with 
a mean age of 29.8 years  and mean ± SD  amplitude of 17.7 ^V ± 22.2 (p-value for 
cone flicker ERG amplitude difference < 0.01).
DiSCUSSiON
EYS represents a major arRP gene, as can be appreciated from the w idespread  ethnic 
orig ins of families with arRP due to EYS mutations thus far reported.9- 10 In the present 
study, w e  s h o w  that mutations in EYS are currently the most frequent cause  of non- 
syndromic arRP in the Israeli population, mainly due to founder mutations in two 
ethnic groups (M o rocca n  and Oriental Jews). The five novel EYS mutations reported 
here account for at least 7 %  of the arRP families (10 out of 141 families) that w e  have 
thus far recruited from the Israeli and Palestinian populations. The most common 
mutation w e  identified in this study (p.Thr135LeufsX25) is a founder mutation in the 
M o ro cc a n  Jew ish  population accounting for about 19%  (12 out of 64 chromosomes) 
of non-syndromic arRP alleles in this population, and is therefore currently the most 
common cause  of RP in J e w s  of M o ro cc a n  ancestry.
Similar to previous studies, most of our patients with EYS mutations manifested typical 
and rather severe arRP. One exception is an isolated ca se  w ho  initially presented 
with a milder phenotype (sector RP) and w a s  homozygous  for a null mutation in exon 
43. A lthough one might expect that the nonsense-mediated m R N A  decay  (N M D )  
mechanism  would prevent protein production of this mutant allele, it is tempting 
to speculate that some transcripts will escape degradation, as  reported in many
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F i g u r e  4. A  graph representing cone 30-Hz ERG amplitude (Y-axis) versus the age (X-axis) at which 
ERG data was first obtained from 11 patients with EYS mutations (filled diamonds) versus 240 patients 
diagnosed with RP (open squares). Each data point represents the average cone flicker amplitude of the 
two eyes of each patient.
other c a se s  (see Holbrook et al.22 for review), manifesting a milder, more localized, 
phenotype. M utations that are likely to result in a sim ilar effect, however, w ere 
reported to cause  the typical w idespread  and severe RP phenotype.9 Only one patient 
to date w a s  reported to manifest a different retinal phenotype, cone-rod dystrophy 
(CRD), due to a null mutation located at the very end of the carboxy-term inus of EYS, 
thereby resulting in the absence  of only the last 10 amino acids. Her older sibling, 
though, d isplayed RP,9 probably due to other factors influencing clinical expression. 
W e  included 61 fam ilies with autosom al recessive  cone dominated d isea se s  (mainly 
CRD) in our autozygosity analysis, but only one (in w h ich  no EYS mutations w ere identi­
fied) w a s  hom ozygous at the EYS locus, indicating that mutations in EYS are a rare 
cause  of CRD in our population. It is interesting to note that all EYS mutations thus 
far reported,9- 10 as well a s the five novel mutations reported here, are null mutations 
(either frameshift or nonsense). A  large number of EYS  m issense  ch an ge s are 
known -  som e of w h ich  appear a s entries at d b SN P  -  but none of them is currently 
considered as a cause of disease. Su ch  m issense changes, in combination with a null 
mutation on the counter allele, might result in a milder retinal phenotype. Another 
possib le explanation for the lack of pathogenic m issense  mutations in EYS is the 
ability of the protein to tolerate single am ino-acid alterations, affecting only a specific 
protein domain, due to the multiple functional dom ains (e.g. EGF-like and Laminin 
A  G-like dom ains) in the EYS protein. This phenom enon resem bles the mutation 
spectrum  of well-studied retinal genes, including CHM23 and the RPGR-ORF15 
terminal exon,24-26 in w h ich  only null mutations have been reported so  far. Su ch  genes 
will therefore cause  a retinal phenotype only if no protein is generated. One can also
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a ssum e that some of the polymorphic m issense  change s  might result in an expressed 
protein with reduced activity. This makes EYS an attractive candidate for modulating 
retinal d isease  severity in ca se s  caused  by mutations in other retinal genes, mainly 
those encoding proteins that interact with EYS, such  as PROM1.9 Since EYS w a s  
only recently identified, further EYS mutation ana lyses  are likely to result in a more 
accurate and comprehensive EYS mutation spectrum.
The most common mutation w e  identified here (p.Thr135LeufsX25) is a founder 
mutation in the M o ro cc a n  Jew ish  sub-population. The history of the Jewish  
population in North Africa (including M orocco ,  Algeria, Libya, and Tunisia) is ancient 
and complicated. The population w a s  founded about 2,000-2,600 yea rs  ago and 
s ince then underwent a number of historic events that had a dramatic effect on the 
population size, including a few w a v e s  of immigrations (during the first temple period 
about 600 years  BCE  and in 1492 due to the expulsion from Spain), the conversion 
of Berber tribes to Juda ism  (during the sixth and seventh centuries), and the 
persecution of a major part of the community in 1033 and 1232. By  1948, the Jew ish  
M o ro cc a n  population (the major North African Jew ish  population) w a s  estimated 
to contain 270,000 individuals, most of w hom  immigrated to Israel once the state 
w a s  established in 1948. Using the EST IAG E  program, wh ich  w a s  designed for rare 
d iseases, w e  estimated the age of the most recent common ancestor to be relatively 
young, 26 generations (or 650 years) ago. This young age is supported by the fact 
that the mutation w a s  found in J e w s  originated from M o ro cc o  (and not other North 
Afr ican countries), and by the relatively large size of the shared hom ozygous  region 
in most of the studied patients. To date, the estimated ages  of only two founder 
mutations in the M o ro cc a n  Jew ish  population have been reported and found 
to be relatively ancient (2,600-2,700 years  ago).27- 28
In summary, in this study w e  report the mutation spectrum of EYS in a cohort of Israeli 
and Palestinian RP patients wh ich  includes five novel mutations and s h o w  that EYS 
is the most frequently mutated arRP gene currently known in the Israeli population.
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SUPPLEMENTAL DATA
dbSNP 
RS ID 
rs1327277 
rsl327272 
rsl4I4503 
rsl326588 
rsI321508 
rs746600 
rs1896974 
rsl937147 
rs3857604 
rsl413921 
rsl4I3920 
rs559421 
rsl 883930 
rsI000809 
rs2397132 
rs609122 
rs4129429 
rs4129428 
rs655630 
rsl883632 
rs727384 
rsl 409098 
rsl298144 
rsl 150884 
r$1316576 
rs578499 
rsl853334 
rsl 566753 
rs988913 
rs952647 
rsl358815 
rsl964875 
rs726783 
rsl020867 
rsl020866 
rsl517229 
rs213789 
rs3846820 
rs3846823 
rs2345326 
rs676420 
rsl343991 
rs2346299 
rsl417694 
rsl417693 
rs951849 
rsl585367 
rs2146149 
rsl922954 
rsl 390272 EYS rs975618 
rsl 502990 
rs958706 
rs2251342 
rsl962252 
rsl351S67 
rsl 464074 
rs4131870 
rsl 112645 
rsl378133 
rs779492 
rsl328732 
rsl571427 
rs951494 
rs802186 
rsl075263 
rsl 160663 
rsl891530 
rs763354 
rs701697 
rs829472
Physical 
Position (Mb
S h a re d
h a p lo ty p e
BB C
AA A
BB G
BB G
AA A
BB T
BB G
AA C
BB C
AA A
AA A
BB T
BB G
BB G
BB T
BB T
AA A
AA C
BB T
AA G
AA G
BB T
AA A
AA C
AA C
BB G
BB G
AA C
AA C
BB G
AA C
BB G
AA C
BB T
BB G
AA C
BB T
AA A
BB G
BB T
BB T
BB T
BB T
AA A
S U p p L E M E N T A R Y  F IG U R E  1. (See appendix for color figure)
The autozygous region identified in Moroccan Jewish patients who are homozygous for the 
c.403delA,406G>T,410_424del15 mutation. The appropriate region of the Affymetrix 10K 
microarray analysis is depicted, covering the EYS  gene and flanking markers on chromosome 6. 
The genotype data of the following patients are presented: 1, M 0 L050 1  II:1; 2, M 0 L066 2  IV:3; 3, 
M 0 L 0 3 1 8  II:13; 4, M 0 L 0 3 1 8  II-9; 5, M 0 L 0 3 1 8  III:5. For each marker, the genotype is presented 
as homozygous (A A  or BB), heterozygous (AB) or unknown (NoCall). The A  and B alleles were 
arbitrarily determined for each allele by Affymetrix and the corresponding nucleotide is presented 
on the right along the shared homozygous region. Red indicates A A ’ genotype; blue indicaties 'BB’ 
genotype, and green indicates A B ’ genotype.
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S U P P L E M E N T A R Y  F IG U R E  2. A  pie chart showing the contribution of arRP genes 
in the Israeli and Palestinian populations. (See appendix for color figure)
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CHARTER 5C MUTATIONS IN EYSARE FREQUENT CAUSE OF RP IN ISRAEL

In this thesis  w e  identified the genetic defects mainly in patients with cone-rod 
dystrophy or retinitis pigmentosa, using high density genome-wide S N P  arrays, 
followed by homozygosity mapping or linkage analysis.
STRENGTH AND LiMITATIONS OF HOMOZYGOSiTY MAPPiNG
In this thesis, 108 CRD patients (95 probands) were  analyzed by genome-w ide S N P  
genotyping arrays, followed by a sea rch  for homozygous  regions. This led to the 
identification of the causative mutation in 8.5% of probands (Chapter 2). Mutations 
were  detected in 2 out of 7 con sangu ineou s  probands (28%) and 6 out of 88 non- 
con sangu ineou s  probands (7%). A  comparable effectiveness of homozygosity 
mapping has  been described previously in LCA  patients, for wh ich  the mutation 
w a s  detected in 3 0 %  of con sangu ineou s  families and in 3 %  of non-consangu ineous  
families.1 In a group of con sangu ineou s  patients affected by Bardet-Biedl syndrome 
(BBS), homozygosity mapping led to the identification of the mutation in all families.2
These numbers implicate that homozygosity mapping is mostly effective in 
con sangu ineous  patients. However, this approach has  advantages and disadvantages 
in both types of families. In a sporadic patient from a con sangu ineous  family, the 
chance that the mutation occurs  homozygously  is high, but the homozygous regions 
are large and numerous. For diagnostic purposes  in a genetically heterogeneous 
disease, several homozygous regions may overlap with known disease-associated 
genes, wh ich may complicate the search for the causative mutation.3 W h e n  searching 
for new  d isease genes, the total size of homozygous regions may be so large, that 
finding the causative gene defect may be too challenging. In non-consangu ineous  
patients, on the other hand, the chance s  are lower that an affected individual carries 
homozygous mutations. However, if an individual carries homozygous mutations, the 
chance s  to find them are higher because  of a limited number and smaller size of 
homozygous regions. This is s how n by the identification of the EYS gene (Chapter 5A). 
Several other studies have also led to the identification of new  mutations or d isease 
loci using homozygosity mapping in non-consangu ineous  families.4-6 Homozygosity 
mapping can thus be effective in both con sangu ineous  and non-consangu ineous  
families, w hen  using the right families for the right purposes (Table 1).
W h ich  non -consangu ineous  families are most suitable for this type of research, and 
in wh ich  of the regions can the causative mutation be found? First of all, a detailed 
pedigree of the family, including information about the origin of the maternal and
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TABLE 1. Suitability of type of fam ilies in relation to purpose of screening.
Type of 
family
Purpose
Consanguineous
siblings
Consanguineous 
sporadic patient
Non-consanguineous
siblings
Non-consanguineous 
sporadic patient
Isolated
population*
Mixed
population
Isolated
population*
Mixed
population
Diagnostic
screening ++++ +++ ++++ +/- + -
Discovery of 
novel gene ++ + ++++ +/- + -
++++/+++ highly suitable; ++/+, suitable; +/-, possibly suitable; unsuitable.
*, isolated is used here in a broad perspective, namely all families in which the parents have 
a higher than average chance to be related. For example, a family in which the grandparents 
originate from the same village or the same geographical region, a population that is isolated 
based on religious or cultural dissimilarities from the surrounding population, an island 
population, a population with a relatively high rate of inbreeding, etc.
paternal grandparents, is useful to estimate the chance s  for successfu l  homozygosity 
mapping. Estimating relative re latedness based on a higher percentage of genome- 
wide homozygosity than expected, appeared to be unreliable in a population in which 
genea logy  w a s  known and w h o se  D N A s  were analyzed for ~10,000 S N P s  (10K array).7 
On the other hand, it is stated that the proportion of the genome that is homozygous 
in an individual (the inbreeding coefficient) is a measure of the degree of relatedness 
between his/her parents.8-11 Moreover, the percentage of homozygosity w a s  higher 
than the average in patients in w hom  a mutation w a s  detected by homozygosity 
mapping (1.06% versu s  0.47%; Chapter 2). Altogether, the value of this percentage 
in estimating the probability to find a homozygous  mutation remains debatable.
The observation that many mutations are located in (one of) the largest reg ion s1, 12 
is logical as  larger regions on average contain more genes, and thus have a higher 
chance  to harbor the mutation.
There are several explanations w h y  w e  did not detect the causative mutations in 87 
out of 95 probands (91.5%). First, 49 of the patients were  not screened  for mutations in 
ABCA4. Ba sed  on the published 4 0 %  prevalence of ABCA4mutations in CRD patients, 
w e  expect ~20 of the patients studied in this thesis  to carry a mutation in this gene. 
CRD is usually  caused  by a compound heterozygous combination of a null mutation
173
and a moderately severe ABCA4  mutation.13 For example, in a total of 32 CRD patients 
15 com pound heterozygous mutation, 14 heterozygous mutations, and only three 
hom ozygous mutation w ere  previously detected.14, 15 Consequently, hom ozygosity 
m apping m ay not be an efficient tool to detect ABCA4  mutations in CRD patients. 
Furthermore, patients may carry an intronic or a promoter mutation in one of the 
arCRD  genes, w h ich  cannot be detected by sequenc ing  exons and intron-exon 
boundaries. Alternatively, the causative  gene defect could reside in a region that is 
sm aller than our minimum threshold. A lso, our cohort conta ins 52 sporad ic male 
patients, of w h ich  46 remain unsolved. The inheritance in som e of these men could 
be X-linked, with mutations in X-linked CRD genes such  a s RPGR. And  finally, several 
patients are expected to carry mutations in novel CRD genes, w h ich  remain to be 
identified in future studies.
Approxim ately 3 5 %  of patients from an average population, like the cohort studied in 
this thesis, carry a hom ozygous defect,16-20 and thus the maximum percentage of 
detectable mutations is expected to be ~3 5%  (= 26 patients). The dataset described  in 
Chapter 2 already led to the identification of a mutation in 8 probands, and will thus 
theoretically lead to the d iscovery  of mutations in new  genes in approximately 18 
more patients. Especially in com bination with next generation sequencing, a s will be 
explained in one of the subsequent paragraphs, this dataset represents a valuable 
re source to identify new  genes associa ted  with CRD.
In conclusion, hom ozygosity m apping can be a powerful, but not nece ssarily  an 
efficient method to detect new  genes and new  mutations in con san gu in eou s a s well 
a s no n -con sangu ineous patients, as show n  in this thesis by the d iscovery  of a new  
gene (Chapter 5A), and the identification of 9 novel mutations in ten families (Chapter 2). 
Altogether, w e  identified the genetic defect in patients of a total of 32 families 
(Chapter 2, 3, 4, 5ABC). In the further paragraphs, the value of this m olecular know ­
ledge in scientific terms, and the actual benefit for the patient will be d iscussed.
iNSiGHT iNTO ETiOLOGY OF RETiNAL DYSTROPHIES
Prior to the genetic era, m any com ponents of the phototransduction ca scade  were 
d iscovered  by physio logists, w ho  clarified small parts of the w hole  m echanism , for 
example through electrophysio logical experim ents on animal photoreceptor cells.21 
Currently, additional com ponents of the visual p ro ce sse s  are mostly elucidated by the 
identification of protein networks,22 and by genetic studies, like the d iscovery  of EYS
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(Chapter 5A). The identification of new  genes  associated with retinal dystrophies 
may lead to insights into new  pathways that can play a role in the etiology of these 
diseases. The m echan ism s of autosomal recess ive  retinal dystrophy, as far as known 
now, include mainly disruption of photoreceptor outer segm ent  morphogenesis, 
interruption of the transport a c ro s s  the photoreceptor connecting cilium, a defective 
retinoid cycle, dysfunction of the RPE cells, and defective phototransduction through 
continuous activation or inactivation.23- 24 Still, the function of (newly) identified 
d isease -assoc ia ted  genes  (for example, ADAM9, EYS, PRCD, RD3, SPATA7; Table 1, 
Chapter 1) remain to be elucidated. Usually, the function em erges  from studies on 
protein localization and interactions, and/or information about retinal abnormalities 
in spontaneous  or transgenic animal models.23- 25 and refs therein With regard to EYS, the 
hypothesized role of the EYS protein (photoreceptor morphogenesis)  w a s  derived 
from studies in the Drosophila eye, in w h ich  eys has a function in maintaining the 
interrhabdomeral space, and interacts with other proteins that are associated with 
human retinal dystrophies (CRB1, PROM1),26 as d iscussed  in Chapter 5A. The function 
of EYS in the human retina, however, remains to be determined.
Although some protein functions are already elucidated, clinical information can 
confirm what w a s  presumed before, and can add new  insights. For example, the role 
of CaBP4  in the synaptic terminal27 w a s  corroborated by the phenotype of two 
patients carrying mutations in CABP4 (Chapter 3), s ince their electro-negative mixed 
ERG re sponses  demonstrate that the transm iss ion from photoreceptor cells to the 
bipolar cells is disturbed. N e w  insight w a s  gained, as  w e  observed that mutations in 
CABP4 lead to a disturbed cone function, but relatively preserved rod function. CaBP4 
in mice w a s  previously found to be expressed in cones  and rods.28 In humans, either 
CABP4 may be expressed predominantly in cones, or d isturbance of its function may 
have a greater effect in cones  than in rods.
GENETIC KNOWLEDGE M AY  LEAD TO NEW  THERAPEUTIC 
POSSiBiLiTiES
The very best example of the necess ity  of identifying the genetic defect is the 
s u c c e s s  of the RPE65 gene therapy clinical trials.29-33 Although retinal dystrophies 
have a lways  been considered untreatable, patients w h o  are visually severely 
handicapped due to mutations in RPE65 can now  be treated by a subretinal injection 
of recombinant adeno-assoc iated virus (AAV) carrying RPE65 complementary D N A  
(cD N A )  to supply functional RPE65 to the RPE cells. Phase-I clinical trials revealed
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no undesirable side-effects, and led to the improvement of visual function in most 
of the 21 treated patients thus far.29-33 Patients carrying mutations in RPE65 are 
suitable for gene-therapy, as they have a useful visual function in childhood, retinal 
imaging su gg e s t s  that photoreceptor cell death occu rs  late in the d isease  process,34 
RPE65 is a relatively small gene that can be carried by an AAV-vector, and RPE65 has 
an enzymatic function, a deficiency of wh ich  can be more easily compensated than 
for example a gene that plays a role in photoreceptor development. Not all genes  will 
be suitable for AAV-mediated gene-therapy; for example, the EYS c D N A  is too large 
to be carried by an AAV-vector.
The identification of genetic defects is ne ce s sa r y  to gain a broader understanding 
of d isea se  m echan ism s  in general, w h ich  in turn can lead to the development 
of other therapeutic options. A n  example is the development of a therapy for 
Duchenne  m uscu la r  dystrophy (DMD). In the majority of ca ses,  D M D  is cau sed  by 
deletions or duplications in the Duchenne  m uscu la r  dystrophy (D M D )  gene that lead 
to the truncation of the dystrophin protein.35 Deletions or duplications in this gene 
that do not result in protein truncation lead to a relatively mild phenotype: Becker 
m uscu la r  dystrophy.35- 36 Ba se d  on this genetic mechanism, Aartsm a  et al. developed 
a mutation-specif ic therapy in w h ich  the disrupted exon, that c a u se s  the frameshift, 
is blocked by so-ca lled  ant isense o ligonucleotides (AONs).37 The targeted exon(s), 
w h ich  shou ld  have a length of a multiple of three nucleotides, is/are then skipped 
in the splic ing p rocess,  and as a result the m R N A  remains in frame. In this way, the 
therapy ch a n ge s  D M D  into Becker  m uscu la r  dystrophy, w h ich  potentially g ives the 
patient a higher quality of life and longer life expectancy. Proof-of-concept studies 
in patients affected with D M D  show ed  a partly recovered synthe s is  of dystrophin, 
and although the functional improvement of the patients still needs  to be tested, 
this type of therapy seem s  promising.38- 39
Phenotypic variability dependent on the genetic defect has also been found in patients 
carrying mutations in CEP290. Patients carrying two nonsense mutations in CEP290 
usually suffer from a systemic or even lethal d isease (Joubert syndrome and Meckel 
Gruber syndrome, respectively),40-43 while a nonsense mutation (p.Arg151X) that leads 
to exon skipping (nonsense-associated altered splicing; N A S )  results in a single-organ 
disease with relatively mild symptoms (early-onset severe retinal dystrophy; EOSRD) 
(Chapter 4). Possibly, imitating N A S  by using antisense oligonucleotides to block an 
exon that harbors a syndrome-causing nonsense mutation could lead to a milder 
phenotype. Obviously there are many obstacles, as patients will need to be treated 
intrauterine to change the disease course.44-47 This would only be possible if the parents
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of a patient are known to carry CEP290 mutations and if a prenatal diagnostic test can 
be performed. Furthermore, few  nonsense  mutations would be suitable for this type of 
therapy, since it should be located in an exon that has a multiple of three nucleotides 
that encodes part of a protein domain that can be m issed to som e extend. Therefore, 
this therapy is not likely to be of broad use, but in case  of mutations in CEP290, this type 
of therapy could be interesting to investigate further.
Anothe r exam ple of m utation-specific therapy is the PTC124 treatment; a method 
that a im s at m utations resu lting in a premature term ination codon (PTC). A  PTC is 
a signa l for a ribosom e to stop translation of the m RNA, w h ich  sub sequen tly  leads 
to a truncated protein that cannot fulfill its function, and will be degraded 
by a m echan ism  called non sen se  mediated m R N A  decay.49-51 Initially, high co n ce n ­
trations of am inog lyco side s w ere  found to promote read-through of a PTC.52, 53 
However, clinical trials revealed som e d isadvan tages, including a low  potency and 
a high renal and otic toxicity.54-57 Subsequently, a high-throughput sc re en in g  of low 
m olecu lar-w eight com pounds led to the identification of PTC124 a s  n o n se n se ­
su p p re sso r  with a h ighest affinity for U G A  stopcodons, fo llow ed by UAG  and U A A .58 
PTC124 re cogn ize s a PTC as being premature, and instead of ending the translation, 
a random  am ino acid is inserted at that position. The ribosom e will then continue to 
translate the m RNA, w h ich  will thus result in a full-length protein. Patients affected 
by cystic fib rosis due to n o n sen se  m utations in CFTR have been treated in a phase-
II clin ical trial, w h ich  resulted in an increase  in ch loride transport in most of the 23 
treated patients, im plicating a restoration of the function of CFTR.59, 60 PTC124 has 
a lso  been used in D M D  patients, w h ich  sh o w s  that th is type of treatm ent may be of 
b roader use, and thus may be of interest for patients affected by a retinal dystrophy 
due to a n o n sen se  mutation.61
In conclusion, although m any experimental treatm ents are still far from clinical 
applications, an inc rease  in m olecu lar genetic know ledge  may provide new  
su gg e st io n s  to develop novel therapies. M o le cu la r genetic testing in a patient 
w ill becom e essentia l to determ ine the eligibility for gene- or m utation-specific 
therapies.
177
BENEFiT OF MOLECULAR KNOWLEDGE iN THE CLiNIC
Although the perspective on therapy for retinal dystrophies looks more promising than 
it ever did, only few patients can as yet enjoy its benefits. Therefore, the question arises: 
what does the molecular knowledge currently bring to the patient? The answer to this 
question will be different for every patient, depending on his/her personal situation and 
personality; some people for example prefer to know the disease prognosis, while others 
prefer not to know. Some reasons in favor of molecular screening are mentioned below.
Perhaps the most important aspect of a molecular d iagnosis is genetic counseling; 
patients may have considerable worries about pass ing on the mutation to their 
children. Detailed documentation of the family history can often provide the mode of 
inheritance. However, in isolated ca se s  or in small families, the distinction between 
autosomal recessive, autosomal dominant and X-linked recessive inheritance can 
be difficult, while this knowledge has a great influence on the predictions about 
heritability (Figure 1). D iscuss ing heredity is an issue in which the clinician can provide 
a clear answer, with which he/she can take away some of the patient's worries. 
Furthermore, knowing the genetic defect may improve diagnostic accuracy.62 Some 
retinal dystrophies have a very similar presentation in the initial stage, and a study from 
W e i s s  and Biersdorf in 1989 showed that a patient with retinal dystrophy or congenital 
blindness on average visited seven ophthalmologists before the d iagnosis w a s  
made.63 Although this number may not be accurate currently, determining the correct 
d iagnosis can still be a challenge, especially in very young patients w ho  are not yet 
able to participate well in ophthalmic examinations and/or ERG recordings. Therefore, 
knowing the genetic cause may give a better clue towards the final d iagnosis in an 
early stage of the disease, and can distinguish between a stationary or a progressive 
disorder.62 Another argument in favor of finding the genetic cause is that dietary advice 
may be dependent on the genetic defect. Vitamin A  supplementation can be helpful 
for slowing down progression in patients with retinal dystrophy,64 but probably has a 
detrimental effect on the phenotype of patients carrying mutations in ABCA4, a s  w a s  
shown in Abca4rh mice.65 Furthermore, a molecular d iagnosis may be of great help to 
a patient when syndrome-causing mutations would be detected in an early stage. For 
example, an LCA patient w ho  is affected due to mutations in IQCB1 (NPHP5), is at high 
risk to develop nephronophthisis later in life (known as Senior-Loken Syndrome).66 
67 W h en  mutations in IQCB1 are detected, an early clinical a ssessm ent  of the kidney 
function may lead to the d iagnosis of nephronophthisis in an early stage, when dietary 
restrictions and taking preventive medications may postpone the moment that a patient 
becomes dialysis-dependent (N.C. van de Kar, personal communication, 2010).
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F iG U R E  1. Recurrence risk when one of the parents is affected or mutation carrier, 
presented with different modes of inheritance.
Circle, woman; square, man; diamond shape, either boy or girl; dot within symbol, carrier of 
mutation; black symbol, affected person; grey symbol, no affected status known, chance to 
become affected is indicated; +, normal allele; M , mutant allele; X+, normal X-chromosome; X M, 
X-chromosome with mutation.
The last and probably most com plex argum ent for genetic screen ing  is its contribution 
to predicting the prognosis of the disease. For som e genetic defects, a reliable prediction 
about the d isease  p rognosis  can be given. For example, som e LC A-assoc iated  genes 
lead to a phenotype with clear characteristics (in refractory error, photophobia 
or night b lindness, progressivity) specific for mutations in that particular gene.62' 68 
Know ledge of the genetic defect in a child carrying a mutation in such 
a gene provides therefore a reasonab ly  reliable prognosis.
This thesis, on the other hand, sh o w s  several exam ples in w h ich  a genetic d iagnosis 
cannot be used for establishing a p rognosis  (Chapter 3, 4 and 5A). First, mutations 
in CABP4 w ere previously a ssocia ted  with congenital stationary night b lindness 
(C SN B ).69 However, in the patients carrying mutations in CABP4 (Chapter 3), the cones 
w ere primarily affected, and the rods w ere  relatively spared. A lso, the course  of 
d isease  seem ed to be p rogre ssive  during childhood in previously published patients 
carrying mutations in CABP4,69 Chapter 4 sh o w s  that a non sen se  mutation in CEP290, 
usually causing  LCA, unexpectedly led to a relatively mild phenotype, in w h ich  the 
visual acuity is higher than usually seen in LCA  patients. In Chapter 5 two families 
are presented in w hom  the patients carried the sam e p.Tyr3156X mutation in the
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EYS gene, but the age of onset in one family is much earlier (adolescence) than in 
the other family (forties), and their visual field defects differ as  well (central defects 
ve rsu s  a relatively well-preserved visual field). Two siblings from another family even 
received two different d iagnoses  (CRD and RP, respectively). Overall, w e  found that 
most of the patients carrying mutations in EYS had a more severe phenotype with 
earlier loss  of visual acuity and peripheral visual field (Chapter 5A, 5B, 5C) than the 
two families with p.Tyr3156X mutations.
In conclusion, knowing the molecular defect may be of benefit for a patient with 
regard to genetic counseling, diagnostic accuracy, dietary advice, and early detection 
of systemic abnormalities. However, with regard to prognostic counseling, molecular 
d iagnoses  must be provided with great care, and a prognos is  should only be made 
w hen  combining the genetic information carefully with the clinical appearance. 
Predicting the course  of a retinal d isease may become more reliable w hen  large 
genotype-phenotype studies, including detailed documentation 
of follow-up examinations, will be performed.
PHENOTYPIC VARiABiLITY AND MODiFiER ALLELES
Bes ide s  the above-mentioned examples of phenotypic variability, many other 
publications s h o w  variability associated with mutations in one gene as well.48, 70-74 
This diversity in phenotypes may be explained by the characteristics of the causative 
mutation (allelic heterogeneity), by environmental influences and/or by modifier 
alleles.75 A  clear example of allelic heterogeneity is the ABCA4  gene, in which 
mutations can lead to Stargardt d isease  (STGD1), CRD and RP, and variants can 
even be 'on ly ' a risk-factor for age-related macular degeneration.14, 76, 77 In this gene, 
a genotype-phenotype correlation explains the variability of the phenotypes, since 
combinations of so-called hypomorphic or mild mutations with severe mutations 
lead to the mildest phenotype (STGD1), and combinations of null mutations lead 
to the most severe phenotype (RP).78, 79
Intriguing is the large variability among patients carrying the same genetic defect,48 
wh ich  cannot be attributed to allelic heterogeneity. The variation in phenotypes is 
regularly attributed to the presence of a modifier allele.48, 80-90 and Chapter 4 A  modifier 
allele is a genetic variant that by itself does  not cause  a disease, but that does 
exert a modifying effect on a disease, either deteriorating or ameliorating the 
phenotype.75, 91, 92 Modifier alleles have been described in Joubert syndrome and
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B B S ,  wh ich  both involve retinal dystrophy, and the modifying effect of these alleles 
w a s  confirmed in zebrafish.86-88, 93, 94 In case  of the heterozygous frameshift mutation 
in MERTK a s  hypothesized modifier of the CEP290-assoc iated phenotype (Chapter 4), 
only segregation analysis  substantiated this hypothesis. Further evidence for the 
functional re levance of the MERTK variant can be obtained by using animal model 
(mouse, zebrafish) studies.
Is it possible that heterozygous mutations frequently influence disease severity? 48'
80-90 ctauter 5a Rivolta et al.95 already calculated a carrier frequency for arRP gene defects 
of 10%, assum ing that a total of 67 arRP genes  could be causative, each for an equal 
percentage of patients. Currently, 26 genes  are implicated in arRP, and each gene is 
mutated in a different percentage of patients. Therefore, a more accurate calculation 
based on the Hardy We inberg  equilibrium (Supplemental Table 1) s h o w s  that with the 
current knowledge, w e  can predict a carrier frequency of 1/8 in the general population. 
It is estimated that mutations in these genes  account for ~ 5 0%  of arRP. A ssum ing  that 
many more genes  will be identified, all contributing to a small percentage of cases, 
the total carrier frequency could even be as high as 1/4. Therefore, the chance to 
carry an additional mutation in one of the arRP genes  is rather high. The 'mutational 
load' in the general population may be substantially higher as  this estimate does  not 
include mutations associated with other autosomal recess ive retinal dystrophies. It 
is anticipated that new  sequencing technologies in combination with detailed clinical 
ana lyses will reveal the role of possible modifier alleles in modifying the phenotype.
Another interesting factor influencing phenotypic variability w a s  shown in transgenic 
mice, in which a mutated gene w a s  introduced in mouse strains with different genetic 
backgrounds (congenic mice). Although all mice carried the same mutation, clinical 
appearance varied considerably dependent on the genetic background.96, 97 This 
s how s  that it is the mutation in its genomic context that cau se s  a disease, and that the 
inheritance of retinal dystrophies is possibly more complex than is currently thought.
CURRENT MOLECULAR (DiAGNOSTiC) SCREENiNG
S ince most retinal dystrophies are genetically extremely heterogeneous (Chapter 
1, Table 1), for each d isease many genes  need to be screened to find the genetic 
cause. Since a few years, high-throughput screen ing methods, like the arrayed 
primer extension (APEX) micro-array (Asper Ophthalmics, Tartu, Estonia), have 
enhanced diagnostic screen ing  tremendously, leading to a rapid mutation detection
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in ~ 3 3 %  of CRD patients,15 50 -60%  of LCA  patients (A.I. den Hollander, personal 
com m unication 2010),17 and ~1 5 %  of C S N B  patients.98 The A P E X  m icro-array harbors 
o ligonucleotides that can test for the p resence of previously identified mutations in 
all ge ne s associa ted  with one d isease  (for example, autosom al recessive, autosom al 
dom inant or X -linked RP, LCA, C SN B , B B S , U sher syndrom e) or all known mutations in 
one gene (for example, ABCA4) (w w w .asperophthalm ics.com ). The limitation of this 
screen ing  method is that unknow n mutations in the known genes are not identified 
un le ss they are point mutations that accidentally occu r at the sam e position a s the 
known variants, and mutations in unknow n genes can never be found in this way. 
Furthermore, the distinction between for example RP, LCA, C SN B , and CRD can be 
difficult, and it may therefore not be straightforward to choose  the correct A P E X  
array. Moreover, CRD patients can now  only be screened  for mutations in ABCA4. 
Also, due to the rapid detection of new  mutations it is difficult to keep the A P E X  
m icroarrays up to date. Ideally, there w ould  be a screen ing  method in w h ich  all 
known genes for all retinal dystrophies, including syndrom ic variants, could be 
fully screened  in order to be able to detect all mutations in the known genes.
A  m icroarray-based re sequencing technology is available and used for d iagnostic 
purposes, for example a m icroarray that can screen  up to ~30,000 nucleotides 
from 11 arRP genes.99 Th is m icroarray is able to screen  all nucleotides of all genes 
included. However, it is not a flexible and cheap method, a s updated ve rs ion s need 
to be 'red e s ign ed ' and material co sts  are high. A lso, it is not sensitive enough a s it is 
not able to detect small deletions or duplications associa ted  with arRP that constitute 
a significant fraction (5 -  15%) of mutations.
NEXT GENERATiON SEQUENCiNG AND iDENTiFYiNG NOVEL 
RETiNAL DYSTROPHY GENES
W ith the introduction of new  seq u enc ing  techno log ies, collectively called 'next 
generation se q u e n c in g ' (NGS), com prehensive  ana ly s is  of all know n retinal 
dystrophy ge ne s  may becom e cost-effective.100-102 Ba se d  on the difference in 
capac ity  of the va riou s platform s used, either se lected genom ic regions, selected 
genes, or the entire genom e are sequenced. Currently, N G S  is deployed to 
sequ ence  all exons of the w ho le  genom e ('exom e sequenc ing '), or to sequ ence  
a targeted region, that is estab lished  by hom ozygosity  m apping or linkage ana lysis 
('targeted sequenc ing '). In a re search  setting, N G S  a lready led to the identification 
of new  d isea se  ge ne s,101, 103, 104 and it is likely to be instrum ental to identify many 
new  retinal dystrophy ge ne s in the near future.
CHARTER 6 GENERAL DISCUSSION
FUTURE PERSPECTIVE OF HOMOZYGOSiTY MAPPiNG
Exome sequencing w i l l  l ikely be the most cos t-e f f ic ien t  screening method in the 
near future. Figure 2 depic ts a predic t ion for the fu ture  routes of genetic  screening.
In a d iagnostic  sett ing, exome sequencing, fo l lowed by b io-informatic  focus on the 
known retinal dystrophy genes, w i l l  lead to the identif ication of the causative mutation 
in more than 50% of patients. If no mutation is detected in the known ret inal dystrophy 
genes, the search for a genetic  cause w i l l  p robably be performed in a research 
sett ing. There are three potentia l outcomes w hen  evaluating the results of exome 
sequencing (Figure 2). The quickest road to the identif ication of a causative mutation 
and the h ighest guarantee tha t  a var iant  indeed is causative for a retinal dystrophy, 
is w hen  homozygous or compound heterozygous trunca t ing  mutations are detected 
in a gene tha t  is h ighly  expressed in the ret ina and/or likely to be involved in a retinal
F IG U R E  2 . F low chart of proposed m olecu lar screening fo r d iagnostic  and research purposes.
M  +, m u ta tion  detected; M  -, no m u ta tion  detected; dotted boxes, perform ed in  diagnostic setting; 
fu ll-lined  boxes, perform ed in  research setting. D otted a rrow  implicates tha t the process o f find ing 
the causative variant from  the rem aining variants w ill be very challenging.
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process. Second, homozygous or compound heterozygous missense changes can be 
detected in genes involved in retinal processes. An unambiguous protocol to evaluate 
pa thogenic i ty  needs to be developed in order to prove tha t  a var iant is indeed causing 
the disease, as listed in Figure 2. The third, and by far  the most challenging possibility, 
is to de tect  the causative variant among the remain ing hundreds or thousands of 
variants, w h ich  could be variants tha t  are not c learly  trunca t ing ,  or variants residing 
in genes of w h ich  a role in a retinal process could  be d if f icu lt  to prove. A t  th is  stage, 
homozygosity mapping or linkage analysis  result ing in a s ign if icant lod-score could 
be of value, by pointing out homozygous regions that one could f irst focus  on, thereby 
decreas ing the number of variants tha t  need to be veri fied. A l though more insight into 
pa thogenic i ty  of variants w i l l  become available, determin ing w h ich  of the variants in 
all exons of ~25,000 genes may still be challenging.
chapter 6 g e n e ra l d iscu ssio n
s u p p l e m e n t a l  d a t a
S U P P L E M E N T A L  T A B L E  1. Carrier frequencies of causative vai iants in RP genes.
A. Carrier frequencies of mutations in known arRP genes. B. Carrier frequencies of mutations in known arRP 
genes and of 43 hypothesized arRP genes
A  gene % q2 * 2pq* B gene % q2 2pq*
EYS 5 1/70000 1/132 EYS 5 1/70000 1/132
USH2A 5 1/70000 1/132 USH2A 5 1/70000 1/132
PDE6A 4 1/87500 1/148 PDE6A 4 1/87500 1/148
PDE6B 4 1/87500 1/148 PDE6B 4 1/87500 1/148
CNGA1 2 1/175000 1/210 CNGA1 2 1/175000 1/210
CRB1 2 1/175000 1/210 CRB1 2 1/175000 1/210
RPE65 2 1/175000 1/210 RPE65 2 1/175000 1/210
SAG 2 1/175000 1/210 SAG 2 1/175000 1/210
ABCA4 1,5 1/233333 1/242 gene A 2 1/175000 1/210
CERKL 1,5 1/233333 1/242 gene B 2 1/175000 1/210
CNGB1 1,5 1/233333 1/242 gene C 2 1/175000 1/210
IDH3B 1,5 1/233333 1/242 ABCA4 1,5 1/233333 1/242
LRAT 1,5 1/233333 1/242 CERKL 1,5 1/233333 1/242
MERTK 1,5 1/233333 1/242 CNGB1 1,5 1/233333 1/242
NR2E3 1,5 1/233333 1/242 IDH3B 1,5 1/233333 1/242
NRL 1,5 1/233333 1/242 LRAT 1,5 1/233333 1/242
PROM1 1,5 1/233333 1/242 MERTK 1,5 1/233333 1/242
RGR 1,5 1/233333 1/242 NR2E3 1,5 1/233333 1/242
RHO 1,5 1/233333 1/242 NRL 1,5 1/233333 1/242
RLBP1 1,5 1/233333 1/242 PROM1 1,5 1/233333 1/242
RP1 1,5 1/233333 1/242 RGR 1,5 1/233333 1/242
SPATA7 1,5 1/233333 1/242 RHO 1,5 1/233333 1/242
TULP1 1,5 1/233333 1/242 RLBP1 1,5 1/233333 1/242
PRCD 0,5 1/700000 1/418 RP1 1,5 1/233333 1/242
IRBP 0,5 1/700000 1/418 SPATA7 1,5 1/233333 1/242
Total 50% -1/7000 1/8 TULP1 1,5 1/233333 1/242
16x new gene 16 x 1,5 16 x 1/233333 16 x 1/242
17x new gene 17 x 1 17 x 1/350000 17 x 1/296
7x new gene 7 x 0,5 7 x 1/700000 7 x 1/419
PRCD 0,5 1/700000 1/419
IRBP 0,5 1/700000 1/419
Total 100% -1/3500 1/4
In  a Hardy-W einberg equilib rium , the frequency o f the w ild -type  allele is denoted p and o f the 
recessive m utan t allele q, p+q=1, in  w h ich  p is assumed to be close to 1. *, q2 is the prevalence 
o f a homozygous recessive allele, and 2pq is the carrier frequency, and p2 + 2pq + q2=1.
%, percentage o f patients affected by m utations in  that gene. Assum ption: prevalence arRP 1:3500.
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Over the last tw o  decades, approximate ly  one hundred genes have been identified, 
tha t  are associa ted w ith  retinal dystrophies. In many patients, though, the genetic 
cause is stil l unknown. In th is  thesis, w e  attempted to identify new  genes and 
gene mutat ions in patients w i th  autosomal recessive retinal dystrophies, using 
homozygosity mapping and linkage analysis. W e mainly  focused on patients affected 
by cone-rod dystrophy (CRD), but also patients w i th  retin it is  pigmentosa (RP) and 
Leber congenita l amaurosis  (LCA) w e re  included in th is  study.
C h a p te r 1 provides a general in troduct ion to the retinal anatomy, the processes that 
lead to vision, and an in troduct ion to the c l in ica l and genetic  aspects of the three 
retinal dystrophies involved in this  thesis. Furthermore, it describes the rational of 
homozygosity mapping; a method that is often used for  identifying the genetic  defect 
in patients from consanguineous famil ies, but that is re lat ive ly  new  in the search for 
mutat ions and new  genes in non-consanguineous patients.
In c h a p te r  2 the results of homozygosity mapping in a cohort of 95 CRD-probands are 
described. Signif icant homozygous regions (> ~3 Mb) w e re  detected in the majority 
of non-consanguineous patients (76/99; 77%), and in all (9/9) consanguineous patients. 
Screening of the known retinal dystrophy genes residing in these homozygous 
regions led to the detect ion of new  causative mutat ions in five genes (ABCA4,
CABP4, CERKL, KCVN2 and PROM1) in seven probands. Moreover, overlap of a 
homozygous region w ith  the RP25 locus led to the identif ication of a new  gene (EYS). 
Detailed c l in ica l evaluation of patients carry ing mutat ions in CRD-associated genes 
(ABCA4, CERKL, PROM1) revealed a w id e  varie ty  of retinal appearances on fundus 
photographs, au tof luorescence and in vivo ret inal microscopy. The phenotypes of 
patients carry ing mutat ions in genes not associa ted w ith  CRD (CABP4, EYS, KCNV2) 
indeed appeared to be d i f ferent than CRD.
C h a p te r 3  describes the detect ion of the CABP4 p.Arg216X mutation in tw o  siblings 
and the associa ted phenotype. M uta t ions  in CABP4 w e re  previously  described in 
patients w i th  congenita l sta t ionary night b lindness (CNSB), w he reas  the tw o  siblings 
investigated w e re  in it ially d iagnosed w i th  cone-rod dysfunct ion. Detailed clinical 
evaluation, including 15 Hz e lec trore t inogram (ERG) measurements, revealed a 
dis t inct ive phenotype that w a s  character ized by reduced visual acuity,  photophobia, 
and abnormal co lo r vision. ERGs showed e lectronegative  mixed rod-cone responses 
and severe ly  reduced cone responses, but w i th  relatively  preserved isolated rod 
responses. Since these patients did not experience night blindness, w e  considered 
the name CSNB inappropria te. As the phenotype and the genotype ind icated a defect
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in the pho to recepto r synapse, w e  in troduced a new  name for th is  type of disease, 
namely  congenita l c o n e -ro d  synaptic disorder.
In c h a p te r  4 A  family  is described w ith  four affected individuals; one affected by 
RP, one a f fected by LCA, and tw o  affected by a phenotype less severe than LCA, that 
w e  coined early -onset severe ret inal dystrophy (EOSRD). Linkage analysis fo l lowed 
by mutation analysis in the LCA patient and her tw o  cousins (with EOSRD), revealed 
compound heterozygous mutat ions in CEP290; the most prevalent LCA-causing 
mutation c.2991+1655A>G, w h ich  is a hypomorphic mutation, and a novel p.Arg151X 
mutation. Since tw o  nonsense mutat ions usually lead to a CEP290-associated 
syndrome w i th  at least neuro log ica l and renal symptoms, w e  hypothesized that 
p.Arg151X represents a hypomorphic mutation in order to cause a relatively  mild 
phenotype. Reverse t ranscr ip tase  (RT) PCR of CEP290 mRNA revealed three splice 
forms in indiv iduals carry ing the p.Arg151X mutation; one w i ld type  PCR product, 
representing the al lele w i th o u t  p.Arg151X, one PCR product missing exon 7, and one 
PCR product missing exons 7 and 8. The aberrant splice forms are probably  caused 
by a mechanism called nonsense-associated altered splic ing. As the mutant mRNA 
maintain the open reading frame, the predic ted proteins -  lacking 18 or 25 amino 
acids, respect ive ly  -  may maintain funct iona l properties, and p.Arg151X indeed is 
likely to have a hypomorphic character. Homozygosity mapping in a dis tant family 
member affected by RP revealed a homozygous framesh if t  mutation in MERTK. This 
mutation w a s  heterozygously  present in the LCA patients, and absent in the two 
cousins affected by EOSRD, leading to the hypothesis  tha t  the heterozygous MERTK  
mutation may have a modifying ef fec t  on the phenotype.
C h a p te r 5 A  presents the d iscovery  of EYS, w h ich  w a s  fac i l i ta ted by the detect ion of 
a homozygous region, shared by tw o  non-consanguineous sib lings, that reduced the 
size of the RP25 locus. The RP25 locus w a s  already defined in 1998, but the causative 
gene remained undiscovered. Based on severa l gene-pred ic t ions w e  hypothesized 
tha t  one gene, residing in the reduced RP25-locus, might be larger than previously  
assumed. RT-PCR of retinal cD N A  indeed revealed a t ranscr ip t  of 10,475 nucleotides 
in size, spanning approximately  2 mil lion nucleotides of the genome, w h ich  makes 
th is  new ly  identified gene one of the largest genes known and the largest gene 
spec if ica l ly  expressed in the eye. The gene appeared to be an ortholog of the 
D rosoph ila  eyes sh u t(e ys )-sp a ce m ake r  gene, and there fore  the new  human gene 
w a s  coined 'eyes sh u t hom olog '; abbrevia ted EYS. Based on the funct ion of eys  in 
Drosophila , the EYS protein is hypothesized to play a role in the pho to recepto r outer 
segment morphogenesis . Muta t ion  analysis in CRD and RP patients w ith
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a h o m o zyg o u s  re g io n  a t th e  EYS lo c u s  re v e a le d  tw o  d if fe re n t t ru n c a t in g  m u ta tio n s  in 
th re e  D u tch  fa m ilie s . One m u ta tio n  (p.Tyr3156X) c a u se d  CRD in one p a tie n t and  RP in 
h e r b ro th e r, and  led  to  a v e ry  m ild  RP in th re e  p a tie n ts  fro m  a s e c o n d  fa m ily . A n o th e r 
t ru n c a t in g  m u ta tio n  (p .P ro2238P ro fsX 16) in a th ird  fa m ily  led  to  a c la s s ic  ty p e  o f RP
To d e c ip h e r  th e  p re v a le n c e  o f EYS m u ta tio n s  in RP p a tie n ts , w e  p e rfo rm e d  m u ta tio n  
a n a ly s is  in 245 RP p a tie n ts , m a in ly  o f D u tch  o r ig in . T h is  re s u lte d  in th e  id e n tif ic a t io n  
o f th e  c a u s a tiv e  m u ta tio n s  in te n  RP fa m ilie s , p re s e n te d  in c h a p te r  5B, and w ith  
th a t th e  p re v a le n c e  o f EYS m u ta tio n s  in a u to so m a l re c e s s iv e  RP p a tie n ts  fro m  The 
N e th e r la n d s  is e s tim a te d  to  be 5%. C h a p te r 5C p re s e n ts  th e  p re v a le n c e  o f m u ta tio n s  
in EYS in th e  Is ra e lia n  and P a le s tin ia n  p o p u la tio n s . M u ta t io n  a n a ly s is  o f EYS in 
p a tie n ts  h a v in g  a h o m o zyg o u s  re g io n  a t th e  EYS lo c u s  led  to  th e  id e n tif ic a t io n  o f 
th e  c a u s a tiv e  m u ta tio n  in fo u r  RP p a tie n ts . S u b s e q u e n t s c re e n in g  fo r  th e  id e n tif ie d  
m u ta tio n s  in a c o h o rt o f 177 RP p a tie n ts  re v e a le d  s ix  m o re  p a tie n ts  c a r ry in g  m u ta tio n s  
in EYS. The p re v a le n c e  o f EYS m u ta tio n s  in a u to so m a l re c e s s iv e  RP p a tie n ts  fro m  the  
Is ra e lia n  and P a le s tin ia n  p o p u la tio n  is e s tim a te d  to  be 7%.
The age o f o n s e t o f th e  E Y S -a sso c ia te d  RP p h e n o typ e  w a s  b e tw e e n  th e  se co n d  
and fo u r th  d e c a d e  o f life  in D u tch  (5B) as w e ll as Is ra e lia n -P a le s t in ia n  (5C) p a tie n ts , 
s ta r t in g  w ith  n ig h t b lin d n e s s , fo llo w e d  by g ra d u a l c o n s tr ic t io n  o f th e  v is u a l f ie ld , and 
a d e c lin e  o f v is u a l a c u ity  la te r  in life . The fu n d u s  d is p la y e d  bo ne  s p ic u le s , g e n e ra lize d  
a tro p h y  o f th e  re tin a l p ig m e n t e p ith e liu m  and c h o r io c a p illa r is , and a tro p h ic  m a c u la r 
c h a n g e s  o c c u rr in g  la te r in life . A lto g e th e r , th e  E Y S -a sso c ia te d  p h e n o ty p e  in th e  D u tch  
and th e  Is ra e lia n -P a le s t in ia n  c o h o rts  see m e d  to  be ra th e r  h o m o g e n e o u s .
In C h a p te r 6  th e  re su lts  d e s c rib e d  in th is  th e s is  are d is cu sse d  in o rd e r to  p o in t o u t the  
im p lic a tio n s  fo r  s c ie n tis ts , o p h th a lm o lo g is ts  and p a tien ts . The s tre n g th s  and lim ita tio n s  
o f ho m ozygo s ity  m a pp ing  are d iscu sse d , lea d in g  to  th e  c o n c lu s io n  th a t h o m ozygo s ity  
m a pp ing  can  be e ffe c tiv e  in c o n sa n g u in e o u s  as w e ll as n o n -c o n s a n g u in e o u s  fam ilie s . 
Id e n tify in g  th e  g e n e tic  d e fe c ts  in p a tie n ts  w ith  re tin a l d y s tro p h ie s  is o f im p o rta n ce  fo r 
p ro v id in g  c le a r  in fo rm a tio n  a b o u t h e red ity , it g ives  in s ig h t in d isea se  e tio lo gy , and it 
is in d isp e n sa b le  fo r  d e ve lo p in g  n e w  th e ra p ie s , and to  d e te rm in e  w h ic h  p a tie n ts  w ill 
be e lig ib le  fo r  gene th e ra p y . P rov id in g  in fo rm a tio n  a b o u t th e  p ro g n o s is  based on the  
g e n e tic  d e fe c t re m a in s  d if f ic u lt  in p a tie n ts  w ith  re tin a l dys troph y , b e ca u se  w e  do not 
y e t k n o w  th e  im p a c t o f m o d if ie r  a lle les . A s  c a lc u la te d  in th e  d iscu ss io n , a p p ro x im a te ly  
1/4 pe op le  like ly  c a r ry  a m u ta tio n  in one o f th e  a u tosom a l re ce ss ive  RP genes, and 
th e re fo re  p a tie n ts  have a h igh  c h a n ce  to  c a r ry  a th ird  m u ta tio n  (a s o -c a lle d  m o d ifie r 
a lle le ) th a t m ay have an a d d itio n a l d e te r io ra tin g  e ffe c t on th e  p h o to re ce p to r.
CHARTER 7 SUMMARY
In the near future, the curren t  m olecu la r  screening techno log ies  w i l l  be expanded 
w i th  next generat ion sequencing (NGS) methods, w h ich  are able to screen mil lions of 
nucleotides in one experiment. Upon identifying a novel retinal disease gene by NGS, 
homozygosity mapping data can be used to se lect patients for sequence analysis in 
o rder to identify other patients w i th  mutat ions in the same gene. As w ho le  genome 
exon (exome) NGS reveals an enormous number of sequence variants in each patient, 
homozygosity mapping in a subset of patients may also fac i l i ta te  the discr im inat ion 
of pathologic  versus benign variants.
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De afgelopen tw e e  decennia  zijn er ongeveer honderd genen ontdekt die 
geassocieerd  zijn met retina dystrofie. Echter, bij veel patiënten is het genetisch 
de fect  nog onbekend. In dit p roe fschr i f t  hebben w e  getracht om met behulp van 
homozygotie  mapping en koppel ingsstudies analyse n ieuwe genen en genmutat ies te 
ident i f iceren bij patiënten met een autosomaal recessieve kege l-s taaf dystrofie  (CRD), 
retin it is  pigmentosa (RP) en amaurosis  congenita  van Leber (LCA).
H o o fd s tu k  1 bevat een algemene in leiding in de anatomie van de ret ina, de processen 
die leiden to t  zicht, en een in troduct ie  in de klin ische en genetische aspecten van 
de drie vormen van ret ina dystrofie  die in dit p roefschr i f t  aan bod komen. Daarnaast 
w o rd t  het principe van homozygotie  mapping uitgelegd. Homozygotie mapping is 
een methode die regelmatig  gebru ik t w o rd t  om het genetisch de fect  op te sporen in 
famil ies w aar in  de ouders van een patiënt aan elkaar gere la teerd zijn (consanguine 
famil ies). De methode is echter  nog relat ie f ongebru ike l i jk  voor het opsporen van 
mutaties en n ieuwe genen in n ie t-consanguine families.
In h o o fd s tu k  2 w orden  de resultaten beschreven van homozygotie  mapping bij 
95 CRD probanden. Signif icante homozygote gebieden (> ~3 Mb) we rden  gevonden 
in de meerderheid  van de n ie t-consanguine patiënten (76/99; 77%) en in alle (9/9) 
consanguine patiënten. Muta t ie  analyse van de bekende retina dystrofie  genen 
die zich in een homozygotie gebied bevonden heeft  geleid to t het v inden van de 
oorzakeli jke mutatie in v ij f  genen (ABCA4, CABP4, CERKL, KCVN2 en PROM1) bij 
zeven patiënten. Daarnaast bleek een homozygoot gebied te overlappen met het 
RP25 locus, w a t  leidde to t  de ontdekking van een n ieuw  RP gen (EYS). Fundus 
foto s, autof luorescentie  en OCT onderzoeken bij patiënten met een mutatie in 
een CRD gen (ABCA4, CERKL, PROM1) toonden een grote variatie  in de gevonden 
ret ina afwijk ingen. Het fenotype van patiënten met mutaties in een gen dat niet 
geassocieerd  is met CRD bleek inderdaad geen CRD te zijn.
H o o fd s tu k  3 beschri j f t  de ontdekking van de CABP4 p.Arg216X mutatie en het 
b ijbehorende fenotype. M uta t ies  in CABP4 w a ren  voorheen geassocieerd  met 
congenita le  s tationaire nachtb l indheid (CSNB), te rw i j l  beide patiënten met 
de p.Arg216X mutatie de diagnose 'kege l-s taa f dysfunct ie '  hadden gekregen. 
Oogheelkundig  onderzoek, inc lus ief een 15 Hz e lec tro re t inogram (ERG), toonde 
een fenotype gekarakteriseerd door een ver laagde visus, fo tofobie  en abnormaal 
kleurenzien. Het ERG toonde e lec tronegatieve gemengde staaf-kegel responsies, 
extreem verlaagde kegel responsies, maar re lat ie f gespaarde staaf responsies. Het 
fe it  dat de patiënten niet nachtb lind zijn, maakte de naam CSNB ongeschik t. Omdat
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het fenotype en genotype w ijzen op een de fect  in de fo to recep tor  synaps, hebben we 
de naam 'congenita le  kegel-s taaf synaps aandoening ' voorgeste ld  voor dit fenotype.
In h o o fd s tu k  4 w o rd t  een famil ie beschreven met vier aangedane personen: één 
met RP, één met LCA en tw ee  personen met een fenotype dat milder is dan LCA, dat 
w e  juvenie le  ernstige retina dystrofie  (EOSRD) hebben genoemd. Linkage analyse 
gevolgd door mutatie analyse in de LCA patiënte en haar neefje en nichtje  met 
EOSRD b rach t samengeste lde heterozygote mutaties in CEP290 aan het licht: de 
vee lvoorkomende LCA-veroorzakende hypomorfe c.2991+1655A>G mutatie en de 
n ieuwe p.Arg151X mutatie. Twee s topmutat ies leiden meestal to t  een syndroom 
met neuro log ische en renale symptomen. Daarom zou de p.Arg151X mutatie 
een hypomorfe mutatie moeten zijn om een relat ie f mild fenotype te kunnen 
veroorzaken. Bij reverse t ranscr ip tase  (RT) PCR van het CEP290 mRNA vonden we  
drie versch i l lende splice-varianten: een w i ld type  PCR product dat afkomstig is van 
het allel zonder p.Arg151X, een p roduct w aarb i j  exon 7 ontbreekt, en een product 
w aarb i j  exon 7 en 8 ontbreken. The afw i jkende spl ice-vormen w o rden  waarsch i jn l i jk  
veroorzaakt door een mechanisme dat 'nonsense-assoc ia ted  altered splic ing ' 
w o rd t  genoemd. Aangezien het mutante mRNA het open reading f rame behoudt, zal 
het afgelezen e iw it  -  dat 18 of 25 aminozuren mist -  mogeli jk  nog funct ionee l zijn.
De p.Arg151X mutatie lijkt daarmee dus inderdaad een hypomorfe mutatie te zijn. 
Homozygotie mapping in een famil ie lid met RP leidde daarnaast to t  het vinden van 
een mutatie in MERTK. Deze mutatie w a s  ook heterozygoot aanwezig  bij de LCA 
patiënte, en afwezig  bij de tw e e  patiënten met EOSRD. Onze hypothese is dat deze 
heterozygote MERTK  mutatie een modif icerend effect heeft  op het fenotype.
H o o fd s tu k  5A  presenteert de ontdekking van het EYS gen. Een Nederlandse broer 
en zus bleken een homozygoot gebied te delen binnen het 15 Mb RP25 locus. Het 
RP25 locus w a s  al beschreven in 1998, maar het oorzakeli jke gen w a s  nog onbekend. 
Binnen het 5 Mb homozygote gebied dat de patiënten deelden bleek een gen te 
liggen w aa rvan  w e  voorspelden dat het een groter gen zou zijn dan voorheen werd  
aangenomen. M et  behulp van RT-PCR van ret ina cD N A vonden w e  inderdaad een 
t ranscr ip t  van 10.475 nucleotiden lang, dat zich over 2 mil joen basen in het genoom 
uitspreid en daarmee één van de langste genen is in het genoom, en het langste gen 
dat specif iek to t  expressie komt in het oog. Het gen bleek een ortholoog te zijn van 
het eyes sh u t(e ys )-sp a ce m ake r  gen in Drosophila , en is daarom 'eyes sh u t h o m o loog ' 
genoemd, afgekort als EYS. Gebaseerd op de funct ie  van eys  in Drosophila , li jkt het 
EYS e iw it  een rol te spelen in de ontw ikke l ing  van het fo to recep to r  buitensegment.
Bij CRD en RP patiënten met een homozygoot gebied rond EYS w erden  twee
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v e rs c h il le n d e  m u ta tie s  in p a tië n te n  u it d r ie  N e d e rla n d s e  fa m ilie s  o n td e k t. De h o m o ­
zyg o te  p.Tyr3156X m u ta tie  v e ro o rz a a k t CRD in een p a tië n te  en RP b ij h a a r b roe r, en 
le id t to t  een m ild  en la a t-o p tre d e n d e  vo rm  van  RP in een a n d e re  fa m ilie . De tw e e d e  
g e ïd e n tif ic e e rd e  m u ta tie  (p .P ro2238P ro fsX 16) le id d e  to t  een k la s s ie k  RP fe n o ty p e  in 
een d e rd e  fa m ilie .
Om de p re v a le n tie  te  b e p a le n  va n  m u ta t ie s  in EYS b ij RP p a tië n te n , h e b b e n  w e  
m u ta tie  a n a ly s e  u itg e v o e rd  b ij 245 RP p a tië n te n , w a a rv a n  de m e e s te  N e d e rla n d s .
D it re s u lte e rd e  in de id e n t if ic a t ie  va n  de o o rz a k e lijk e  m u ta t ie s  b ij 10 RP fa m ilie s , 
b e s c h re v e n  in h o o fd s tu k  5B , en d a a rm e e  li jk t  de p re v a le n tie  va n  EYS in a u to s o m a a l 
re c e s s ie v e  RP p a tië n te n  in N e d e rla n d  o n g e v e e r 5% te  z ijn . H o o fd s tu k  5C p re s e n ­
te e r t  de p re v a le n tie  va n  EYS m u ta t ie s  in de Is ra e lis c h e -P a le s t ijn s e  p o p u la tie . 
M u ta t ie  a n a ly s e  va n  EYS b ij p a t ië n te n  m e t een h o m o z y g o o t g e b ie d  ro n d  EYS h e e ft 
g e le id  to t  de id e n t if ic a t ie  va n  de m u ta tie  b ij v ie r  RP p a tië n te n . Een c o h o r t  va n  121 
RP p a tië n te n  is v e rv o lg e n s  g e s c re e n d  v o o r de a a n w e z ig h e id  va n  deze m u ta tie s , 
en w e rd e n  in zes p a tië n te n  g e v o n d e n . D a a rm e e  li jk t  de p re v a le n tie  va n  m u ta t ie s  in 
EYS in a u to s o m a a l re c e s s ie v e  RP p a tië n te n  in de Is ra e lis c h e -P a le s t ijn s e  p o p u la tie  
o n g e v e e r 7%  te  z ijn .
De d ia g n o s e  RP in h e t E Y S -g e re la te e rd e  fe n o ty p e  w e rd  g e s te ld  tu s s e n  de 20 en 40 
ja a r  b ij z o w e l de N e d e rla n d s e  (5B) a ls  de Is ra e lis c h -  P a le s tijn se  (5C) p a tië n te n , en 
b e g in t m e t n a c h tb lin d h e id  g e vo lg d  d o o r v e r lie s  van  h e t p e r ife re  g e z ic h ts v e ld  en 
een a c h te ru itg a n g  va n  de v isu s  la te r in h e t b e lo o p . De fu n d u s  v e r to o n t b e e n b a lk je s  
p ig m e n ta tie , g e g e n e ra lis e e rd e  a tro fie  van  he t re tin a  p ig m e n t e p ith e e l en de c h o r io - 
c a p il la r is  en a tro f is c h e  m a cu la  v e ra n d e r in g e n  la te r in h e t b e lo o p . H et E Y S -g ere la - 
te e rd e  fe n o ty p e  li jk t  in de N e d e rla n d s e  en Is ra e lis c h e -P a le s t ijn s e  p a tië n te n  
v r ij h o m o g e e n  te  z ijn .
In h o o fd s tu k  6 w o rd e n  de im p lic a t ie s  van  de re s u lta te n  u it he t he le  p ro e fs c h r if t  
b e d is c u s s ie e rd . R e fle c t ie  op de m o g e lijk h e d e n  en o n m o g e lijk h e d e n  va n  h o m ozygo tie  
m a p p in g  le id d e n  to t  de c o n c lu s ie  d a t h o m o zyg o tie  m a p p in g  e f fe c t ie f  kan  z ijn  in zo w e l 
c o n s a n g u in e  a ls  n ie t-c o n s a n g u in e  fa m ilie s . H et id e n tif ic e re n  va n  h e t g e n e tis c h  d e fe c t 
is va n  b e la n g  om  d u id e lijk h e id  te  k rijg e n  o v e r de o v e re rv in g , om  in z ic h t te  k rijg e n  
in de e tio lo g ie  van  de a a n d o e n in g , v o o r h e t o n tw ik k e le n  va n  n ie u w e  vo rm e n  van 
th e ra p ie , en om  in z ic h te li jk  te  m a ken  w e lk e  p a tië n te n  in a a n m e rk in g  kun nen  kom en 
v o o r g e n th e ra p ie . Een v o o rs p e llin g  van  de p ro g n o se  op b a s is  van  he t g e n e tis c h  
d e fe c t b li jf t  m o e ilijk , o m d a t de im p a c t va n  m o d ific e re n d e  a lle le n  op h e t fe n o ty p e  nog 
o n d u id e lijk  is. Z o a ls  b e re ke n d  in de d is c u s s ie , is w a a rs c h ijn l i jk  1 op de 4 m ensen
CHARTER 7 SAMENVATTING
drager van een mutatie in een autosomaal recess ie f  RP gen, w a a rd o o r  de kans groot 
is dat een patiënt een derde mutatie (modif ie r allel) d raagt dat voor een verergering 
van het fenotype zorgt.
In de nabije toekomst zullen de mogeli jkheden voor mutatie analyse uitgebreid 
w o rden  met zogenaamde 'next generat ion sequenc ing '  (NGS) technieken, waarb i j  
mil joenen nucleotiden in één experim ent gescreend kunnen worden. W anneer  
NGS analyses leiden to t  de ontdekking van n ieuwe genen geassocieerd  met retina 
dystro fie , dan zal homozygotie  mapping een rol kunnen spelen in de select ie  van 
patiënten om te screenen voor mutaties in zo'n n ieuw  gen. Daarnaast zal er een 
enorme hoeveelheid  varianten gevonden w o rden  bij NGS van alle exonen in het 
genoom (het exoom), en kan homozygotie  mapping bij dergeli jke analyses bijdragen 
aan het maken van het ondersche id  tussen pathogene en n iet-pathogene varianten.
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c u r r íc u l u m  v it a e
Karin W il lem ijn  Littink w e rd  geboren op 25 juni 1981 in Sleeuwijk . Zij volgde haar 
gymnasium ople id ing op het A lexander Hegius Lyceum (tegenwoord ig : Etty Hillesum 
Lyceum) in Deventer, en startte aanslu itend in 1999 haar studie Geneeskunde aan de 
Katholieke Universitei t Nijmegen (tegenwoord ig : Radboud Universitei t Nijmegen).
In het s tudie jaar 2001-2002 onderbrak zij haar studie om een jaar als ful ltime 
commissie lid  en vicevoorz it te r  de Batav ierenrace ('s w e re lds  grootste estafette loop) 
te organiseren.
Van 2002 to t  en met 2007 vervolgde zij haar studie Geneeskunde en liep zij stage 
onder begeleiding van Dr. Robert Koenekoop in het McGil l Ocular Genetics Laboratory 
(Montréa l Children's Hospital Research Institute, McGil l University Health Centre) 
in Montréa l,  Canada. Daar verzamelde ze klin ische gegevens van patiënten met auto­
somaal dominante retin it is  pigmentosa uit één grote famil ie, en deed ze de genetische 
screen ing bij andere retina dystro fie  patiënten.
Na deze eerste kennismaking met molecula ire genetica begon zij in februar i  2007 
aan haar promotie -onderzoek, in het b l indheid-genetica lab onder begeleiding van 
Prof. Dr. Frans Cremers, Dr. Ingeborgh van den Born en Dr. Anneke den Hollander, 
in een samenwerk ingsverband tussen Het Oogziekenhuis Rotterdam en de sect ie 
M olecu la ire  genetica van de afdeling Antropogenet ica  in het UMC St Radboud.
De resultaten daarvan zijn in dit p roefschr i f t  beschreven.
In 2010 ontving zij een Young Investigators Travel A w ard  voor de 'XIVth International 
Symposium on Retinal Degenerat ion ' in Mont-Tremblant,  Canada. Van juni to t 
november 2010 w a s  zij werkzaam  als pro ject manager voor een TOP-subsidie project 
in blindheid- en doofhe idgenetica, onder supervis ie  van Prof. Dr. Frans Cremers,
Dr. Hannie Kremer en Dr. Anneke den Hollander.
Na een korte kennismaking met oogheelkunde in Indonesië, zal zij per 1 februari 2011 
starten met de opleid ing tot oogarts  in Het Oogziekenhuis Rotterdam.
CURRICULUM VITAE
CURRÍCULUM ViTAE
Karin W il lem ijn  Littink w a s  born on June 25th 1981 in Sleeuwijk, the Netherlands.
She attended secondary  school at A lexander  Hegius Lyceum (currently : Etty Hillesum 
Lyceum) in Deventer, and therea fte r  started her medical studies in 1999 at the 
Catholic University Nijmegen (currently : Radboud University Nijmegen).
In the college year 2001-2002 she tem porar i ly  delayed her studies to part ic ipate 
as fu ll t ime organizer and v ice-pres iden t of the Batav ierenrace, the w or ld  largest 
running relay.
From 2002 to 2007 she continued her medical studies and did her scient i f ic  in ternship 
under the superv is ion of Dr. Robert Koenekoop in the McGil l Ocular Genetics Labora­
to ry  (Montréa l Children's Hospital Research Institute, McGil l University Health Centre) 
in Montréa l,  Canada. She co l lected DNA and c l in ica l data from a large family  w ith  
autosomal dominant retin itis pigmentosa, and screened several other ret inal dystrophy 
patients in order to identify the genetic  defect.
A f te r  th is  in troduct ion into m olecu la r  genetics, she started her PhD research in 
February 2007 in the b lindness-genetics lab supervised by Prof. Dr. Frans Cremers,
Dr. Ingeborgh van den Born and Dr. Anneke den Hollander. The pro ject w a s  a co l labo­
ration between The Rotterdam Eye Hospital and the div ision of M o lecu la r  Genetics in 
the Department of Human Genetics at Radboud University Nijmegen M ed ica l  Centre. 
The results of th is  study are presented in th is  thesis.
In 2010 she w a s  awarded a Young Investigators Travel Grant to attend the 'X lV th 
In ternat ional Symposium on Retinal Degenerat ion ' in Mont-Tremblant,  Canada.
From June to November 2010 she w orked  as a pro ject manager to start  up a TOP 
subsidy pro ject in the genetics of blindness and of non-syndromic hearing loss, 
under supervis ion of Prof. Dr. Frans Cremers, Dr. Hannie Kremer, and Dr. Anneke 
den Hollander.
A f te r  a short in troduct ion to ophtha lmology in Indonesia, she w i l l  s tart  her formal 
t ra in ing as an ophthalmologist in February 2011 at The Rotterdam Eye Hospital.
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DANKWOORD
Sommige promovendi zijn opgeluch t als het boekje dan eindeli jk  af is, anderen wil len  
er eigenli jk  niet meer mee ophouden. M issch ien  ve rw ach t te  ik de eerste maanden 
to t  de eerste groep te behoren; nu w e e t  ik dat ik du ideli jk  to t  de laatste groep behoor. 
Onderzoek doen is leuk! Zeker ook door alle mensen die aan dit onderzoek hebben 
bijgedragen, en die mijn t ijd als promovenda zo leuk hebben gemaakt.
A l le reers t  heel veel dank aan mijn promotor Frans Cremers en co-promotores 
Ingeborgh van den Born en Anneke den Hollander.
Beste Frans, ik ben blij dat jij mijn promotor bent. Ik heb erg veel van je geleerd door jouw 
oog voor detail en je kritische blik. In het begin ging jouw  kennis vaak iets te snel voor 
mij - terw i jl  jij dacht dat ik mijn 7-jaar oude minimale genetica-kennis nog w e l paraat zou 
hebben. M aar  jouw  manier van begeleiden, waarin  je mij ook de kans gaf om mijn kennis 
van buiten het lab in te zetten, gaven mij steeds meer vertrouwen in mezelf binnen dit 
onderzoek. Niet alleen je begeleiding op onderzoeksterrein, maar ook jouw  aandacht 
voor factoren rondom onderzoek, zoals persoonlijke ontwikkeling, 'verplichte' koff ie­
pauzes en het stimuleren van alle initiatieven op het gebied van uitjes en gezelligheid, 
maken jou een superleuke 'baas', ook al mogen w e  dat woord  niet gebruiken...!
Beste Ingeborgh, je hebt mij vana f het begin altijd w e ten  te motiveren. Zeker toen ik 
het allemaal nog w a t  moeil ijk  vond in het lab, zorgden de te le foongesprekken met jou 
w e e r  voor posit ievere gedachten. M aa r  eigenli jk  zijn die te le foongesprekken alle drie 
de jaren belangrijk  gebleven. Jij lu is terde naar alles w a t  ik maar kw ij t  w i lde , en dat 
heeft  me veel geholpen. Daarnaast w a s  jij voor mij de belangrijke link naar de 
kl in ische were ld ,  en heeft  jo u w  kennis en krit ische blik op de klin ische en genetische 
data veel toegevoegd aan alle art ikelen in dit proefschrif t .  Jij bent als 'physic ian- 
researcher '  echt een voorbeeld voor me en ik hoop dat w e  samen nog veel artikelen 
kunnen schri jven.
Beste Anneke, jouw  begeleiding begon al toen ik nog in Montréal mijn wetenschappeli jke 
stage deed en ik je nog maar een paar keer had gezien. Jo u w  prettige manier van 
begeleiden - toen al - is altijd zo gebleven. Ondanks jouw  volle agenda kon ik altijd op 
je rekenen, je reageerde altijd hartstikke snel op al mijn vragen en e-mails, en je wis t 
de t ijdsdruk die ik soms voelde fijn te relativeren. Ook bedankt voor jouw  talent om een 
kromme zin helemaal mooi te maken door een paar woorden aan te passen. Een 
manuscript dat door jou gezien w as  kwam per definitie mooier terug!
DANKWOORD
Beste Rob, jij bent co-au teur van alle art ikelen in dit boekje en dat laat duideli jk  zien 
w a t  jo u w  aandeel aan dit p roe fschr i f t  is. Het begon met EYS, en hopel ijk is het nog 
lang niet voorbij.  Jij nam me mee in de w e re ld  van RACE, m inipreppen, kloneren 
(klonen :-) ), en dat RNA niet eng is, en daarmee raakte ik pas echt verzeild in de 
labwereld . En ARVO's en RD2010 samen, supergezellig. Ik heb heel erg veel van je 
geleerd! Superbedankt voor alles: it w a s  bery bery nEYS, HOEIII!
Heel erg veel dank ook aan Mar i jke  en Ellen; zonder jull ie (en de honderden of door 
EYS w aarsch i jn l i jk  w e l  duizenden PCRs die jul lie gedaan hebben) w a s  dit proefschr i f t  
er niet geweest.  PCR-en ging nog nooit  zo eff ic iënt als toen w e  met z'n drieën EYS 
onder handen namen! Mar i jke, niet alleen jo u w  inzicht en bijdrage in het project, 
maar ook het feit  dat je een geweld ige ' lab -coach '  voor me w a s  (Het kleine boek van 
Knorretje ligt nog steeds binnen handbereik) hebben veel b i jgedragen aan dit boekje 
en aan mijn plezier op het lab. Ellen, ook jij hebt superveel w e rk  verzet voor de 
art ikelen in dit boek. Hartstikke bedankt daarvoor en voor de gezellige lab-buurvrouw  
die je w a s !  Irma, I also w a n t  to thank you here, because you w e re  my f irst lab mentor, 
w h o  guided me through my fi rst steps into the lab wor ld .  And beside tha t  you made 
me a big sushi- fan as w e l l !  M uch a s  grac ias por todo!
Lieve Suus en Syl, jul lie staan naast me de grote dag en daar ben ik erg trots  op!
Ook ben ik superbli j met de tijd die ik met jull ie in het lab én buiten het lab heb 
doorgebracht;  jullie zijn echte vr iend innen voor me geworden. Suus, jo u w  creativ ite it  
in mailtjes, ep jes-post en noo it-grappigs als het w e rk  (of de v ierdaagse!)  w e l  een 
beetje af le id ing kon gebruiken maakten me altijd aan het lachen. Syl, alles w a t  jij 
zegt li jkt gewoon altijd te kloppen, met jo u w  goede adviezen bent jij echt mijn orakel. 
Jull ie  zijn al lebei gew e ld ig ! !  Bedankt dat jul lie mijn paranim fen w i l len  zijn.
Bjorn, 'mijn ' student; ik vond het heel erg leuk om je te begeleiden en om te zien hoe 
jij het naar je zin had in onze groep. Ik zal mijn best doen om alle door jou vergaarde 
RLBP1/RDH5/LRAT data snel te kunnen submit ten, beloofd.
Ook veel dank aan Saskia, Christel en Tesy voor het zo nauwkeur ig  bijhouden van 
alle DNA's en bijbehorende gegevens. Zolang jul lie in de buurt  zijn is altijd alles terug 
te vinden.
M any many thanks to all the lab colleagues. Especially the blindness genetics 
colleagues, and all fore ign guests w ho  stayed w ith  us for a while: Susanne, Mari jke, 
Alejo, Kostas, Rob, Ellen, Frederieke, Alberta, Anneke, Frans, Maleeha, Kentar,
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Almudena, Marta, Imran, Ajmal, Simone, Krysta, Anna; I had so much fun w ith  you! 
Inside the lab, w ith  our stupid language jokes ( "H ow  goes it? It goes"), the running 
through the lab after discovering a mutation, champagne after the f irst EYS publication, 
home-made bami and pisang goreng from Kentar, sneaking through the lab to decorate 
for Frans' anniversary, etc etc. But also outside the lab, w ith  the 'moleculinary dinners', 
the PROMI-dinner, the afternoons out, SinterKostas and his black Petes, goodbye- 
dinners and - lunches for our guests (who became more like close colleagues to us...). 
Special thanks also to Arij it  and Arjan; those f irst months, they seem so far away. But in 
those months that I spent in the postdoc room w ith  you, you establ ished a really nice 
scientif ic  basis for me and helped me to understand w h a t  science is about.
Ook alle andere An tropogenet ica  collega's  (en niet-collega's) bedankt! M e t  name 
Peer, Christ ian, Eugene, Gleb, Andrew, Jamie, Heleen, Sonja, alias "h e t  vr ijdagavond 
onderzoeksteam", Konny (next year w e  w i l l  do the v ie rdaagse together!  uhm...?), 
Ramprasath (was also great to meet your parents, cousin !), A le jandro and Sandra 
(for the nice p icn ics /d inners  the Latin Am erican  way), Alfi (hope to see you soon 
in Indonesia), Erwin, Ferry, Erik, Alex, Mar loes, Eveline, Mart i jn  (met jul lie erbij is 
het altijd een leuk feestje; bij de 4Daagse W oensdagavond op het Koningsplein, 
Vastelaovend, na het Dagje Uit, enz), de Dagje-Uit  Commissie 2009 (was eigenlijk 
w e l  erg gezellig om te organiseren!).  Alle "The Fast and the Curious" en "2  Fast, 2 
Cur ious"-hard lopers  bij de Zevenheuvelenloop en de Bruggenloop (ik train  w e l w e e r  
mee dit jaar!), en natuurli jk  het 4daagse-team en alle supporters bedankt. Het w as  
echt geweld ig  om op zo'n gezellige en ta lentvo lle  afdeling te w erken !
Veel dank ook aan alle oogartsen, klinisch genetici en alle andere co-auteurs die een 
bi jdrage hebben geleverd aan dit onderzoek /  M any thanks to all the ophthalmologists, 
clin ical geneticists and other collaborators w ho  contr ibuted generously to this research; 
especially Jeroen Klevering, M ies van Genderen, Frans Riemslag, Jan W illem Pott, Carel 
Hoyng, Caroline Klaver, M ary  van Schooneveld, Klaus Rohrschneider, Dror Sharon, Dikla 
Bandah-Rozenfeld, Eric Pierce, Hester Kroes, Joke Verheij, and Robert Koenekoop. 
Robert, jij ook extra bedankt voor de geweldige tijd die ik in jouw  lab had in Montréal, 
jo uw  vermogen mij zo te motiveren voor de genetische onderzoeks-wereld en alles w at 
ik toen en daarna van je geleerd heb.lOok w i l  ik graag alle patiënten bedanken die -  vaak 
zonder enig eigenbelang en soms van heel ver -  een keer naar het ziekenhuis kwamen 
om nog een extra onderzoek te ondergaan.
Ook alle collega arts-onderzoekers in het ROI bedankt. Ook al w erk te  ik nogal op grote 
afstand van het ROI, bij de gelegenheden w aa r in  ik jull ie tegenkw am  (NOG, ARVO) 
voelde ik me toch een beetje co llega. Suzanne, bedankt voor alle in teressante data
w a a r  ik mee verder kon werken , en voor het delen van jo u w  ervaringen. En Linda, 
via deze w eg  nog eens veel succes  gewenst met jo u w  RP onderzoekspro ject!
N icole  van de Kar en Lucy Platvoet; jul lie beiden zijn voor mij een soort mentor. 
M issch ien  w is ten  jull ie het niet eens, maar jull ie hebben een groot aandeel gehad 
in mijn motivatie  om me in de onderzoekswere ld  te (bl ijven) storten. Bedankt voor 
alle inspirerende en motiverende woorden.
Het eind van dit onderzoek betekent ook een eind aan een lange tijd in Nijmegen. 
Daarom w i l  ik dit dankwoord  ook gebru iken om mijn vr ienden te bedanken voor de 
geweld ige t ijd  die ik dankzij  jull ie en met jullie in Nijmegen en buiten Nijmegen heb 
gehad. Studievr ienden, W W 41-ers ,  bunnies, huisgenoten, Bata-vrienden; hopeli jk 
volgen er nog veel meer b iert jes bij de Kluizenaar, bij de Foyer (oh nee, die is gesloten; 
n ieuwe leuke kroeg vinden...), f i lms bij Lux, vakanties, East of Easterns, dagen van 
het Levensl ied, Batav ie renraces, Hart-van-Brabantlopen, zomerfeesten, enz. Hopelijk 
komen er leuke n ieuwe Rotterdamse tradit ies bij zoals De Parade of het zomercarnaval 
in Rotterdam; mijn deur zal w ag e n w i jd  open staan! M e t  name Heleen en Gabie, al 
vanaf het a l le reerste Nijmeegse begin in 1999 zijn jullie in het dagel ijks leven mijn 
'paran im fen ' geweest;  superbedankt daarvoor!
Als  laatsten, de allerbelangrijksten:
Pap, mam, Sas, Rob en oma; 'g ew oon '  bedankt, omdat jullie er altijd zijn!
(M ooi verhaal, lekker kort!)
Dear Alejo, being together  w i th  you is the best result  of this  research! :-) Thank you 
for  our wonderfu l  t ime together!
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CHAPTER 2
Patient 50417 Patient 50397 Patient 54684 Patient 51456 Patient 20695
ABC A4, c.6729+5_19del 15 CERKL, c.375C>G; p.C125W CERKL, c.375C>G; p.C125W CERKL, c.847C>T; p.R283X PROM1, c.1142-1G>A
F iG U R E  3 . fundus photographs, autofluorescence and spectra l domain (spectra lis ) 
o d  images of cRD patients w ith  conclusive genetic defects.
The retina o f patient 50417 (ABCA4, c.6729+5_19del15; age 44) shows (a) extensive retinal pigment 
epithelium (RPE) cell loss, choroidal sclerosis and pigmentary macular changes on fundoscopy 
(B) marked loss o f central lipofuscin accumulation on fundus autofluoresence (FAF), and (c) a 
disorganized retina in w hich the six layers are not detectable, the fovea is extremely thin, w ith  loss o f 
the inner/outer segment junction. Extensive debris accumulation is noted. Patient 50397 (CERKL, 
p.C125W; age 48) has (D) a pigmentary maculopathy w ith  choroidal sclerosis, (E) absence o f central 
FAF, except in a tiny  island, indicating nearly complete loss o f lipofuscin deposition, and (F) very 
extensive retinal remodeling and an unusual subretinal cystic structure in the fovea. His older brother 
(54684, age 51), although carrying the same m utation in CERKL, has (G) extensive retinal, RPE and optic 
disc atrophy and sclerosis, (H) loss o f central FAF, w ith  a peculiar salt and pepper pattern o f FAF outside 
the central retina, and (I) th inning and disorganization o f the retina. A  CERKL nonsense mutation 
(p.R238X) in patient 51456 (age 53) resulted in (J) extensive choroidal sclerosis, (K) loss o f FAF, and 
(L) retinal remodeling w ith  loss o f inner/outer segment junction. The retina o f patient 20695 (PROM1, 
c.1142-1G>A; age 18) showed (M) central atrophic lesions in the fovea and severely attenuated retinal 
vessels. N o  autofluorescence and spectral domain O C T  images were available for this patient.
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CHAPTER 3
A . B .
F IG U R E  5. caBp4 protein model.
a . R ibbon m odel o f the calcium  b ind ing  domains in  norm al CaBP4.
B. M o de l showing the deleted calcium  b ind ing domains (gray). Yellow balls: calcium  atoms.
APPENDIX (c o lo r  FIGUREs)
CHAPTER 4
F IG U R E  3 . Retinal imaging of patients VI-3 and VI-6.
A. Photograph o f  the m idperiphera l fundus o f  patient V I-3  at the age o f  5, showing 
a marbled appearance. B. Fundus photograph o f  the same patient V I-3  at the age 
o f  11, w h ich  shows that the marbled appearance had disappeared, and m ild  a trophy 
o f  the RPE was noted. C. M ean autofluorescence image (30°) o f  the le ft eye o f  patient 
V I-3 , calculated from  12 single images (488 nm ), showing a well preserved signal in  the 
posterior pole w ith  decreased intensity in  the macular region. D. Spectral dom ain O C T  
o f the le ft eye o f  patient V I-3  at the age o f 11 shows a recognizable photoreceptor layer, 
in tact re tina l layers, and disappearance o f  the foveal dimple. E. Fundus photograph o f 
le ft eye o f  patient V I-6 , showing preserved RPE in  the macular region w ith  an extremely 
hypopigm ented area along the vascular arcade, w h ich  extends to  the periphery.
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A .
B .
c .
D.
E.
F iG U R E  4. CEP290cDNA analysis of the e ffec t of the c.4510>T varian t on splicing.
A. Agarose (3%) gel electrophoresis showing three m ajor PCR products in  carriers 
o f  p .A rg 1 5 lX  and one m ajor p roduct in  the six con tro l individuals. B. Agarose gel 
electrophoresis showing GUSB as the reference gene product. C -E . PCR sequences 
o f  c D N A  o f  pa tient V I-3  (CEP290 c.451C>T/c.2991+1655A>G), showing (C) m R N A  
conta in ing all exons, b u t showing a low  peak for the m u tan t heterozygous T  at position 
451 (arrow). (D) m R N A  missing exon 7, and (E) m R N A  missing exons 7 and 8. *Low- 
intensity p roduct cou ld  n o t be am plified  fo r sequence analysis. Based on the size, it 
cou ld contain the CEP290 m R N A  lacking exon 8 only, w h ich  should be 315 bp; tlow - 
intensity p roduct ~200 bp was analyzed by sequence analysis and appeared to  be the 
CEP290 m R N A  lacking exon 6 on ly (192 bp). Since CEP290 lacking exon 6 is present 
in  patients as w e ll as con tro l individuals, i t  appears to  be a norm al splice variant
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F IG U R E  1. Genomic s tructu re , cDNA fragm ents, and protein domains of EYS.
A. Upper panel: the RP25 chromosomal region at 6p12.1-q133, the 5.0 M b  homozygous region 
iden tified  in fam ily  A , and the five know n genes w ith in  the homozygous region. Exons 1 and 2 
o f KHDRBS2 reside in  the critica l region. In  the m iddle, the exon predictions are depicted on
the basis o f RefSeq (in blue), Genescan (in black), and Ensembl (in red), w ith  the use o f the M arch  
2006 UCSC genome b u ild  (hg18). Below  the genomic-exon annotation is the exon structure 
o f hum an EYS (exons drawn to scale; in tron  sizes can be found in  the top panel). The complete 
nucleotide sequence o f human EYS cD N A  is presented in  Figure S2. For details o f the exon- 
in tron  structure, see Table S5. The 5’- and 3’- UTRs are indicated in black boxes; the colors 
o f the prote in-coding exons correspond w ith  those o f the p rote in  domains in  (B). Lower panel: 
reverse-transcription PCR fragments o f hum an EYS w ith  retina R N A  and EYS-specific prim ers 
(arrowheads) or 5’- and 3’- RACE adaptor prim ers (squares). The 5’-U TR , the open reading 
frame, and the 3’-U T R  altogether measure 10,475 nucleotides (see Table S5). Exon 42 (63 bp) 
is alternative ly spliced in re tina R N A  (see Figure 2). For details o f RT-PCR studies, see Figure S1.
B. Prote in-dom ain structure o f EYS and its Drosophila o rtho log  (GenBank ID  ABH07112.1).
N ote  the conspicuous conservation o f the order o f EGF-like and Lam in in  A  G-like domains 
between human and Drosophila. The p.Pro2238ProfsX16 fram eshift m u ta tion  truncates several 
EGF-like and Lam in in  A  G-like domains, whereas the carboxy-term inal p.Tyr3156X m utation 
truncates the last ten am ino acids o f hum an EYS. Abbreviations are as follows: EGF, epidermal 
g row th  factor domain; cbEGF, calc ium -bind ing EGF-like domain; EGF-like, EGF-like domain; 
LamG, Lam in in  A  G-like domain. The asterisk denotes glycosaminoglycan (GAG) attachment 
sites predicted by Husain and coworkers.26 Two putative O-glycosylation sites are predicted in 
the human prote in (Thr1268 and Thr1424). Deta iled characteristics o f the human EYS protein 
domains are presented in Figure S2
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FiGURE 3. Mutation analysis of EYS in Rp patients.
A . Family A
Q-
1-1
-O
I-2
à 5 è ò ò ù
11-1 II-2 II-3 II-4 II-5 II-6 
M1/M1 M1/+ M1/M1 M1/+ +/+ M1/+
a . Pedi grees o f three families w ith  individuals affected w ith  RP. Below the individuals, genotypes 
are presented for either the p.Tyr3156X change (M 1, families A  and B) or the p.Pro2238ProfsX16 
change (M 2, fam ily  C) detected to segregate w ith  the disease. M 1 /M 1  and M 2 /M 2  represent 
homozygous mutants; M 1 /+  indicates heterozygous carriers, whereas +/+ indicates individuals 
carry ing tw o w ild -typ e  alleles.
B .
p.Tyr3156X
(M1)
p.Pro2238ProfsX16
(M2)
Asn Val X
A A T G T T T A A G A
J
Asn Val Tyr Asp
A A T G T T T A T G A
Thr Pro Ser Gin
A C C C C A T C A C A
Thr Pro lie Thr
A C C C C T A T C A C
Wildtype
Wildtype
B. Upper panel: partia l sequence 
o f the EYS gene showing the nonsense 
c.9486T >A change, in  an affected 
ind iv idua l (fam ily A , I I - 1) and an 
unaffected sibling (fam ily A , II-5).
The m uta tion  replaces a tyrosine 
residue by a te rm ina tion  codon 
(p.Tyr3156X). Preceding am ino acids 
are indicated above the sequence trace. 
Low er panel: partia l sequence o f the 
EYS gene showing the c.6714delT 
change, in an affected ind iv idua l 
(fam ily C, II-1) and a con tro l 
individual. The m utation results 
in  a frame shift and, eventually, in  
premature te rm ina tion  o f the protein 
(p.Pro2238ProfsX16). A m in o  acids 
are indicated above the sequence trace.
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c .
Human
Chimpanzee
Horse
Chicken
Zebrafish
Drosophila
I E L IK - L E  
IE L IK - L E  
K IE L IK - S E  
¡KKIQL K
i 0 q t c e |
I ISDFSTYQ
p.Tyr3156X
I
v y d g d e q n Sv t —
VYDGDEQNgVT---
GDEQN-------
GDHRN-------
VYiG^E---------------
|g s c d l h g @e p l t v
c. Sequence comparison o f the 25 most C -te rm ina l am ino acids o f the hum an EYS prote in 
and several vertebrate and invertebrate orthologs. Residues identical in  all sequences are 
w h ite  on a black background, whereas sim ilar am ino acids are w hite  on a gray background. 
Residues tha t are present in  at least three o f the six proteins are indicated in black on a light 
gray background. Residues constitu ting the most C -te rm ina l Lam in in  A  G-like domain 
in  the Drosophila p ro te in  are underlined. Accession numbers o f the prote in  sequences 
used fo r sequence com parison are as follows: chimpanzee, XM_527426.2 (RefSeq); horse, 
XM_001918159.1 (RefSeq); chicken, XM_426198.2 (RefSeq); zebrafish, BX005106.5 (EMBL); 
Drosophila, ABH07112.1 (GenBank).
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BF IG U R E  4 . c lin ica l characte ristics of Rp patients w ith  a homozygous p.Tyr3156X mutation in EYS.
a . Fundus photograph o f the righ t eye o f patient II-1 o f fam ily  A , showing m ild  pallor o f the optic 
disc, a peripap illa ry crescent, attenuated re tinal vessels, and bone-spicule pigm entations. A n  area 
o f sharply demarcated choriore tina l atrophy is located nasal to the fovea, w ith  s im ilar atrophic 
lesions along the vascular arcades, conflating to  diffuse atrophy in the m idperiphery.
B. Fundus photograph o f the posterior pole and nasal peripheral re tina o f the righ t eye o f patient 
II-6  o f fam ily  B, showing m ild  pa llor o f the op tic disc, severely attenuated vessels, pronounced 
atrophic changes in the (m id) pe riphe ry that spare the posterior pole, and extensive bone spicules 
in  the peripheral retina.
c. Scotopic and photop ic ERG o f the righ t eye o f patient II-3  o f fam ily  A  and a norm al subject. 
Scotopic m ixed response (ISCEV measurement; 2500 m cds/m 2) had a b-wave am plitude 
o f 274 | iV  (norm al > 195 |iV, mean 424 |iV ). The b-wave am plitude o f the photop ic response 
(ISCEV measurement; 2500 m cds/m 2) was 58.8 |iV  (norm al > 69 |iV, mean 79 |iV).
APPENDIX (c o lo r  FIGUREs)
s u p p l e m e n t a l  F IG U R E  s 1 .  Details of RT-pcR study of EYS.
Prim er sequences are listed in  Supplemental Table S1. AP (filled square) and N A P  (open square) 
denote RACE adaptor and nested adaptor primers, respectively. Filled and open arrowheads 
represent regular and nested RT-PCR primers. Dashed line denote p rim ary  RT-PCR products.
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C/3 1 ÉHDKSIVILS LMVFHSSFlj GKTCRRQLVE EWHPQPSSYV VNWTLTENIC 
51 LDFYRDCWFL GVNTKIDTSG NQAVPQICPL QIQLGDILVI SSEPSLQFPE 
101 INLMNVSETS FVGCVQNTTT EDQLLFGCRL KGMHTVNSKW LSVGTHYFIT
151 VMASGPSPCP LGLRLNVTVK
201 Hi®B«il!lii^ iaMBlELDACSFK PCKNNGSCIN KRENWDEQAY ECVCHPPFTG
251 KNCSEIIG® QPHVCFHGNC SNITSNSFIC ECDEQFSGPF CEVSAKPCVS 
301 LLFWKRGICP NSSSAYTY^! PKGSSSQNGE TDVSEFSLVP CQNGTDCIKI
351 SNDVMCICSP IFTDLLCKSI QTSCESFPLR NNATCKKCEK DYPCSCISGF
401 tiEinsctiKAimiMMMAiMmtoMmmumMmiMdMmmrtFLKK
451 VYLIHQHLCY CGVTFHGICQ DKGPAQFEYV WQLGFAGSEG EKCQGVIDAY 
501 FFLAANCTED ATYVNDPEDN NSSCWFPHEG TKEICANGCS CLSEEDSQEY
c
30
^  551 ry[lcflrwag NMYLENTTDD QENECQHEAV CKDEINRPRC SCSLSYIGho 601 SVNVDYCLG NHSISVHGLC LALSHNCNCS GLQRYERNIC EIDTEDCKSA 
651 SRKNGTTSTH LRGYFFRKCV PGFKGTQCEI 
355
@EEI NECDSDPCMN GGLCHESTIP GQFVCLCPPL YTGQFCHQRY 
851 NLCDLLHNPC RNNSTCLALV DANQHCICRE EFEGKNCEjlD VK^CLFLSCQ 
901 DYGDCEDMVN NFRCICRPGF SGSLCEllftl8»aMaa«g«K<{l8MCMHTiO»l)Mglifi
¡gLDVNKC KISPCLDEEN CVYRTDGYNC LCAPGYTGIN
1001 SBiM f l r i a M f c B a t tnandclsn!
1051 CLHGRYTELI NEYPCSCDAD GTSTQCI^IKI NDCTSIPCMN EGFCQKSAHG
n o i MsmmpRmtfMssÉtòiMKSidn caepelnsvi clnggicvdg pghtfdcrcl
1201 ECIPNSCVHE LCMENEPGST CLCTPGFMTC SIGLLCGDEI RRITCLTPIF
1251 QRTDPISTQT YTIPPSE0LV SSFPSIKATR IPAIMDTYPV DQGPKQTGIV
1301 KHDILPTTGL ATLRISTPLE SYLLQELIVT RELSAKHSLL SSADVSSSRF
1351 LNFGIRDPAQ IVQDKTSVSH MPIRTSAATL GFFFPDRRAR TPFIMSSLMS
1401 DFIFPTQSLL FENCQTVALS ATP0TSVIRS IPGADIELNR QSLLSRGFLL
1451 IAASISATPV VSRGAQEDIE EYSADSLISR REHWRLLSPS MSPIFPAKVI
1501 ISKQVTILNS SALHRFSTKA FNPSEYQAIT EASSNQRLTN IKSQAADSLR
1551 ELSQTCATCS MTEIKSSREF SDQVLHSKQS HFYETFWMNS AILASWYALM
1601 GAQTITSGHS FSSATEITPS VAFTEVPSLF PSKKSAKRTI LSSSLEESIT
1651 LSSNLDVNLC LDKTCLSIVP SQTISSDLMN SDLTSKMTTD ELSVSENILK
1701 LLKIRQYGIT MGPTEVLNQE SLLDMEKSKG SHTLFKLHPS DSSLDFELNL
1751 QIYPDVTLKT YSEITHANDF KNNLPPLTGS VPDFSEVTTN VAFYTVSATP
1801 ALSIQTSSSM SVIRPDWPYF TDYMTSLKKE VKTSSEWSKW ELQPSVQYQE
1851 FPTASRHLPF TRSLTLSSLE SILAPQRLMI SDFSCVRYYG DSYLEFQNVA
lnpqnnisle fqtfssygll lhvkqdsnlv dgffiqlfie ngtlkyhfyc
1951
2051 PSKAVKNYHI NNCRSQGFML SPTASFVDAS DVTQGVDTMW TSVSPSVAAP
2101 SVCQQDVCHN GGTCHAIFLS SGIVSFQCDC PLHFTGRFC^ KDAGLFFPSF
2151 NGNSYLELPF LKFVLEKEHN [RTVTIYLTIK TNSLNGTILY SNGNNCGKQF 
LHLFLVEGRP SVKYGCGNSQ NILTVSANYS INTNAFTPIT IRYTTPVGSP 
2 2 1 GVVCMIEMTA DGKPPVQKKD TEISHASQAY FESMFLGHIP ANVQIHKKAG
^ ^ ^ ^ ^ ^ ^ ■ eff iidearhgkn ienchvpwca HHLCRNNGTC
ISDNENLFCE CPRLYSGKLC QFASCENNPC GNGATCVPKS GTDIVCLCPY 
GRSGPLCTDA INITQPRFSG TDAFGYTSFL A Y S R ISDISHHHHHHI  
ANNHSALQNN LIFFTEQKGH GLNGDDFLAV GLLNGSVVYS YNLGSGIASI
rglgnpeghp
NAGRSVGQCH A.qmillllli^ l^B@lliaill^ ^^ Jiltiil<dilii^J ^ j FTV.q 
TCDPEHDPPH HCSRGATCIS LPHGYTCFCP LGTTGIYCEQ ALILIVILEK 
PKPAERKVKK EALSISDPSF RSNELSWMSF AS
GSTWHIIKAG RVGAEGYLDL DGINVTEKAS TKMSSLDTNT DFYIGGVSSL
Lm LTEFGAKGGS NVGDCDGTAC 
GYNTCRNGGE CTVNGTTFSC RCLPDWAGNT CNQSVSCLNN LCLHQSLCIP 
NKTSFSTAKF MGNSYIKYID PNYRMRNL| 
TTISLNFSTT KTEGLIVWMG IAQNEENDFL AIGLHNQTLK IAVNLGERIS 
VPMSYNNGTF CCNKWHHVVV IQNQTLIKAY INNSLILSED IDPHKNFVAL 
NYDGICYLGG FEYGRKVNIV TQEIFKTNFV GKIKDVVFFQ EPKNIELIKL 
EGYNVYDGDE QNEVT
Protein motifs :
BBBEnSE; EGF-like domains;
Laminin A G-like domains
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CHAPTER 5B
F IG U R E  4 . Fundus photographs of pa tients carry ing  m utations in EYS.
a . Fundus photograph o f the central retina o f the r igh t eye o f patient C II-6 showing the fundus 
in  an end-stage o f the disease. The fundus is characterized by  a very pale, w axy op tic disc, severely 
attenuated retinal vasculature, and extensive choriore tina l atrophy w ith  m in im a l residual retinal 
p igm ent ep ithelium  at the m acular region.
B. Fundus photograph o f the tem poral peripheral re tina o f patient C II-6  showing heavy irregular 
pigm entations in  the (m id)periphera l retina.
c. Fundus photograph o f the central re tina o f the righ t eye o f patient K II-2  showing a p ink, w axy 
op tic disc, m oderately attenuated re tinal vessels, and generalized choriore tina l atrophy w ith  
macular sparing.
D. Fundus photograph o f the upper tem poral peripheral re tina o f patient K II-2  showing classic 
bone spicules in periphery. The red telangiectatic-like vessels at the temporal retina (Figure 4C, 4D) 
are no t visible w ith  h igher resolution and on fluorescein angiography, and therefore seem to be 
artifacts.
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CHAPTER 5C
A .  wt C.403
I
C.406
I
141 142 143
' O ^A  A_T_G CAC A C J  G^TT AAT TCT A ^G  T £ 0  C_TG AGT OTT 
13:
r
io_
136 7 138 139
C.410 424del 15
LÜj g_2JLU al^a tîS LU  t^ì °l^a t u
Â S  3%  400 401 402 &  4^ 4 foS &  4^ 7 4*8 4 ^ 4?0
M utant
Heterozygote
c.1211 1212insA
IC G  A ATGC AC C  TT TTAGT GTT GGGACACAT TAT TTTA
T CA G GATTTACT G A
Heterozygote
D . \ u  c.4361 4362 
\
GGGCTTCTTTGTGGTGATGAAATAAGGAGAATTACCTGTTT \ G CT GC C TCC ATAAGTGC AAC TC CAG TTGTC TCTAGG
M utant 
Heterozygote
Mutant
Homozygote
c.4361 _4362CC> AG
G G G CT TÇT T TOT GOT G AT K A A ATAAGGAGAATTACC T G TT T
0 C T GCC TAGATAAGT GCAAC T C C A G TTGTCTCTAGG
Heterozygote c8218 S2]9Je]CA
F IG U R E  2 . The chromatograms of the five novel EYS mutations.
For each mutation, the w ild-type (wt) sequence is depicted w ith  the homozygous or heterozygous 
sequences when available. The m utation location is indicated by either an arrow  (for a nucleotide 
change) or a horizonta l line (for a sequence change affecting more than a single nucleotide).
A. c. 403delA,406G>T,410_424del15; p.Thr135LeufsX25 (exon 4).
B. c.1211_1212insA; p.Asn404LysfsX2 (exon 8). C. c.3715G>T; p.G lu1239X (exon 25).
D. c.4361_4362CC>AG; p.Ser1454X (exon 26). E. c.8218_8219delCA; p.His2740TyrfsX27 (exon 43).
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Am
F IG U R E  3 . Fundus imaging and v isua l fie lds.
Representative fundus images and Goldm an visual fields o f the le ft eyes o f patient TB24 III:2 
(panels A -D ) at age 63 and patient M O L0501 II:3 (panels E -H ) at age 52 are shown. The typical 
funduscopic findings o f RP are present, includ ing bone spicule-like pigm entation, pallor o f 
the op tic discs, and narrow ing o f b lood  vessels (A,E). M acular involvem ent is evident also on 
autofluorescence imaging (B,F) and OCT, w ith  re tinal th inn ing  and atrophy (D,H). N ote  more 
severe foveal a trophy in patient M O L0501 II:3 w h ich  correlates w ith  the lower visual acu ity o f this 
patient (Table 2). V isual fields are m arkedly constricted in b o th  patients (C,G).
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S U P P L E M E N T A R Y  F IG U R E  1.
The autozygous region iden tified  in M oroccan Jewish patients w ho are homozygous for the 
c.403delA,406G>T,410_424del15 m utation . The appropriate region o f the A ffym e trix  10K 
m icroarray analysis is depicted, covering the EYS gene and flanking markers on chromosome 6. 
The genotype data o f the fo llow ing  patients are presented: 1, M 0 L 0 5 0 1  II:1; 2, M 0 L 0 6 6 2  IV:3; 3, 
M 0 L 0 3 1 8  II:13; 4, M 0 L 0 3 1 8  II-9; 5, M 0 L 0 3 1 8  III:5 . For each marker, the genotype is presented 
as homozygous (A A  o r BB), heterozygous (AB) or unknow n (NoCall). The A  and B alleles were 
arb itra rily  de term ined for each allele by  A ffy m e trix  and the corresponding nucleotide is presented 
on the r igh t along the shared homozygous region. Red indicates A A ’ genotype; b lue indicaties 'BB’ 
genotype, and green indicates A B ’ genotype.
APPENDIX (COLOR FIGURES)
S U P P L E M E N T A R Y  F IG U R E  2 . A pie cha rt showing the con tribution 
o f arRP genes in the Israe li and Palestin ian populations.
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ABBREVIATIONS
aa amino acid
AAV adeno-associa ted virus
ad autosomal dominant
APEX alle le-specif ic  primer extension
ar autosomal recessive
ARMS ampli fication-refractory
mutation system
BBS Bardet-Biedl syndrome
bp base pair
cDNA complementary deoxyribo-
nucleic acid
CF counting fingers
CRD cone-rod dystrophy
CSNB congenita l stationary night
blindness
DNA deoxyribonucle ic  acid
EBV-LCL Epstein-Barr virus transformed
lymphoblastoid cell lines
F
tD
E epidermal growth factor
EOSRD early-onset severe retinal
dystrophy
ERG electroretinogram
m G
O
m exonic splice enhancer
FFAF fundus autofluorescence
HM hand movements
ISCEV international socie ty for clinical
electrophysio logy of vision
JBTS Joubert syndrome
LCA Leber congenital amaurosis
LP light perception
Mb megabases
M IM Mendelian inheri tance in man
MKS Mecke l-Gruber syndrome
mM millimolar
mRNA messenger ribonucle ic  acid
^V microvolt
NAS nonsense-associated altered
splicing
NGS next generation sequencing
NMD nonsense-mediated decay
NP not performed
NR non recordable
nt nucleotide
OCT optical coherence tomography
OD right eye (oculo dextro)
OMIM online Mendelian inheritance
in man
OS left eye (oculo sinistro)
PCR polymerase chain reaction
PTC premature termination codon
RACE rapid ampli fication of
cDNA ends
RP retinitis pigmentosa
EPR retinal pigment epithelium
SLSN Senior Loken syndrome
SNP single nucleotide
polymorphism
STGD Stargardt disease
UTR untranslated regions
w t wildtype
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